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Abstract 
Currently, diagnostic tests for mesenteric ischaemia and infarction are inadequate due 
to poor sensitivity and specificity.   In addition, many potential markers appear too 
late to be clinically useful.   At present, definitive diagnosis can only be made at the 
time of surgery, which is not ideal as surgery is often to be avoided in critically ill and 
elderly patients.   A clinically useful, minimally invasive test is likely to decrease the 
currently very high mortality rate and allow monitoring of ‘at risk’ patients during 
their hospital stay. 
 
A two-dimensional electrophoresis based proteomic approach was undertaken to 
assess plasma protein differences between patients with surgically confirmed bowel 
infarction and control Intensive Care patients.   The major protein differences were 
found to be members or variants of acute phase proteins.   Serum amyloid A showed 
the largest difference between the two patient groups, and this protein was 
investigated in greater depth.   An analysis was performed to compare the diagnostic 
ability of several commonly used indicators of critical illness and bowel infarction 
with serum amyloid A and phospholipase A2.   Although none of the variables were 
ideal for clinical use, plasma phospholipase A2 activity showed the best 
discriminatory power, as determined by Receiver Operating Characteristic curves. 
 
From a review of the literature, phospholipase A2 (PLA2) appeared to be increased in 
the bowel as a result of ischaemia and infarction.   In one patient, matched tissues 
were obtained, and PLA2 activity was found to be significantly higher in infarcted 
bowel tissue compared to ischaemic bowel tissue.   PLA2 activity was significantly 
greater in bowel lumen than tissue, suggesting that the protein was being released, and 
may enter the circulation.   PLA2 activity was increased in the plasma of bowel 
infarction patients compared with control patients, though the difference was not 
significant.   The phospholipase activity exhibited a number of similarities to typical 
phospholipase A2 proteins, but also showed a number of inconsistent characteristics.   
For this reason, we wished to identify the protein responsible for the increased 
phospholipase activity in infarcted human bowel.                                                                                          
 
The PLA2 activity in human bowel could not be abolished by immunoprecipitation of 
the PLA2 isoforms IIA (well described in bowel) and V (a closely related isoform).   
To investigate these proteins, a native urea protein gel devised for snake venom 
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phospholipase A2 was modified for use with mammalian phospholipase A2.   The 
modified gel was used to show that the protein with phospholipase activity from 
infarcted gut was different from normal gut PLA2 and type IIA PLA2.   A number of 
extensions were devised for these native gels and were found to be useful both in this 
investigation and for venom investigations. 
 
Protein purification was undertaken to identify the protein responsible for the 
increased phospholipase activity in infarcted bowel.   Protein was purified from 
infarcted human bowel using a number of techniques that exploited unusual 
characteristics of the protein.   The purification techniques each retained the native 
activity of the protein and the purification could therefore be monitored with a 
phospholipid hydrolysis assay at each stage.    
 
The protein identified by mass spectrometry was an excellent match for cyclophilin B, 
an inflammatory protein that had previously been identified in rat bowel at the mRNA 
level (Hasel et al, 1991, Kainer & Doris, 2000).   As the purification progress had 
been monitored throughout with a phospholipid hydrolysis assay, cyclophilin B was 
an unexpected identification, as it is not known to have phospholipase activity.   
Cyclophilin B was removed from the highly purified samples via 
immunoprecipitation and this process abolished all phospholipase activity.   The 
addition of cyclosporin A, (the pharmaceutical ligand of cyclophilin B), did not effect 
the phospholipase activity.   Cyclophilin B protein was found in normal and infarcted 
human bowel using Western blotting.   Cyclophilin B protein also appeared to be 
present in the bowel lumen and plasma of several patients with bowel infarction, but 
not in control patients.   Immunohistochemistry confirmed the ubiquitous nature of 
cyclophilin B that had been reported by other groups. 
 
This project has investigated the use of two dimensional gel electrophoresis based 
proteomics to identify proteins present in the plasma of patients with confirmed bowel 
infarction and control intensive care patients.   The major protein classes observed 
were members of the acute phase proteins, which highlights the need for pre-
fractionation of plasma to identify lower abundance, disease associated proteins.   A 
series of potential plasma markers were compared using Receiver Operating 
Characteristic Curves.   Although no ideal marker was clear from this analysis, 
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Abstract 
phospholipase activity appeared to warrant further investigation.   Phospholipase 
activity was investigated in human infarcted bowel.   Protein purification identified 
cyclophilin B as a bowel protein that showed unusual phospholipid hydrolysing 
activity.   Cyclophilin B is a ubiquitous protein in intestinal cell types in both normal 
and infarcted tissue.   There appears to be release of cyclophilin B into bowel lumen 
and plasma under conditions of mesenteric ischaemia and infarction. 
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purification of one of the proteins of interest, and the examination of this protein in 
human mesenteric ischaemia and infarction.   The investigations suggest that the 
levels of a number of these disease associated proteins are increased during 
mesenteric ischaemia and infarction in the bowel and in plasma. 
 
 
 
 
Name:  Kristen Glenister 
Signed: 
Date: 
Supervisors: Dr. Charlie Corke and Associate Professor Tom Watson. 
 
 XIX
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The aims of this study are as follows: 
 
1. To use Proteomics to assess whether an abundant and specific disease 
associated protein was evident in the plasma of patients with confirmed bowel 
infarction.    
2. To assess the potential of a variety of disease associated proteins as clinically 
useful diagnostic markers of mesenteric ischaemia and infarction. 
3. To study potential disease associated proteins in greater depth in relation to 
mesenteric ischaemia and infarction using appropriate biochemical and 
antibody assays and protein purification techniques where necessary. 
4. To develop or refine techniques that are useful to the study of disease 
associated proteins where necessary. 
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Chapter 1 Introduction 
Chapter 1: Clinical introduction: 
 
In 1926 A.J. Cokkinis stated starkly: 
“occlusion of the mesenteric vessels is apt to be regarded as one of those conditions of which 
diagnosis is impossible, the prognosis hopeless and the treatment almost useless”. 
Despite the significant medical advances that have been made since this statement, the 
problems associated with the diagnosis and prognosis of mesenteric ischaemia remain 
substantial.   Ischaemia results from the insufficient blood supply to an organ or tissue, in the 
case of mesenteric ischaemia the organ affected is the intestine.   If the ischaemia persists, 
tissue necrosis, or infarction will invariably follow.   Infarction of the intestine often leads to 
gangrene and perforation of the gut wall.    
 
As the period of ischaemia increases, the prognosis becomes more grave, and by the time 
infarction has occurred, the condition has a 50-90% mortality rate during hospital treatment 
(Aydin et al, 1998, Flinn & Bergan, 1997, Howard et al, 1996, Klempnauer et al, 1997).   
Interestingly, not long after Cokkinis made his grave synopsis the mortality rate due to 
mesenteric infarction was 70% (Hibbard, Swenson & Levin, 1931), which has not changed 
significantly in the past 70 years.   Early diagnosis is critical for effective treatment, and to 
keep the mortality rate as low as possible but this remains difficult due to vague symptoms, 
lack of clinically useful diagnostic tests (Bradbury et al, 1995) and broad groups of ‘at risk’ 
patients. 
 
The occurrence of mesenteric ischaemia/infarction is quite low in comparison to other 
circulatory disorders (Flinn & Bergan, 1997), accounting for approximately 0.1-0.2% of 
hospital admissions (Aydin et al, 1998, Howard et al, 1996, Wadman, Syk & Elmstahl, 2000).   
Mesenteric infarction can occur as a complication of hospitalization.   In a study spanning six 
years, Newman and colleagues (1998) found that a quarter of mesenteric infarction cases 
occured as secondary events after hospitalisation, and, in the majority of cases, was the cause 
of death.   Approximately one half of these cases were due to non-occlusive mesenteric 
ischaemia or NOMI (Newman et al, 1998).   NOMI is a particularly severe condition due to a 
high mortality rate and lack of any treatment other than resection of necrotic tissue.   NOMI is 
associated with a high mortality rate due to the critical nature of the illness and typically 
advanced age of the patients involved (Boley et al, 1977).    The use of drugs to reverse 
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hypotension in shock patients in ICU is common, but is likely to compromise blood supply to 
the small bowel (Boley, Brandt & Sammartano, 1997, Newman et al, 1998).     
 
Elderly people, particularly those with cardiac conditions, are most at risk of mesenteric 
ischaemia.   When considering the incidence of this condition, other factors must be 
considered: 
- the number of recognised cases has increased over the past few decades due to increased 
awareness of the condition and an increased number of intensive care units (Bradbury et al, 
1995, Rogers & David, 1995), 
- the reported incidence is likely to be a substantial underestimation, as up to half of cases are 
only detected at autopsy (Wilson et al, 1987), and the rates of autopsy in Victorian hospitals 
have decreased by approximately 50% since the introduction of the Human Tissue Act of 
1982 (Vic.), (McKelvie & Rode, 1992),  
- the incidence is likely to continue to increase with the ageing population, 
- patients with ‘low grade sepsis’ may have sub-clinical mesenteric ischaemia, particularly 
those that later develop Multiple Organ Dysfunction Syndrome (MODS) (Montgomery, 
Venbrux & Bulkley, 1997).   The prevalence of sub-clinical mesenteric ischaemia cannot be 
assessed without accurate diagnostic tests. 
 
Mesenteric ischaemia can be divided into chronic or acute conditions. Chronic mesenteric 
ischaemia is rare (Flinn & Bergan, 1997, Grendell & Ockner, 1989).   This condition is 
associated with marked weight loss due to avoidance of food as eating aggravates the 
condition (Grendell & Ockner, 1989).   Acute mesenteric ischaemia can be categorised as 
being due to arterial occlusion (due to an embolus or thrombosis) or venous occlusion 
(thrombosis or strangulation), or alternatively may be non occlusive in nature as a result of 
inadequate blood flow (NOMI).   
 
The high mortality rate is the result of not only the severity of the disease and its tendency to 
cause remote organ injury (Montgomery, Venbrux & Bulkley, 1997) but also due to: 
- the failure to make a diagnosis until infarction has already occurred 
- the tendency of the gut to develop signs of ischaemic damage or infarction even after the 
vascular problems have been corrected (Rogers & David, 1995) 
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- the proportion of NOMI cases, where the condition reflects poor general circulatory 
perfusion and cannot be treated until infarction has occurred (Boley, Brandt & Sammartano, 
1997). 
 
The question of whether the gut is particularly susceptible to ischaemic episodes is 
controversial.   Villi tips have been observed to be hypoxic even under normal perfusion 
states, due to short circuiting of oxygenated blood at the base of the villi (Kong et al, 1998).   
The mucosa is much more dependent on constant blood supply than the underlying 
connective tissue layers (Marshak & Lindner, 1967).   In a normal resting state the mesenteric 
vascular bed holds a third of the body’s total blood volume and receives a quarter of the 
cardiac output (Schoenberg & Berger, 1993).   Under conditions of low blood volume or 
pressure this reserve is called upon, and for this reason many clinicians consider the bowel 
susceptible to ischaemia during shock states (Deitch, 1992, Koike et al, 1992, Mansour, 1999, 
Montgomery, Venbrux & Bulkley, 1997).   The gut is thought to show poor tolerance to 
hypoxic insult (Mansour, 1999). 
 
Other groups consider the gut to be resistant to hypoxic damage.   The bowel wall is capable 
of extracting extra oxygen under conditions of decreased blood flow (Patel, Kaleya & 
Sammartano, 1992, Rogers & David, 1995) and the splanchnic region in general has a high 
capacity to increase oxygen extraction as required (Rowell et al, 1984).   In an animal model 
of septic shock, the microcirculation to the jejunal mucosa has been shown to remain constant 
despite systemic blood flow reduction of approximately 50% (Hiltebrand et al, 2000). 
 
Signs and symptoms of mesenteric ischaemia: 
The signs and symptoms associated with mesenteric ischaemia are characteristically vague, 
non specific and can vary greatly between patients.   The first sign may be severe abdominal 
pain which is perceived by the clinician as being ‘out of proportion to physical findings’ on 
abdominal examination  (Gredell & Ockner, 1989).   Other signs that suggest the diagnoses 
are an elevated white blood cell count, vomiting, diminished or hyperactive bowel sounds, 
tachycardia and hypotension, however, all of these features are non-specific. 
 
Intestinal pathophysiology in response to ischaemia: 
The ischaemic bowel initially turns a paler colour (Rogers & David, 1995), but darkens as the 
ischaemic period progresses (Carter & Camilleri, 1997).   Affected regions of the bowel wall 
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then haemorrhage and appear purple to blackish red. The mucosa ulcerates and appears white 
to green (Carter & Camilleri, 1997).   The mucosa sloughs off into the lumen, which can 
cause gastrointestinal bleeding (Flinn & Bergan, 1997).   After 24 to 48 hours the bowel 
becomes thin and friable (Carter & Camilleri, 1997).   The lumen fills with blood and mucous 
and ultimately perforates.    
 
At a microscopic level, damage due to ischaemia begins at the villi tips and this superficial 
damage is evident within minutes of occlusion (Carter & Camilleri, 1997).   Histological signs 
such as mucosal cell necrosis and submucosal venous congestion are evident within an hour 
(Rogers & David, 1995).   As the ischaemic insult continues damage progresses deeper into 
the mucosa (Montgomery, Venbrux & Bulkley, 1997), see Figure 1.1 below.    
 
 
 
Figure 1.1   The axis of ischaemic injury. 
Mucosal damage during ischaemia occurs from the villi tips in toward the mucosa.   
Acknowledgement to Jacqui Glenister for the design and drawing of this figure. 
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Biochemical level changes during ischaemia: 
The insufficient blood supply to the gut during mesenteric ischaemia causes significant 
cellular damage, but the resumption of blood supply may cause further damage (reperfusion 
injury), see Figure 1.2.   This became more evident when increasing numbers of patients who 
had successful revascularisation of their gut developed intestinal and cardiopulmonary 
problems post surgery (Schoenberg & Beger, 1993).    
 
 
Figure 1.2.   The development of Ischaemia Reperfusion injury. 
Modified from Bulkley G.B.  Free radical-mediated reperfusion injury: A selective 
review.  Br. J. Cancer 1987; 55: 66-73, with permission from author and Nature 
Publishing Group.    
 
If the period of ischaemia is relatively short, the damage caused by reperfusion is greater than 
that caused by the ischaemia (Bradbury et al, 1995).   As the period of ischaemia increases the 
ischaemic component becomes more detrimental than reperfusion, and when infarction 
occurs, there is no effect due to reperfusion (Bradbury et al, 1995).  
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During ischaemia xanthine dehydrogenase is converted to xanthine oxidase (Montgomery, 
Venbrux & Bulkley 1997).   When oxygen supply is restored the purines which have 
accumulated during ischaemia are metabolised by xanthine oxidase (which requires oxygen, 
unlike its precursor) (Montgomery, Venbrux & Bulkley 1997) forming excess amount of 
tissue damaging superoxide O2•-.   Reperfusion injury is thought to be primarily due to 
reactive oxygen species and increased activity of phospholipase A2 (Schoenberg & Beger, 
1993).   Free radicals can cause cell membrane damage, mucosal edema and ulceration 
(Schoenberg & Beger, 1993).   Phospholipase A2 hydrolyses phospholipids to produce fatty 
acids and the corresponding lysophospholipids.   Lysophospholipids can cause cellular 
damage, for example, lysophosphatidylcholine (LysoPC) is known to be cytotoxic 
(Schoenberg & Beger, 1993) and increases intestinal permeability (Otamiri et al, 1987).   
Inhibitors of phospholipase A2 have been shown to be protective against reperfusion damage 
to gut tissue (Otamiri et al, 1987, Otamiri & Tagesson, 1989).    
 
Efforts to limit tissue damage from reperfusion have been unsuccessful, which is likely to be 
due to the lengthy and severe periods of hypoxia seen in clinical situations (Montgomery, 
Venbrux & Bulkley, 1997).    
 
Current diagnosis of mesenteric ischaemia: 
Radiographic investigations are often of little use in the diagnosis of mesenteric ischaemia 
(Grendell & Ockner, 1989) particularly in the early stages (Carter & Camilleri, 1997).   Plain 
films often only display definite signs when necrosis has already developed (Sutton, 1987).   
Reviews of the value of computerised tomography (CT) in the diagnosis of mesenteric 
ischaemia and infarction have been mixed.   Rogers and David (1995) concluded that CT was 
able to suggest intestinal ischaemia but was unable to provide a definite diagnosis.    
 
Conversely, Klein and colleagues (1995) found CT to be highly sensitive (82%), able to 
correctly diagnose 18 of 22 cases of intestinal ischaemia.   This study also concluded that CT 
was able to rule out other causes of surgical acute abdomen (Klein et al, 1995).   For the 
diagnosis of arterial occlusion, angiography is preferred due to the accuracy of diagnosis and 
the ability to infuse vasodilatory drugs or even fibrinolytic agents in rare cases (Klein et al, 
1995).   Angiography is associated with a number of disadvantages including potential 
nephrotoxicity, exposure to radiation and its invasive nature (Sreenarasimhaiah, 2003).   
Angiography is of less value after the condition has proceeded to infarction (Corder & Taylor, 
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1993).   Improvement in ultrasound technology and expertise mean that the absence of flow 
can be reliably demonstrated in major abdominal arteries and veins (unless there is significant 
gaseous distension). Where expertise exists this can be useful.    In one small German study, 
few cases (2 of 11 patients) were correctly diagnosed pre-operatively by imaging (plain X-
ray, sonography, CT or angiography) (Klempnauer et al, 1997). 
 
In 1995 a paper stated that ‘little clinical work has been done to evaluate the use of MRI’ 
(Magnetic Resonance Imaging), (Rogers & David, 1995), but more recently, MRI has been 
reported to be a ‘highly accurate and non invasive method of diagnosing mesenteric 
ischaemia’ (Sreenarasimhaiah, 2003).    
 
Intraluminal pCO2, measured by gastric tonometry, has been proposed as a way of monitoring 
ischaemia and infarction.   This technique has not been widely adopted because of the 
relatively high cost of the catheters required, the inability of the probes to monitor large areas 
of bowel and poor correlation between the disease state and measurement results (Corke & 
Glenister, 2001).  
 
As mesenteric infarction is a disease of older patients, often with significant co-morbidities 
and a frequently unclear clinical picture, there may be a useful role for laparoscopy.   Where 
laparoscopy demonstrates profound, extensive infarction the patient is spared full laparotomy 
(since resection in massive infarction is often impractical).    When laparoscopy reveals 
normal bowel laparotomy may also be avoided, though unfortunately bowel ischaemia cannot 
be completely excluded by laparoscopy as the serosal surface can appear normal despite 
mucosal necrosis (Kurland, Brandt & Delaney, 1992).   Observation of limited bowel 
infarction on laparoscopy can be followed by laparotomy and resection.   Where the bowel 
viability is unclear the laparoscope may be left in situ (with a purse ring suture to secure it) 
and a second look bedside laparoscopy performed 12-24 hours later (Dr. C. Corke, personal 
communication). 
 
Diagnosis of mesenteric ischaemia via blood tests: 
Many plasma based pathology tests have been proposed to diagnose mesenteric ischaemia but 
none have been useful in a clinical setting because of low specificity, low sensitivity, but most 
importantly markers appear only after infarction has already occurred.   Lange and Jackel 
(1994) concluded that elevated serum lactate was ‘the best marker of mesenteric ischemia to 
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date’.   Raised serum lactate is not a specific finding but suggests that a life threatening 
condition exists.   The usefulness of lactate increases as a diagnostic marker when the possible 
diagnoses of shock, diabetic ketoacidosis, renal and hepatic failure can be excluded (Lange & 
Jackel, 1994).  
 
Amylase was shown to be significantly elevated in a canine model of mesenteric ischaemia 
(Aydin et al, 1998) but in a clinical setting has been shown to be only moderately elevated 
(Corder & Taylor, 1993).   In addition, approximately one half of patients with confirmed 
infarction show normal levels of amylase (Wilson & Imrie, 1985).   Total creatine kinase 
(CK) is of little value in differentiating patients with gut infarction from other patients with 
abdominal symptoms, or from healthy controls (Fried et al, 1991).   The isoform of creatine 
kinase CK-BB has been suggested to have some value in predicting gut infarction, with 63% 
sensitivity at 100% specificity (Fried et al, 1991), but this protein is labile and prompt 
analysis is critical, which limits its practicality for clinical use (Smirniotis, Labrou & Tsiftses, 
1989).   Serum phosphate has been shown to be a strong indicator of mesenteric ischaemia 
(Jamieson et al, 1982) but normal concentrations cannot rule out ischaemia or infarction 
(Carter & Camilleri, 1997).   Hexosaminidase levels only become elevated after necrosis 
(Polson, Mowat & Himal, 1981).   Diamine oxidase (Bounous et al, 1984) and intestinal fatty 
acid binding protein (I-FABP) (Kanda et al, 1995, Kanda et al, 1996) have shown some 
promise but have only been investigated in very small groups of patients.   Lactate 
dehydrogenase has been found to be elevated during intestinal infarction compared with 
‘surgical abdomens’, with a sensitivity of approximately 73% (Calman et al, 1958).   In a 
recent review, discussion of any blood based diagnostic tests of intestinal ischaemia was 
notably lacking, highlighting the void in this area (Sreenarasimhaiah, 2003).   The comparison 
of the various markers that have been proposed is reviewed and summarised in the following 
tables. 
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Potential marker Reference Control group(s) How accurate are these markers? 
Lactate 
dehydrogenase. 
Calman et 
al, 1958. 
Peritonitis, 
obstructive 
jaundice, 
distended 
abdomen, 
fractures & 
normal controls. 
73% sensitive in patients with infarction.   Elevated LDH could indicate 
necrotic intestine or another source of damaged tissue.  A single normal 
LDH reading could not exclude intestinal infarction. 
Hexosaminindase  Polson,
Mowat & 
Himal, 
1981. 
Abdominal pain 
or tenderness. 
Indicator of necrosis. 
Phosphate Jamieson et 
al, 1982. 
 Only patients 
with acute 
abdomen & gut 
ischaemia. 
80% had elevated phosphate.   The 20% that did not show elevated 
phosphate had blood taken late after onset of symptoms, so phosphate may 
have been cleared via urine. 
Diamine oxidase Bounous et 
al, 1984. 
Normal, healthy 
controls & 
cardiac patients 
with no 
abdominal 
symptoms & one 
NOMI patient. 
One bowel infarction patient showed 7 times normal value, but two showed 
below normal levels.   The elevated level seen in the bowel infarction patient 
fell to an approximately normal level even though necrotic tissue was not 
resected.   High diamine oxidase levels could indicate pregnancy or lung 
carcinoma.  Low levels are seen in celiac disease & Crohn’s disease. 
Amylase, lactate 
dehydrogenase, 
phosphate. 
Wilson et al, 
1987. 
Only acute 
mesenteric 
ischaemia 
patients. 
Amylase elevated in 27 of 52 patients tested, lactate dehydrogenase elevated 
in 5 of 7 patients tested, phosphate elevated in 2 of 3 patients tested. 
Creatine kinase (total 
CK) and isoforms 
MB and BB. 
Fried et al, 
1991. 
Group I: normal 
healthy controls. 
Group II: acute 
abdominal signs. 
Total CK and CK-MB levels were not significantly raised in patients with 
infarction.  CK-BB showed 100% specificity, 63% sensitivity. 
Table 1.1.   Clinically assessed markers of intestinal ischaemia/infarction: 
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Lactate  Lange &
Jackel, 
1994. 
 Acute abdominal 
signs. 
100% sensitive, 42% specific, but elevated levels were not indicative of 
bowel ischaemia/infarction. 
Intestinal fatty acid 
binding protein 
Kanda et al, 
1995. 
Healthy 
volunteers. 
Only two patients in study.   I-FABP was undetectable in healthy controls 
and after bowel resection. 
Intestinal fatty acid 
binding protein, 
AST, LDH, ALP & 
CK. 
Kanda et al, 
1996. 
Normal healthy 
controls and acute 
abdominal pain. 
Small study group, (only 5 cases of mesenteric infarction).   Patients with 
strangulated bowel and patients with mesenteric ischaemia showed high 
levels of I-FABP, significantly different from healthy controls and patients 
with other sources of abdominal pain.   AST: 60% sensitivity, LDH: 60% 
sensitivity, ALP: 0% sensitivity, CK: 40% sensitivity. 
Lactate  Klein et al, 
1995. 
None. 17/22 bowel infarction patients showed elevated levels. 
Lactate, amylase, 
alkaline phosphatase 
Newman et 
al, 1998. 
Mesenteric 
infarction patients 
only, divided into 
primary or 
secondary 
development. 
Lactate was the only predictor of mortality. 
α glutathione S-
transferase, AST, 
ALT, amylase 
Delaney et 
al, 1999. 
Acute abdominal 
patients. 
Sensitivity, specificity results: α glutathione S-transferase (100%, 86%, 
though there may be significant levels seen in liver insult, see Gearhart et al, 
2003, below), AST (70%, 50%), ALT (73%, 60%), amylase (25%, 63%).    
Lactate  Klotz et al, 
2001. 
Open heart 
surgery patients  
+/- NOMI. 
No significant difference found. 
Table 1.1 continued.   Clinically assessed markers of intestinal ischaemia/infarction: 
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Table 1.1 continued.   Clinically assessed markers of intestinal ischaemia/infarction: 
 
α glutathione S-
transferase, amylase, 
lactate, AST, ALT. 
Gearhart et 
al, 2003. 
Patients with 
suspected acute 
mesenteric 
ischaemia.   60% 
of patients 
showed some 
form of 
mesenteric 
ischaemia (small 
bowel ischaemia, 
colonic ischaemia 
or both). 
α glutathione S-transferase was the most accurate predictor of acute 
mesenteric ischaemia (74% accuracy) compared with conventional tests (47-
69% accuracy).   α glutathione S-transferase could not distinguish between 
ischaemia and necrosis.   Elevated levels of α glutathione S-transferase may 
reflect hepatic ischaemia.   The negative predictive value of combined α 
glutathione S-transferase, white blood cell count and lactate was high. 
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Table 1.2.   Animal models of mesenteric ischaemia/infarction: 
  
Potential marker Reference Animal model & 
Controls used. 
How accurate are these markers? 
Alkaline 
phosphatase. 
Barnett, 
Davidson & 
Bradley, 
1976. 
Dog. Control 
laparotomy. 
50% of animals with necrotic bowel tissue had no detectable alkaline 
phosphatase.   2/6 dogs with induced pancreatitis also showed detectable de 
novo levels of intestinal alkaline phosphatase but also showed duodenal 
necrosis. 
Diamine oxidase Wollin, 
Navert & 
Bounous, 
1981. 
Rat. 
Sham laparotomy.
Occlusion of superior mesenteric artery for either 30, 60 or 90 minutes 
resulted in increased levels of diamine oxidase in serum.   Diamine oxidase 
was thought to be released from intestinal epithelium into interstitial fluid.   
A portion of this enzyme thought to then be released into blood via 
lymphatics. 
Phosphate Jamieson et 
al, 1982. 
 Dog. Controls not 
described, SMA 
or SMV occluded.
Phosphate levels were elevated at 2 hours and continued to rise until 6 hours.   
Statistics were not reported. 
ALP, CK, LDH & 
AST, GOT, amylase. 
De Toma et 
al, 1983. 
Dog.  6 
laparotomy 
controls, 6 ligated 
superior 
mesenteric artery. 
Non specific.   There was no significant difference between control dogs and 
those dogs with bowel infarction. 
ALP, creatine kinase, 
lactate 
dehydrogenase. 
SGOT, DAO. 
Thompson, 
Bragg & 
West, 1990. 
Dog.  SMA 
ligation, or 
occluded then 
released & 
laparotomy 
controls. 
LDH, SGOT and ALP had low sensitivity.   Creatine kinase had greater 
sensitivity and overall accuracy than other enzymes tested. 
ALP, LDH, AST & 
CK. 
Kurland, 
Brandt & 
Delaney, 
1992. 
Dog. Controls not 
described. 
No markers were found to be sensitive or specific to intestinal ischaemia. 
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Table 1.2 continued.   Animal models of mesenteric ischaemia/infarction: 
 
MDA, ALP, LDH, 
amylase, AST, GGT 
& CK. 
Aydin et al, 
1998. 
Dog. 
Sham laparotomy.
MDA levels significantly higher after ligation.   Other proteins were 
significantly elevated compared with sham operated controls. 
Von Willebrand’s 
factor, 
myeloperoxidase, 
protein carbonyl. 
Abu-Zidan 
et al, 1999. 
Rat. 
Sham laparotomy 
& anaesthesia 
controls. 
Protein carbonyl significantly higher in I/R rats than sham controls.  Protein 
carbonyl correlated with Von Willebrand’s factor. Myeloperoxidase levels 
were not significantly different between groups. 
Cytosolic β-
glucosidase. 
Morris et al, 
1999. 
Guinea Pig. 
Sham laparotomy 
& anaesthesia 
controls. 
Low specificity.  Closed loop obstruction resulted in increased levels. 
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In conclusion successful early diagnosis of mesenteric ischaemia and infarction is 
currently dependent on a high degree of suspicion by the physician.  Recently, the 
mortality rate associated with ischaemic bowel was 35%, but when the condition had 
progressed to infarction the mortality rate increased to 68% (Rogers & David, 1995).    
 
At present the only method of definitive diagnosis is surgery (Fried et al, 1991) but 
this is often avoided in critically ill or elderly patients.   However, an accurate 
diagnostic marker would allow surgeons to make risk assessments prior to surgery.   
A diagnostic marker would also allow post operative monitoring of patients that have 
undergone bowel resection, to ensure that the condition has been rectified.   At present 
post operative monitoring is not practical and definitive post operative monitoring for 
ongoing ischaemia depends upon clinical examination or ‘second look surgery’ 12 to 
24 hours after resection  (Rogers & David, 1995). 
 
Were early diagnosis to become more attainable and reliable, treatment could be 
administered earlier and mortality would decrease.  Therefore the ability to make 
accurate diagnosis at an early stage would decrease the mortality rate.    
 
Treatment of mesenteric ischaemia: 
When mesenteric ischaemia is suspected general treatments such as intravenous 
fluids, thrombolytic agents (Flinn & Bergan, 1997), anticoagulants and broad 
spectrum antibiotics (Mansour, 1999, Rogers & David, 1995) can be administered to 
try to improve outcomes.   Surgical treatment primarily aims to revascularize the 
bowel when possible (in early ischemia), but irreversible ischaemia and/or gangrene 
requires intestinal resection (Klempnauer et al, 1997). 
 
Outcomes after mesenteric ischaemia: 
Relatively few studies have focused on the long term prognosis of the patients 
discharged from hospital after mesenteric ischaemia.   One study conducted follow up 
investigations of 31 patients for up to five years after discharge (Klempnauer et al, 
1997).   It was found that only one patient suffered recurring mesenteric ischaemia, 
and died as a result.   This patient, unlike the others was not receiving ongoing anti-
coagulant therapy.   The major causes of mortality during this study were 
cardiovascular events or malignancies.   One fifth of the group suffered from short 
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bowel syndrome.   The severity of this syndrome is inversely correlated  to the length 
of small bowel remaining (in this study there was an average of 170cm of small bowel 
remaining).   An earlier study of patients with infarction due to venous occlusion 
found recurrence of thrombosis in up to 29% of cases, most commonly due to residual 
thrombi (Clavien, 1990).  Of the 31 patients studied, there was a 70% two year 
survival rate and 50% 5 year survival rate.  The average age of the patients was not 
reported. 
 
When large sections of the small intestine require resection, patients must receive 
long term parenteral nutrition for survival.   Parenteral nutrition allows the delivery of 
nutrients independent of the alimentary tract, typically intravenously.   Usually 
parenteral nutrition is only administered on a short term basis (during a hospital stay 
for instance) but longer term nutrition is possible. Prolonged parenteral nutrition is 
associated with significant complication and expense  (Pennington, 1997).   It can be 
difficult to estimate the nutritional requirements of patients, and prolonged nutrition 
independent of the alimentary tract can cause mucosal atrophy (Braga & Gianotti, 
2002), infectious complications, imbalance of gut flora (Deitch, 1993), and decreased 
host immune function (Deitch, 1992). 
 
Importance of gut ischaemia/reperfusion injury to other conditions: 
Gut ischaemia/reperfusion injury (I/R) is an important condition in its own right, but 
is also involved in the development of several other serious conditions.   Under 
conditions of mucosal damage and hypoxia the gut releases factors into circulation 
that may trigger remote organ injury (for example, adult respiratory distress syndrome 
(ARDS), or multiple organ dysfunction syndrome (MODS)) and sepsis.   The identity 
of these gut derived factors and the mechanism of their release are not yet understood.   
Research has focussed on gut derived:   
- bacteria, 
 - bacterial endotoxin, 
 - proteases, 
 - enzymes (for example, phospholipase A2), 
 - nitric oxide, 
 - free radicals, 
 - cytokines. 
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Some of the gut derived mediators (eg cytokines, free radicals) produced under 
ischaemic conditions cause mucosal damage leading to a loss of gut barrier integrity 
(Kong et al, 1998), and leakage into the peritoneal cavity.   Other factors are 
postulated to be transported via the portal circulation or mesenteric lymph.   A 
complex interplay of a variety of factors is likely.   Conditions such as sepsis may 
play a role in the development of gut dysfunction (Bradbury et al, 1995) or may 
develop because of gut dysfunction (Kong et al, 1998). 
 
Phospholipase A2 is thought to be involved in ischaemia induced remote organ injury, 
as PLA2 inhibitors have been shown to reduce bacterial translocation and mucosal 
injury in a canine model of shock (Xu, Lu & Deitch, 1995).   Interestingly, PLA2 
inhibition and calcium channel blocking failed to be fully protective, suggesting that 
other factors, such as oxidising agents, are involved (Xu, Lu & Deitch, 1995).   
Inhibitors of cyclooxygenase, phospholipase A2 or xanthine oxidase have been shown 
to protect against the lung injury caused by laparotomy/intestinal handling in a rat 
model (Thomas, Karnik & Balasubramanian, 2002).   Animal studies suggest that the 
gut serves as a priming bed for circulating polymorphonuclear neutrophils (PMN) 
which then promote remote organ injury, a process that is likely to involve 
phospholipase A2 (Koike et al, 1992, Koike et al, 1995). 
 
Multiple Organ Dysfunction Syndrome: 
Multiple organ failure syndrome (MOFS) was first recognised in 1973 (Tilney, Bailey 
& Morgan, 1973) when it was observed that patients with ruptured aortic aneurysms 
suffered injury to initially uninvolved organs after surgery.   Later it was proposed 
that the term MOFS be updated to Multiple Organ Dysfunction Syndrome (MODS) to 
reflect the continuum of the syndrome (Fry, 2002).   MODS is not an uncommon 
event [incidence of 5-20% in ICU patients (Poole, 2002)] and accounts for up to 90% 
of the deaths of surgical ICU patients (Montgomery, Venbrux & Bulkley, 1997), a 
rate that has not changed significantly since the condition was first described.  
 
MODS is a condition defined as: 
“a generalized autoaggressive inflammatory process” (Goris, 1985, Nyman et al, 
1996).   MODS involves the ‘sequential failure of vital organs caused by generalized 
cellular damage’ (Nyman et al, 1996).   The most common predisposing factors are 
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shock and infection (Deitch, 1992).    The exact cause of MODS is still unclear but 
may be due to exogenous factors (bacteria and toxins), but more importantly, 
mediators produced by the patient (Deitch, 1992), such as cytokines (Magnotti et al, 
1998) or inflammatory mediators.   MODS is diagnosed by the identification of the 
level of function of several organs by general tests (elevated bilirubin, creatinine, 
hematological changes) and clinical observations (requirement for ventilation, 
intolerance to enteral feeding, progressive coma) (Deitch, 1992).   In reference to the 
diagnosis of MODS, Fry (2002) stated that:  “Current diagnosis sophistication is 
inadequate”. 
 
The condition is characterized by three stages.   The first stage involves sepsis, failure 
of the pulmonary system and decreasingly utilisation of oxygen in the periphery 
(McMenamy et al, 1981).   The second stage involves the failure of the hepatic, 
intestinal and renal systems (Deitch, 1992), and the third stage involves cardiac failure 
(McMenamy et al, 1981).   As the number of organs involved increases, so too does 
the mortality rate (Deitch, 1992).   When a single organ is involved, the mortality rate 
is between 15 and 20%, when two organs are involved the mortality rate rises to 40%, 
three organs shows 60-80% mortality, and four or more organs involved is associated 
with close to 100% mortality (Poole, 2002).   The realisation that the organs fail either 
simultaneously or in similar sequences has prompted investigations into a common 
cause of MODS (Goris et al, 1985).   The contribution of gut dysfunction to remote 
organ injury and MODS is yet unknown. 
 
Gut derived factors; bacteria and endotoxin: 
The suspected involvement of bacteria and bacterial endotoxin in the development of 
MODS, have been studied in numerous animal models and in clinical settings.   The 
gut is thought to be the source of bacteria and toxins.   Although healthy duodenum 
and jejunum are relatively sterile (Welsh & Reynolds, 2002), bacteria are present in 
the distal small bowel and colon at levels of 1010 anaerobic and 105 to 108 aerobic 
organisms per gram of bowel tissue (Deitch & Sambal, 2002).   It has been clearly 
demonstrated that the integrity of the gut epithelial barrier is compromised after sepsis 
(Ziegler et al, 1988).   This theory may explain why no identifiable source of sepsis is 
found in 30% of bacteremic patients with MODS (Goris, 1985).   Research has also 
focussed on the route that bacteria and endotoxin pass from the gut into the 
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circulation.   Initially research focused on the portal circulation, but no bacteremia or 
endotoxemia was detectable (Magnotti et al, 1998, Moore et al, 1991).   It was also 
found that endotoxin concentrations were not significantly different in gut I/R or 
laparotomy controls in rats (Koike et al, 1994).   This latter study also demonstrated 
that endotoxin elimination failed to prevent lung injury due to gut I/R (Koike et al, 
1994).   A similar clinical study failed to find bacteria or endotoxin in the portal blood 
of trauma patients, even those that went on to develop MODS (Moore et al, 1991).   
Later studies in animals focussed on the mesenteric lymph as the route of release.   
Entry into the circulation via the mesenteric lymph is an interesting possibility as it 
reaches the lung before any other vascular bed (Deitch & Sambal, 2002, Magnotti et 
al, 1998) (possibly explaining why the lung is the first organ to fail in MODS).   It 
was found that gut derived factors that increase cell permeability and contribute to 
shock induced lung injury were more prevalent in mesenteric lymph than portal 
plasma (Magnotti et al, 1998).   Deitch and colleagues (2001) also concluded that gut 
derived factors carried in mesenteric lymph appeared to be responsible for lung injury 
after shock but bacteria were not responsible.   It has been proposed that although 
bacteria and/or endotoxin are rarely found in either the portal circulation or lymph 
they may still play a role in the development of MODS.   A change in the bacterial 
balance or bacterial overgrowth may trigger a more potent cytokine response in the 
gut after ischaemia/reperfusion injury or shock (Deitch et al, 2001).   It has been 
demonstrated that IL-6 (Biffl, Moore & Moore, 1995, Grotz et al, 1999) and TNF-α 
are released from ischaemic gut and that there is a relationship between the magnitude 
of the ischaemic injury and the cytokine response (Grotz et al, 1999).    Cytokines 
(IL-1, IL-6, TNF) and neutrophils can decrease oxygen supply to the gut by altering 
microcirculation, possibly leading to a self sustaining cycle (Deitch, 1992). 
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POLYACRYLAMIDE GEL STAINING METHODS: 
 
SILVER STAINING: 
 
Silver Staining (BioRad method): 
Immediately after electrophoresis, gels were placed in fixative (40% methanol v/v, 10% acetic 
acid, 30 minutes).   The gels were then placed in oxidising solution (1:10 dilution of BioRad 
Silver Staining Kit stock solution oxidiser, 5 minutes, BioRad, Hercules, CA).   The gels were 
then washed with water (2L with several changes over 15 minutes).   The gels were then 
stained with silver reagent (1:10 dilution of BioRad Silver Staining Kit stock solution, 20 
minutes) and then quickly rinsed with water.   The gels were then developed (8g BioRad 
Silver Staining developer/250mL water, with multiple changes of solution).   The 
development was stopped with an acetic acid solution (5% v/v). 
 
Silver staining: (SilverQuest™, Invitrogen method): 
Silver staining of NuPAGE gels was performed using SilverQuest™ mass spectrometry 
compatible silver staining kit (Invitrogen, Carlsbad, CA).   Immediately after the completion 
of the electrophoretic run the gels were rinsed quickly (ultrapure water).   The gels were then 
fixed (40% ethanol, 10% acetic acid, 20 minutes).   The gels were then washed (30% ethanol, 
10 minutes) before the sensitizing step (10% sensitizing solution, 30% ethanol, 10 minutes).   
The gels were then washed in ethanol (30%, 10 minutes) and then ultrapure water (10 
minutes).   The gels were then stained (100mL, 1% staining solution, 15 minutes) and quickly 
rinsed (ultrapure water, 1 minute).   The developing solution was then added (10% developer, 
1 drop enhancer, 6 minutes) until the desired level of staining was achieved after which the 
stop solution was added directly. 
 
Silver staining (PlusOne Pharmacia Biotech method): 
All solutions were prepared in ultrapure water.   Immediately after electrophoretic run was 
complete the gels were placed in fixative (40% ethanol, 10% acetic acid v/v, 60 minutes).   
The gels were then placed in sensitizing solution (30% ethanol, 0.125% glutardialdehyde 
solution, 0.2% sodium thiosulphate solution, 6.8% sodium acetate w/v, 30 minutes).   The 
gels were then washed with ethanol solution (20% v/v) followed by two washed with water (5 
minutes per wash).   The gels were then stained with silver reagent (0.25% solution of silver 
nitrate, 0.04% formaldehyde, 20 minutes) and then washed with water (2x1 minute).   The 
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gels were then developed (2.5% sodium carbonate, 0.02% formaldehyde, 10 minutes).   The 
development was stopped with an EDTA solution (1.5% w/v).   Gels were then placed in 
water before scanning. 
 
MS Compatible Modification of the PlusOne method: 
This method was modified by Yan et al, 2000 for use with ESI and MALDI. 
The PlusOne method was followed with the following modifications: 
Two fixing steps were employed (15 minutes each).   The sensitiser did not contain 
glutardialdehyde.   The silver solution did not contain formaldehyde.   Formaldehyde (100µL) 
was added to the developer solution.   Acrylamide (1%) was added to the samples after 
heating, before loading onto the gel (Dr. Bruce Kemp, personal communication), to prevent 
re-formation of disulfide bonds. 
 
Protein bands and spots of interest stained by this method were excised from the gels and 
rinsed briefly (ultrapure water).   The gel pieces were destained (50µL, fresh 1:1 solution of 
30mM potassium ferricyanide, 100mM sodium thiosulphate, 8 minutes, then repeated).   The 
destaining solution was discarded.   The pieces were then washed (ultrapure water, two 
washes).   The gel pieces were then incubated in ammonium hydrogencarbonate (100µL, 
50mM, 20 minutes room temperature).   The gel pieces were then cut into small pieces, 
washed in ultrapure water and dried (four changes of acetonitrile).   The gel pieces were then 
dried under vacuum, trypsin digested and submitted for nano-MS. 
 
COOMASSIE STAINING: 
 
Protein stains for gels of samples containing ampholytes: 
Coomassie G250 (CBB-G250) containing stains (Neuhoff et al, 1988) were used in 
preference to Coomassie R-250 (CBB-R250) stains when running gels of samples that 
contained ampholytes.   CBB-G250 did not show the high background and ampholyte staining 
that CBB-R250 did.   For quantitative studies gels were stained with Colloidal Coomassie for 
three days with minimal destaining (Herbert, personal communication). 
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Copper protein stain: 
Copper containing protein stain could also be used for staining gels that contained 
ampholytes.   Copper sulphate (0.5%) was dissolved in water.   Ethanol (final concentration 
27%) and acetic acid (final concentration 10%) and Coomassie R-250 (0.04%) were added 
and solution made up to volume with water.   Gels were destained with ethanol/acetic 
acid/copper sulphate (12%v/v, 7%v/v, 0.5%w/v respectively).   The ethanol could be replaced 
with isopropanol. 
 
ANTIBODY TECHNIQUES: 
 
Preparation of immobilised antibodies, with CNBr: 
Dialysis tubing (6-8MWCO) was boiled in buffer (100mM bicarbonate, 10mM EDTA, 3 
minutes).   Antibody (1mL) of 10B2 (~0.93mg/mL, Cayman Chemicals, Ann Arbor, MI) or 
4A1 (1mg/mL, Boehringer Mannheim) in coupling buffer were dialysed against coupling 
buffer (4L, 4oC, 18 hours).    CNBr Sepharose 4B beads (Pharmacia Biotech, 0.06g) were 
swelled in dilute HCl (1mM HCl, 5 changes of acidic solution).   Beads and dialysed antibody 
were mixed and rotated (4oC, 47 hours).   The beads were then washed with coupling buffer 
(5 volumes, 0.1M NaHCO3 pH 8.3, 0.5M NaCl) and active sites remaining were blocked 
(0.1M Tris-HCl, pH 8.0, 2 hours). 
 
Immunodepletion of PLA2: 
CNBr sepharose-antibody beads (50µL) and samples suspended in PBS were mixed with 
protease inhibitors (1mM PMSF, 50µg/mL aprotinin, 200µM leupeptin) and incubated with 
rotation (4oC, 3.25hours).   The mixture was then centrifuged (750g, 1 minute) and 
supernatent removed.   The beads were washed with PBS (4 times) and SDS loading buffer 
was added (20µL).   The beads were boiled (100oC, 7 minutes) and loaded onto a 4-20% 
gradient Tris-Glycine gel (Invitrogen pre-cast mini-gel), and run according to manufacturer’s 
instructions.   Gels were then silver stained (BioRad silver staining kit). 
 
Immunodepletion of Cyclophilin B: 
Protein G agarose (50µL of 50% solution per sample) was mixed with ice cold PBS (500µL) 
and centrifuged (12 000g, 4oC, 20 seconds).   Supernatent was discarded and the washing 
process was repeated twice.    
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Pre-clearing samples: 
Samples (500µg total protein, cold PBS/protease inhibitor cocktail (Sigma, St. Louis, MO) to 
a volume of 1mL) were added to the protein G agarose beads.   The samples were incubated 
with rotation (4oC, overnight). 
 
Immunodepletion: 
Pre-cleared samples were centrifuged (12 000g, 4oC, 30 seconds) and supernatent removed to 
a fresh tube.   Aliquots were removed for other assays.   Antibody (1µg of polyclonal 
cyclophilin B antibody, Abcam Ltd, Cambridge, UK.) was added to each sample and rotated 
for one hour (4oC).   Washed protein G-agarose (50µg) was then added and the samples were 
again incubated with rotation (4oC, 3 hours).   The supernatent was then collected (12 000g, 
4oC, 30 seconds) for other assays.   The beads were then washed (three washes in ice cold 
PBS) before addition of SDS-PAGE sample buffer (50µL). 
 
Cyclophilin B Immunohistochemistry: 
Cyclophilin B was investigated in sections of human gut (control and infarcted) using the 
Dako immunoperoxidase method, according to manufacturer’s instructions (Dako, Glostrup, 
Denmark).   The primary antibody dilution was optimised to 1:1200, by performing a 
preliminary serial antibody dilution experiment.   The sections were counterstained with 
Gill’s haematoxylin.   Acknowledgement must go to the Pathcare histology laboratory staff 
for the preparation of tissue sections and slides for this work. 
 
Phospholipase A2 sandwich ELISA: 
ELISA plates (Nunc, Weisbaden, Germany) were coated with the monoclonal antibody 9C1 
(100µL per well, 2mg/mL diluted 1:1000 in PBS, Cayman Chemicals, 4oC, 8 hours).   The 
plates were then blocked (1% skimmed milk powder, 0.1% BSA in PBS, 37oC, 16 hours).   
The wells were then washed twice with wash buffer (200µL per well).   A series of sPLA2 
standards were prepared in the range 0-200ng/mL in PBS/0.1% BSA.   The samples were also 
prepared in a series of dilutions from 1/5 to 1/50 in PBS.   The standards and samples were 
added (100µL per well) and were incubated at 37oC for 2 hours.   The wells were then washed 
twice with wash buffer (200µL per well).   Conjugate binding was performed by adding 4A1-
AP (100µL of 0.1% conjugate antibody in 0.1% BSA/PBS).   The plates were incubated 
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(37oC, 60 minutes).   The plates were washed three times with wash buffer and three times 
with carbonate buffer (200µL per well).   p-Nitrophenyl Phosphate (pNPP) (100µL of 15mg 
pNPP in 15mL carbonate buffer) was added and incubated at room temperature for 10 
minutes.   The absorbance of the plates were then read at 405 nm. 
 
PLA2 Western Blotting: 
16% polyacrylamide gels (Invitrogen) were used in this section, and were run according to 
manufacturer’s instructions under non-reducing conditions.   Lanes contained 30µg of total 
protein.  Multimark Multi Coloured Standard (Invitrogen), (5µL) were used for size 
estimation.    
 
The transfer apparatus used was the X-cell-II Blot Module, (Invitrogen).   The transfer was 
completed at 30volts for 1½ hours (12mM Tris, 96mM glycine, 15% methanol).   The 
membrane was then washed with Tris buffered saline (TBS) and carefully dried.   The 
membrane was then blocked (50mL 5% skim milk powder in TBS) overnight at 4oC.   The gel 
was stained with Coomassie R-250. 
 
The blocked membrane was washed in Tris buffered saline-Tween-20 (TBST) (50mL), and 
then incubated in the primary antibody (10mL of 9C1 antibody (5µL) in 1%BSA, 1% skim 
milk powder in TBS) for 1 hour.   The antibody solution was then removed and the membrane 
washed three times with TBST (50mL).   The membrane was incubated in the secondary 
antibody (3.5µL anti-mouse IgG-HRP in 1%BSA, 1% skim milk powder in TBS, 10 mL final 
volume).   The antibody solution was removed and the membrane washed in TBST (3x50mL, 
3x15 minutes) and TBS (50mL, 15 minutes).   Enhanced Chemiluminescence Reagents 
(Renaissance, NEN, Irvine, CA), luminol (700µL) and oxidiser (700µL) were mixed and 
placed on the membrane for 1 minute.   The membrane was blotted dry and covered with 
plastic wrap.   The membrane was exposed to film (Hyperfilm-ECL, Amersham, Little 
Chalfont, Buckinghamshire, UK) for varying time periods (1-60 minutes). 
 
Serum Amyloid A ELISA Assay (TriDelta Phase™ range SAA kit): 
The SAA ELISA (TriDelta, Greystokes, Ireland) assay was performed according to 
manufacturer’s instructions.   Samples of plasma were diluted 1:500, 1:1000 or 1:5000 in 
diluent.   Biotinylated anti-SAA (1:100 in diluent) was applied to wells containing SAA 
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antibody (50µL per well).   Samples and standards then added (50µL per well in duplicate) 
and incubated (60 minutes, 37oC).   The wells were then washed four times with wash buffer.   
Plates were read at 450nm. 
 
Determination of plasma lactate, C-reactive protein and the APACHE-II score. 
Acknowledgement must go to the laboratory staff at Pathcare Pathology, Geelong for the 
analysis of plasma C-reactive protein and lactate.   Acknowledgement must also go to the 
staff of the Intensive Care Unit, Geelong Hospital for the APACHE-II scoring of patients. 
 
Cyclophilin B Western blotting: 
SDS PAGE gels (8-16% iGEL, TrisGlycine, Gradipore) were run according to manufacturers 
instructions, under reducing conditions.   Sample lanes contained 30µg of total protein.   
Prestained protein molecular weight markers (MBI Fermentas, St. Leon Rot, Germany) were 
included for size comparison.   The positive and internal control was a whole cell lysate 
(15µL) from Jurkat cells.   Acknowledgement must go to Caryll Waugh, Douglas Hocking 
Research Institute, for the culture of Jurkat cells.   The same cell lysate was used in all 
Western analyses.   The Jurkat cell pellet (1× 106 cells) was collected (10 minutes, 4oC, 
9000g).   The supernatent (cell culture medium) was removed, and stored (-80oC) for the 
positive and internal control in the Western analyses of plasma samples.   SDS-PAGE sample 
buffer (100µL, containing 0.05M DTT) was added to cell pellet.   The solution was 
thoroughly mixed and incubated (room temperature, one hour).   The solution was then boiled 
(100oC, 5 minutes).   If the Jurkat cell lysate sample was stored, fresh DTT (10% v/v, 0.5M) 
was added and the samples re-boiled before applying to a gel. 
 
Proteins were transferred from SDS-PAGE to PVDF (Amersham) using the CAPS buffer 
system (15% methanol, 0.01% SDS, 10mM CAPS) for 45 minutes at 180 mA.   Membranes 
were blocked (5% skim milk powder in TBS-T) overnight at 4oC.   The primary antibody 
(rabbit polyclonal anti-cyclophilin B, Abcam Ltd.) was applied (0.025µg/mL in TBS-T, 5% 
skim milk powder) for one hour, room temperature with gentle agitation.   The membrane was 
washed extensively (TBS-T).   The secondary antibody (goat anti-rabbit IgG conjugated to 
HRP, Abcam Ltd.) was applied (diluted 1:50 000 in TBS-T, 5% skim milk powder) for one 
hour at room temperature.   The membrane was washed extensively (TBS-T).   The signal was 
detected with chemiluminescence (ECL plus kit, Amersham), according to manufacturer’s 
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instructions.   Images were recorded and image analysis was performed using Kodak Digital 
Science 1D, version 3.0.0. 
 
Membranes were stripped (50oC, 30 minutes) with stripping buffer (2% SDS, 62.5mM Tris-
HCl, pH 6.8, 100mM β-mercaptoethanol), according to the method of Kaufman, Ewing & 
Shaper (1987).   Following stripping membranes were washed extensively (TBS-T), dried and 
stored at 4oC until re-probing. 
 
ALKALINE UREA GELS:  
 
Gels for mammalian phospholipases A2: 
The method used with these gels is a modification of Ahmad, Lawrence and Moores (1994).   
The resolving gel contained acrylamide (12.5%), bis-acrylamide (0.5%), urea (8M) and 
ethanolamine (2%) in ultrapure water.   The gels were polymerised by the addition of 
ammonium persulphate (0.005%) and TEMED (0.1%) under an iso-butanol overlay.   The 
gels were cast in mini gel format.   The surface of the resolving gel was rinsed thoroughly 
with water and then stacking gel solution.   The stacking gel contained acrylamide (7%), bis-
acrylamide (0.3%), Tris (0.01M, pH 6.8) and urea (8M) in ultrapure water.   The gels were 
polymerised by the addition of ammonium persulphate (0.05%) and TEMED (0.2%).   The 
running buffer was dilute ethanolamine (2% in ultrapure water).   The gels were pre-run at 
200V for two hours to remove free radicals and prevent artifactual protein bands, after which 
the buffer was changed.   Wells were rinsed with running buffer before the application of 
samples to remove the products of secondary polymerisation.   Samples were applied to the 
wells in sucrose (50%) or glycerol (50%) containing bromophenol blue as a tracking dye.   
Typical lanes contained 4µg (purified proteins) to 20µg (crude venom) of total protein.   Gels 
were run at 200V in an ice bath until the tracking dye had migrated at least 7cm.   The gels 
were stained with the Neuhoff stain/Colloidal Coomassie (Neuhoff et al, 1988).   Crude 
venom samples were obtained from Sigma. 
 
Blotting/ electrotransfer of proteins from alkaline urea gels to PVDF membrane: 
The PVDF membrane (PALL BioTrace ™ PVDF (Pall, Ann Arbor, MI) or BioRad 
SequiBLOT) was thoroughly wet with methanol before use but was not equilibrated in 
transfer buffer.   Proteins were transferred to PVDF membrane from alkaline urea gels with 
 25
Methods 
the CAPS transfer buffer (10mM CAPS, pH 11.0 with 20M NaOH, 0.01% SDS, 10-15% 
methanol) or the Towbin buffer (25mM Tris, 192mM glycine, 20% methanol, Towbin, 
Staehelin & Gordon, 1970).   CAPS transfer buffer is recommended for basic proteins 
(Szewczyk & Kozloff, 1985).   The transfer was performed at 100-180mA for 45 minutes 
(CAPS) or 150mA for 60 minutes (Towbin) in a stirred blotting apparatus (Mini Trans Blot, 
BioRad).   After the transfer was complete the gel was stained in the Neuhoff stain (to check 
transfer efficiency) and the membrane was washed in ultrapure water (5 minutes).   The 
membrane was then stained quickly (10 seconds) in Coomassie R-250 stain (0.1% w/v 
Coomassie R-250, 40 % v/v methanol in deionised water) before rinsing the membrane with 
methanol.   If required the staining/methanol rinse was repeated until an appropriate level of 
differential staining was achieved.   Both the gel and the membrane were destained in 
methanol solution (30% v/v methanol in ultrapure water). 
 
Transfer of proteins of interest to SDS-PAGE: 
Protein bands of interest from alkaline urea gels were excised with a clean scalpel.   Bands 
were more easily handled if frozen before transfer to SDS-PAGE.   Gel pieces were placed in 
wells of SDS-PAGE or Tricine gels and embedded in molten agarose (0.5% agarose, trace 
bromophenol blue in appropriate running buffer), or reduced and then applied to the gels.   
Gels were run according to the method of Laemmli (1970) for SDS-PAGE or Schagger & von 
Jagow (1987) for Tricine gels.  
 
 Reducing method “A”: Gel pieces were placed in fresh microcentrifuge tubes 
containing molten agarose (100µL, 0.5% agarose, trace bromophenol blue in SDS-PAGE 
running buffer) containing DTT (1 part 0.5M DTT to 9 parts agarose).   Tubes were then 
heated (100oC, 10 minutes).   Gel pieces and the agarose were then loaded into wells of the 
SDS gels. 
 
Reducing method “B”: According to the method of Davie, 1982.   Briefly, gel pieces 
were incubated (room temperature, 30 minutes) in equilibration buffer (10% glycerol, 5% β 
mercaptoethanol, 2.3% SDS, 62.5mM Tris-HCL pH 6.8).   The gel pieces were then placed in 
the wells of the SDS gel and embedded in agarose (0.5%, agarose (Davie, 1982 reported the 
use of 1% agarose) trace bromophenol blue in SDS running buffer). 
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Phospholipase A2 enzyme activity assay of gel pieces: 
The gel was sliced into 1mm slices with a clean scalpel.   Each piece was quickly transferred 
to a microcentrifuge tube containing ethanolamine solution (100µL of 10mM ethanolamine in 
ultrapure water), or Tris buffer (100µL, 50mM pH 6.8) or PBS (100µL) or ultrapure water 
(100µL).   Each piece was macerated with clean forceps.   Aliquots (25µL) were removed 
from each tube to analyse phospholipase A2 activity. 
 
PHOSPHOLIPASE A2 ASSAYS: 
 
Phospholipase A2 enzyme activity assay: 
This method follows that published by Green and colleagues (1991). 
Phosphatidylethanolamine L-1-palmitoyl, 2-arachidonyl, [arachidonyl-1-14C] (NEN), L-3-
Phosphatidyethanolamine 1-acyl-2-[1-14C arachidonyl] (specific activity 54 mCi/mmol) 
(Amersham) or Phosphatidylcholine 1-stearoyl-2-[1-14C arachidonyl] (specific activity 
55mCi/mmol) (Amersham) (5.5nmol) were dried under a stream of cold air or nitrogen.   The 
phospholipid was taken up in deoxycholate (2% w/v in ultrapure water).   Assay buffer (25µL 
per sample, 100mM Tris, pH 8.0, 300mM NaCl, 10mM CaCl2) was then added and this 
mixture pre-warmed (37oC, 10 minutes).   The sample solutions were also pre-warmed (37oC, 
5 minutes).   The substrate was then added to the samples (25µL per sample) and incubated 
(37oC, 30 minutes).   The reaction was terminated with EDTA (10µL per sample, 100mM).   
The reaction solutions (each 30µL) were spotted onto TLC plates and dried with warm air.   
The TLC plates were run in a chloroform/methanol/glacial acetic acid system (90:10:1 v/v/v).   
Autoradiography was used to establish the position of the product (fatty acid) and then un-
reacted phospholipid.   These regions were scraped from the plates and analysed by 
scintillation counting (United technologies, Packard 2000CA Tricarb Liquid Scintillation 
Analyzer). 
 
When the pH profile was being examined the buffers used were: Tris (100mM) for pH 7-9, 
Glycine (100mM) for pH 9.5-10 and sodium acetate (100mM) for pH 6-6.5 to ensure 
adequate buffering capacity. 
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Samples were diluted as required to maintain the hydrolysis to less than 30%, which 
represents the upper limit of linearity for this assay (Seilhamer et al, 1989).   Where the 
phospholipase activity of samples with very different quantities of total protein were 
compared, results were expressed as the specific activity. 
 
The addition of cyclosporin A to the assay: 
Cyclosporin A (Sigma) was dissolved in ethanol (1mg/mL) to form the stock solution.   The 
stock solution was diluted in phospholipase A2 assay buffer (containing the phospholipid) to 
the working concentration (2µg/mL).   The cyclosporin A/assay buffer solution (25µL) was 
then added to the enzyme source (25µL). 
 
Phospholipase A2 and purified protein sources: 
Pancreatic PLA2: Porcine, Sigma. 
Bee venom PLA2: Sapphire Biosciences (Crow’s Nest, Sydney, Australia). 
Haemoglobin: Human, Sigma. 
Cytochrome C: Bovine heart, >99% pure, Sigma. 
Bovine serum albumin: Fraction V, >96% pure, Sigma. 
 
BOWEL TISSUE ANALYSIS: 
 
Ethics approval for use of human bowel and plasma samples: 
All experimental procedures were approved by the Deakin University (Ethics approval 
number EC 116-2001) and Geelong Hospital (Ethics approval numbers 01/31 and 01/44) 
ethics committees.   Tissue was obtained from patients undergoing surgical removal of 
infarcted bowel tissue or removal of normal bowel tissue from patients undergoing right 
hemicolectomy.   Acknowledgement must go to Geelong Hospital theatre staff for their help 
in this regard. 
 
Gross tissue damage rating system: 
Damage to bowel tissue was assessed according to the scale proposed by Sun and colleagues 
(1997). 
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Table 2.1: Gross tissue rating system of Sun and colleagues (1997): 
Rating Features 
1 Mild damage.   Slight reddish discoloration. 
2 Moderate damage.   Red discoloration often with haemorrhage. 
3 Severe damage.   Grossly necrotic, blackish red, friable and lustreless. 
 
 
ONE AND TWO DIMENSIONAL GEL ELECTROPHORESIS: 
 
NuPAGE: 
Bis-Tris gels (10%) were run with the MES buffer system according to manufacturer’s 
instructions.   SeeBlue®Plus2 (Invitrogen) prestained molecular weight markers and 
Mark12™ wide range protein standards (Invitrogen) were used in these gels for protein size 
estimation.   Blotting from these gels was performed using the Mini Trans-Blot® apparatus 
(BioRad) with a CAPS transfer buffer (10mM CAPS, pH 11, 15% methanol) at 180mA for 45 
minutes.   The PVDF membrane (ProBlot™, Applied Biosystems) was wet in methanol and 
equilibrated in transfer buffer.   The gel was rinsed briefly (Milli-Q) and also equilibrated in 
transfer buffer.   The gel was stained (0.25% Coomassie brilliant blue R-250 in 45% 
methanol, 10% acetic acid).   The membrane was stained quickly (60 seconds, 0.1% 
Coomassie brilliant blue R-250 in 40% methanol, 1% aldehyde free acetic acid) before 
quickly rinsing with methanol and soaking in ultrapure water. 
 
Two-Dimensional Electrophoresis of heparin fraction samples: 
Samples were desalted and concentrated by methanol or TCA precipitation.   Samples 
(100µL) were mixed with cold methanol (-20oC, 900µL) and stored overnight (-20oC).   
Alternatively samples (100µL) were mixed with TCA (10mg) and left on ice (30 minutes).   
The samples were then centrifuged (10 minutes, 4oC, 18000g).   The pellets were rinsed with 
cold methanol or acetone (TCA precipitation) before re-centrifugation and were then air dried 
(room temperature, 30 minutes).   1st dimension rehydration buffer containing DTT (2.9mg 
per mL) and biolytes (0.5%) was added (130µL per sample) and samples were vortexed 
repeatedly and quickly centrifuged before placing in contact with IPG strips (pH 3-10, 7cm 
strips).   The proteins were focussed using a ramping current: 
 
 29
Methods 
Stage Voltage (V) Time (hours) 
1 50 12 
2 500 1 
3 1000 1 
4 8000 3.5-8 
 TOTAL 18 500-26 000 volts 
 
The IPG strips were then equilibrated firstly in DTT buffer (15 minutes) and then in IAA 
buffer (15 minutes).   The strips were then loaded onto NuPAGE® gels (4-12% BisTris, 
1.0mm, MES running buffer) or Tris Glycine gels (4-20% Zoom™, SDS running buffer, 
Invitrogen) along with Mark 12 ™Standards (strip loaded) and embedded in agarose (0.5% 
agarose, trace bromophenol blue, in MES buffer).   The gels were run according to 
manufacturer’s instructions.   The gels were then stained with either Coomassie R-250 (0.25% 
CBB-R250 in 45% methanol, 10% acetic acid) or silver stained (PlusOne, Amersham 
protocol).    
 
Proteomics: 
Samples of human plasma were thawed and added to chilled methanol (-80oC, 1.0mL).   
Chilled methanol was added to a final volume of 2mL for each sample.   Samples were 
thoroughly vortexed and placed in a freezer overnight (-80oC).   Samples were centrifuged in 
a pre-cooled centrifuge (12 000g, -4oC, 60 minutes).   The methanol supernatent was removed 
and discarded.   The pellet was resuspended in solubilisation solution containing 1% carrier 
ampholytes (pH 3-10), (230µL solubilisation solution per 100µL original volume of plasma).   
The mixture was repeatedly vortexed and sonicated until the pellet had been dissolved.   If 
required the samples were also subjected to bead beating (4 X 15 seconds, Bio 101 Fast 
Protein™ blue tubes).   Immobilised pH gradient strips (IPG), (pH 7-10, 7cm, BioRad) were 
re-hydrated overnight in solubilisation solution containing 1% carrier ampholytes (pH 3-10, 
200µL per strip).   Samples were centrifuged quickly before cup loading onto the IPG strips.   
The IPG strips were subjected to isoelectric focussing with a ramping current: 
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Stage Votage (kV) Time (hours) 
1 0.1 5 
2 0.3 3-7 
3 0.6 2-3 
4 1 1-3 
5 2 1-3 
6 3-3.5 9-12 
 
At the completion of isoelectric focussing the IPG strips were equilibrated in equilibration 
solution (20 minutes with agitation).   The IPG strips were then embedded in 0.5% agarose in 
cathode buffer containing bromophenol blue (0.001%) on the top of either pre-cast Criterion 
gels (4-20%, Tris-HCl) or freshly prepared large format gradient gels (18x20cmx1.5mm, 8-
18% acrylamide).   The second dimension was performed using the following programme for 
Criterion gels: 
 
Stage Current (mA) Time (hours) 
1 3 per gel 0.5 
2 30 per gel 2 
 
The second dimension was performed using the following programme for large format gels: 
Stage Current (mA) Time (hours) 
1 3 per gel 2 
2 50 overnight 
 
The programme was continued until the dye front had begun to run off the gel.   Gels were 
then fixed for 30 minutes (10% methanol, 7% glacial acetic acid in ultrapure water).   Gels 
were then stained with Sypro Ruby Protein gel Stain (BioRad) for the required length of time.   
Gels were destained (10% methanol, 7% glacial acetic acid in ultrapure water) for 30 minutes.   
Gel images were captured with BioRad Molecular Imager® FX and BioRad Quantity One 
version 4.1.1 software.   Image analysis was performed using Melanie version 3.   Gels 
previously stained with Sypro Ruby were re-stained with colloidal Coomassie G-250 
overnight.   Coomassie stained gels were scanned with the Molecular Dynamics personal 
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densitometer SI and Corel Photo Paint version 8.   Protein differences were assessed using 
Melanie version 3. 
 
PROTEIN IDENTIFICATION: 
 
Montage™ In-Gel Digest96 Kit (Millipore): 
Gel spots were cut and placed in the MultiScreen plate (Millipore, Bedford, MA).   Destaining 
solution (100µL) was added to each well and incubated (room temperature, 20 minutes).   The 
solution was removed under vacuum.   This process was repeated twice.   Acetonitrile 
(100µL) was then added to each well and incubated (room temperature, 10 minutes).   The 
solvent was then removed under vacuum.    The samples were reduced with DTT (100µL, 
10mM in 0.2M ammonium bicarbonate) and incubated (room temperature for 60 minutes or 
37oC for 30 minutes).   The solution was removed under vacuum.   The gel pieces were 
washed using three changes of ammonium bicarbonate (100µL, 0.2M) followed by 
acetonitrile (100µL) with removal of solutions under vacuum.   The proteins were then 
alkylated (100µL of 50mM IAA in 0.2M ammonium bicarbonate) for 20 minutes at room 
temperature.   The solution was then removed under vacuum. The gel pieces were washed 
using three changes of ammonium bicarbonate (100µL of 0.2M) followed by acetonitrile 
(100µL) with removal of solutions under vacuum.   Trypsin solution (50µL diluted to 
approximately 1/10 the mass of protein in the spot in 0.1M ammonium bicarbonate) was then 
added to each well and the plate was incubated overnight (37oC).   The peptides were then 
extracted by adding extraction solution (50µL per well) and incubating (room temperature, 30 
minutes) before collecting the solution in a microtitre plate.   Extra extraction solution (50µL) 
was added to each well, incubated (room temperature, 30 minutes) and then collected.   This 
process was repeated.   The peptide solutions were then concentrated (SpeedVac, Savant).    
 
Nano MS/MS: 
Samples for nano MS/MS were run in 4-12% TrisGly gels (Invitrogen), according to 
manufacturer’s instructions.   Proteins were thoroughly reduced with DTT containing sample 
buffer and heating (100oC, 7 minutes).   After heating the samples were allowed to cool 
before the addition of acrylamide (final concentration of 1%) to form cysteine adducts to 
prevent reformation of disulphide bonds.   Potassium ferricyanide (30mM) and sodium 
thiosulphate (100mM) were mixed in equal proportions.   Excised bands from Tris-Glycine 
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gels were incubated in the ferricyanide/thiosulphate solution (50µL per tube) until the brown 
colour of the silver stain had been removed.   The solution was removed and the gel pieces 
were washed with two changes of water.   The gel pieces were then incubated in ammonium 
hydrogen carbonate (100µL, 50mM, room temperature, 20 minutes).   The gel bands were cut 
into small pieces, washed with water and transferred to new tubes.   Acetonitrile was used to 
rinse and shrink the gel pieces (3x100µL, 1x500µL).   The gel pieces were dried (SpeedVac, 
Savant).   Trypsin (20µL, 0.1µg/mL in 1mM HCl, Promega, Madison, WI) was added, 
followed by digestion buffer (100µL, 50mM NH4CO3, 1mM CaCl2, pH 7.8), and incubated 
overnight at 37oC.  
 
Extraction of peptides : 
Ammonium bicarbonate (100-150µL, 25mM) was added to each tube, centrifuged and then 
incubated, (37oC, with sonication).   Acetonitrile (150µL) was added to each tube, vortexed 
and incubated.   Formic acid (50µL, 5%) was added, vortexed and incubated. Acetonitrile 
(150µL) was added to each tube, vortexed and incubated.   The pooled extracts were then 
dried to approximately 10µL (SpeedVac, Savant). 
 
The peptide solutions were desalted using miniature C18 columns constructed in gel loading 
pipette tips (Eppendorf).   The columns were prepared using C18 resin (Vydac) in 
acetonitrile/water.   The columns were rinsed extensively with methanol, then formic acid 
(5%).   The peptides were bound to the column, and then washed with formic acid (5%).   The 
peptides were eluted into the sample applicator with methanol. 
 
The mass spectrometer used was the API Q-STAR Pulsar i, LC/MS/MS (Applied 
Biosystems).   MS/MS spectra were submitted to Mascot and SwissProt.   Acknowledgment 
must go to Dr. Peter Hoffman (St. Vincent’s Medical Research Institute) for assistance with 
sample preparation and mass spectrometry analysis. 
 
MALDI-TOF MS: 
Protein spots of interest were excised from the gels and placed in microtitre plates with care 
taken to avoid contamination between other spots and outside sources.   Wash buffer (120µL 
per gel piece, 50% acetonitrile, 25mM NH4CO3, pH 7.8) was added to each well.   The plate 
was incubated with shaking (37oC, 10 minutes).   The wash solution was removed and 
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discarded.   This washing process was repeated three times, after which there was no colour 
remaining in the gel pieces.   The gel pieces were then dried under vacuum for 15 minutes. 
 
Sequencing grade trypsin (8µL, 15ng/mL porcine trypsin, (Promega) in NH4CO3, pH 7.8) was 
added to each gel piece.   The plate was then sealed and incubated overnight with agitation 
(37oC).   The plate was spun (SpeedVac Plus, Savant, 5 minutes).   Extract solution (8µL, 
50% acetonitrile, 1% TFA) was added to each well and sonicated for 20 minutes. 
 
An aliquot of each sample (1.5µL) was spotted onto a MALDI plate.   Matrix (1.0µL, α-
cyano-4-hydroxycinnamic acid, 8mg/mL in 50 % acetonitrile, 1% TFA) was added to each 
sample spot on the MALDI plate.   Samples were air dried and analysed.   Acknowledgment 
must go to Dr. Stewart Cordwell (Australian Proteome Analysis Facility) for analysis of 
samples by MALDI-TOF. 
 
Bioinformatics: 
The protein sequences of the ‘theoretical proteins’ identified by MALDI were analysed using 
software from the National Centre for Biotechnology Information (BLASTN, BLASTP) and 
the EXPASy Molecular Biology Server of the Swiss Institute of Bioinformatics. 
 
Nano LC-MS/MS: 
Protein bands of interest were excised from BisTris (Invitrogen) and TrisGly (Gradipore) gels 
with appropriate positive (protein markers) and negative (gel pieces from no protein regions) 
controls.   The protein bands were destained and digested with trypsin.   The proteins were 
analysed by nano LC-MS/MS.   Acknowledgement must go to Dr. Mark Raftery, Biomedical 
Mass Spectrometry Facility, University of New South Wales for the protein digestion and 
mass spectrometry analysis. 
 
Amino terminal amino acid sequencing; 
Rotofor fractions were applied to a ProSorb sample preparation cartridge (Applied 
Biosystems, Foster City).   The cartridge membrane was washed several times with TFA 
solution (0.1%), changing the filtration absorbance filter after each 750µL load.   
Alternatively the samples were applied via PVDF membrane: 
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Protein bands of interest were excised from PVDF membranes and subjected to automated 
amino acid sequencing (Edman degradation) using the Procise automated sequentor (Applied 
Biosystems, Foster City, California).   The phenylthiodantoin (PTH) derivatised amino acids 
were analysed to determine the amino acid sequence.   The Procise PTH system is comprised 
of the Micro-gradient delivery system (model 140C), a UV detector (model 785) and data 
analysis software (model 610A).   Acknowledgement must go to Gary Beddome and Brian 
Shiell (Australian Animal Health Laboratories, CSIRO) for amino acid sequencing. 
 
PROTEIN PURIFICATION: 
 
Ammonium sulphate precipitation: 
The appropriate amount of ammonium sulphate to reach saturations of 15 to 80% (ACS 
reagent grade) was added to samples and agitated by rotating (5 minutes).   The samples were 
then centrifuged (7500g, 4oC, 10 minutes) and supernatent removed.   The precipitate was 
resuspended in buffer or water to the original sample volume.   The supernatent was diluted as 
required to attain original sample volume.   The supernatent and precipitate at each saturation 
level were analysed for total protein (Bradford assay) and phospholipase A2 activity 
(phosphatidylcholine hydrolysis).  
 
Methanol precipitation: 
Methanol (-80oC) was added to samples to equivalent or greater volume and mixed 
thoroughly.   Samples were then stored in freezer overnight (-80oC).   Samples were then 
centrifuged (12000g, 0oC, 60 minutes).   The extended storage followed by extended 
centrifugation at low temperature was essential for pellet formation.   The supernatent was 
removed and discarded.   The pellet was then air dried for a maximum of 5 minutes.   The 
pellet was resuspended in appropriate buffer or electrophoresis sample buffer. 
 
Homogenising bowel tissue: 
The mesentery was removed from bowel tissue.   Bowel tissue was roughly chopped with a 
scalpel.   Tissue was weighed and placed in 5vol/g buffer (10mM Tris, pH 7.4).   Homogenate 
was clarified by centrifugation (2000g, 4oC, 10 minutes ). 
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Heparin Sepharose Affinity Chromatography; 
Heparin Sepharose columns (Amersham Pharmacia Biotech, HiTrap columns) were 
equilibrated with binding buffer (10 volumes, 10mM Tris-HCl, pH 7.4, flow rate of 
approximately 1mL/minute).   Samples were centrifuged (7500g, 5 minutes) before being 
loaded onto pre-equilibrated column.   Non-bound proteins were eluted with buffer (10 to 25 
column volumes, 10mM Tris, pH 7.4) until eluent was clear and contained no protein (by 
detection of absorbance at 280nm).   The bound fractions were then eluted with increasing 
concentrations of NaCl (0-5M NaCl, 10mM Tris, pH 7.4) in stepwise fashion either using a 
single concentrated salt solution or a series of increasingly concentrated salt solutions.   
Fractions were collected at regular time intervals (typically 30 seconds).   Fractions were 
analysed for total protein, phospholipase A2 activity and protein sizes (Tricine PAGE or SDS-
PAGE).  
 
Preparative Isoelectric focusing using the BioRad Rotofor®: 
Heparin column fractions with PLA2 activity eluted under conditions of 0.5M NaCl were 
pooled.   Glycerol and n-octyl glucoside (NOGS) were added to the sample to final 
concentrations of 1% and 0.5% respectively.   Biolytes (pH 3-10, BioRad, 1.5mL) were added 
to the sample (total volume 40 mL).   The Rotofor was pre-run with ultrapure water (15W 
constant power, 5 minutes) to clear any contaminants from the apparatus.   The Rotofor was 
set to run at constant power (15watts, 4oC).   The current was monitored throughout the run 
and the experiment was stopped when the current had reached a plateau (approximately 3.5 
hours).   The fractions were then harvested and analysed for PLA2 activity.   The pH of each 
fraction was determined.   The fractions were also run on a gel (NuPAGE Bis-Tris 4-12% gel 
with Mark 12™ protein standards).   After completion of the gel run the gel was fixed (30% 
methanol, 10% TCA) with sulfosalicylic acid (3.5%) for 1 hour to remove ampholytes.   The 
gel was fixed for a further 2 hours (30% methanol, 12% TCA) to remove excess sulfosalicylic 
acid.   These gels were then silver stained using the PlusOne protocol. 
 
Active Rotofor fractions of pH 8.98 to 9.8 were pooled and NaCl was added to a 
concentration of 1M to electrostatically remove ampholytes.   This solution was mixed and 
incubated (45 minutes, 4oC).   This solution was dialysed against 0.5X PBS (24 hours, 4oC) 
using Slide-A-Lyzer® cassettes (Pierce) with a 3,500MWCO. 
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Electroelution: 
The Mini Whole Gel Eluter apparatus (BioRad) was used to electroelute protein from SDS 
gels.   The gels were run under non-reducing conditions.   The gel was equilibrated in elution 
buffer (20mM CAPS pH 11, 15 minutes with three changes of buffer).   The elution was 
performed (20 minutes, 100mA), and at completion the electrodes were briefly reversed.   The 
fractions were collected and analysed for PLA2 activity.   Pre-stained molecular weight 
standards (See Blue®, Invitrogen) were used to construct a standard curve of mobility and 
protein size.   
 
Vivaspin concentration and desalting: 
Vivaspin centrifugal filter devices (PES membrane, 5 000 MWCO, 500µL capacity, 
Sartorius) were used to concentrate protein samples and exchange buffers.   Samples were 
applied to the upper chamber and centrifuged (10 000g, 10 minutes, 4oC).   PBS (500µL) was 
added and centrifuged (10 000g, 10 minutes, 4oC).   The washing process was then repeated.   
If ampholytes needed to be removed NaCl was added to the sample to a final concentration of 
1M to electrostatically strip protein bound ampholytes (BioRad Rotofor application guide).  
 
TOTAL PROTEIN ASSAYS: 
 
BioRad DC Protein High Range Assay: 
Protein assays were performed according to manufacturer’s instructions.   Briefly, a standard 
curve was constructed using BSA diluted in PBS in the range 0-2mg/mL.   Samples were 
diluted 1:50, 1:100, 1:200 or 1:300 in PBS.   Samples and standards (5µL per well) were 
assayed in triplicate.   The absorbance was read at 750nm. 
 
Bradford Total Protein Assay: 
The protein assay of Bradford (1976) was used routinely.   Standard curve composed of BSA 
in PBS in the range 1-10 µg per 100µL.   Samples diluted in PBS until the absorbance of the 
solution is less than the absorbance of the highest standard.   Protein reagent was added to 
samples and standard in the ratio of 10 parts reagent to 1 part sample or standard.   The 
solutions were mixed thoroughly and the absorbance read at 595nm within 60 minutes of 
addition of protein reagent. 
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Pierce BCA Protein Assay: 
The BCA Protein Assay was used for samples containing carrier ampholytes.   The Pierce 
BCA Protein Assay Kit standard protocol was followed using a sample to working reagent 
ratio of 1:20.   A standard curve was constructed using BSA in the range 0-2000µg/mL.   
Samples were prepared using a method to remove carrier ampholytes (Brown, Jarvis and 
Hyland, 1989).   Briefly, samples containing carrier ampholytes (100µL) were diluted in 
ultrapure water (900µL).   Deoxycholate solution (100µL, 0.15%) was added and solutions 
were incubated (room temperature, 10 minutes).   TCA solution was then added (100µL of 
72% solution) and samples vortexed, then centrifuged (2000g, room temperature, 15 
minutes).   Supernatent was discarded and pellet immediately resuspended in detergent 
solution (5% SDS in 0.1M NaOH).   The BCA working reagent was immediately added 
(2mL).   Absorbance was read at 562nm.  
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RECIPES: 
 
Bradford Protein reagent: 
Method according to Bradford, 1976. 
Coomassie Brilliant Blue G-250  final concentration 0.01% 
Ethanol     final concentration 4.7%   
Phosphoric acid   final concentration 8.5%  
In ultrapure water. 
 
Colloidal Coomassie/Neuhoff reagent: 
Ammonium sulphate (17% w/v) 
Phosphoric acid (4.2% v/v) 
Methanol (34% v/v) 
Coomassie G-250 (0.1% w/v)  
in ultrapure water. 
 
Solubilisation solution: 
5M urea 
2M thiourea 
2mM tributylphosphine 
2% CHAPS 
2% sulfobetaine 3-10 
0.2% carrier ampholyes 
40mM Tris 
0.002% bromophenol blue 
1% ASB14 (BioRad) 
20mM DTT 
0.2% carrier ampholytes pH 3-10 
 
Proteomics: Equilibration solution: 
2.5% acrylamide 
5mM tributylphosphine 
20% glycerol 
6M urea 
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2% SDS 
0.375M Tris-HCl pH 8.8 
 
Tris Glycine SDS running buffer: 
29g Tris base 
144g Glycine 
10g SDS 
to 1L ultrapure water. 
 
Tris Glycine sample buffer: 
2.5mL 0.5M Tris HCl pH 6.8 
2mL glycerol 
4mL 10% SDS 
0.5mL 0.1% bromophenol blue 
ultrapure water to 10mL 
 
Two-dimensional electrophoresis equilibration buffer: 
50mM Tris pH 8.8 
6M urea 
30% glycerol 
2% SDS 
bromophenol blue 
2mL per strip, containing either 10mg/mL DTT or 25mg/mL IAA. 
 
ELISA wash buffer: 
Amounts for 1Litre of buffer: 
NaCl (8g) 
KCl (0.2g) 
NaH2PO4.H2O (0.2g) 
Na2HPO4 (1.96g) 
Tween 20 (0.5mL) 
BSA (10g) added directly before use 
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Carbonate buffer: 
Amount for 500mL, pH 9.8. 
Na2CO3 (1.1g) 
NaHCO3 (1.5g) 
MgCl2 (0.2g) 
 
Phosphate buffered saline: 
Amounts for 1L, pH 7.4. 
Na2HPO4 (1.44g) 
NaH2PO4 (0.24g) 
NaCl (8g) 
KCl (0.2g) 
 
NuPAGE 4X LDS sample buffer: 
Glycerol 40% 
Tris base 6.82% w/v 
Tris HCl 6.66% w/v 
LDS 8% w/v 
EDTA 0.06% w/v 
Serva Blue G-250 0.075% solution 
Phenol red 0.025% solution 
In ultrapure water 
 
NuPAGE 20X MES running buffer: 
MES 1M 
Tris Base 1M 
SDS 69.3mM 
EDTA 20.5mM 
In ultrapure water. 
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Chapter 3: Plasma and Proteomics. 
 
Global techniques: 
Global techniques aim to detect all of the expression products (RNA or protein) in a 
particular sample in a non-targeted, single experiment.   Global analysis may be 
undertaken to identify drug targets, diagnostic markers, markers of infection, markers 
of developmental stages, or organism specific markers.    
 
Nucleic acid based examples of global analysis include differential display RT-PCR, 
serial analysis of gene expression (SAGE) and cDNA micro-arrays.   Protein based 
examples of global analysis include surface enhanced laser desorption ionisation 
(SELDI) protein chips, multi-dimensional HPLC, antibody arrays and two-
dimensional electrophoresis.   There are several advantages and disadvantages 
associated with either nucleic acid and protein based global techniques, as 
summarised in the table below. 
 
NUCLEIC ACID BASED GLOBAL TECHNIQUES: 
Table 3.1: The advantages and disadvantages of nucleic acid based global 
techniques: 
Advantages: Disadvantages: 
Less material required (~5X103cells) 
(Seliger & Kellner, 2002). 
No detection of isoforms is possible 
(Seliger & Kellner, 2002). 
Amplification steps are possible (Seliger 
& Kellner, 2002). 
Alternate gene splicing adds complexity 
(Banks et al, 2000, Wilkins et al, 1995). 
 Only potential functional state is 
indicated (Griffin & Aebersold, 2001). 
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PROTEIN BASED GLOBAL TECHNIQUES: 
Table 3.2: The advantages and disadvantages of protein based global techniques: 
Advantages: Disadvantages: 
Drug targets generally work on proteins 
(Banks et al, 2000). 
Diversity in protein size, pI and 
solubility. 
Post translational modifications can be 
investigated, these are not apparent from 
nucleic acid information (Krishna & 
Wold, 1993). 
Dynamic range varies over 6 orders of 
magnitude (Corthals & Nelson, 2001) 
May provide information about function 
(Griffin & Aebersold, 2001, Seliger & 
Kellner, 2002). 
More material is required (~5×106 cells) 
Abundance and sub-cellular location are 
identified (Griffin & Aebersold, 2001). 
No amplification step is available. 
 
Proteomics: 
Proteomics describes the study of the ‘entire protein complement of the genome’.   
Unlike the genome, the proteome is not a static entity but changes according to: 
 - tissue or cellular source or cell culture conditions, 
 - stage of development of the organism or cell, 
 - pathophysiological state. 
Proteomics is a relatively new field, but is becoming increasingly important to 
biologists with the completion of the Human Genome project and similar milestones 
involving other organisms.   It is believed that approximately one third of the gene 
sequences in genome databases encode for proteins of yet unknown function (Banks 
et al, 2000). 
 
It is proposed that the number of genes in the human genome is in the order of 20 000 
to 25 000 (Stein, 2004) and that at any one time, up to five thousand of these genes 
are being transcribed.   The number of genes provides an underestimate of the number 
of proteins due to: 
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- post translational modifications (Herbert & Righetti, 2000), of which 200 
have been described (Krishna & Wold, 1993), 
 - alternate gene splicing (Wilkins et al, 1995). 
Preliminary studies suggest that the number of protein forms per gene ranges from 
one to two in bacteria to three to six per gene in humans (Banks et al, 2000), resulting 
in up to one million proteins (Herbert & Righetti, 2000).   Another group has 
proposed that up to 10 protein variants exist per locus [Traini, Herbert, Wilkins & 
Williams, unpublished as cited by (Gabor Miklos & Maleszka, 2001)]. 
 
Proteomics involves: 
 - preparation of the sample to extract the maximum number of proteins in the
  maximum yield, 
 - separation of the proteins, or their peptides, 
 - visualisation and differential analysis,  
- identification of the proteins. 
Proteomics has traditionally been associated with two dimensional electrophoresis as 
the technique for separation.    
 
Two dimensional electrophoresis involves the separation of the proteins firstly on the 
basis of the isoelectric point (pI) and then on the basis of molecular weight. The first 
dimension of two dimensional electrophoresis involves isoelectric focusing (IEF) 
which separates proteins according to their isoelectric point.   In the past this step has 
been achieved using carrier ampholytes embedded in polyacrylamide filled tubes to 
create the pH gradient.   Immobilised pH gradient (IPG) strips have largely replaced 
carrier ampholyte based IEF, as they have several advantageous features.   IPG strips 
are composed of a thin layer of polyacrylamide on a supporting plastic film.   The pH 
gradient is covalently coupled to the acrylamide.   IPG strips can tolerate higher 
protein loads, have stable and precisely determined pH gradients and are not 
susceptible to distortion (which could occur with ampholyte based IEF gels).   IPG 
strips are also very accurate and commercially available which limits interlaboratory 
reproducibility problems.    
 
The second dimension involves polyacrylamide gel electrophoresis in the presence of 
sodium dodecyl sulphate (SDS), which separates the isoelectrically focused proteins 
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by molecular weight.   The gels used for the second dimension can be gradient gels or 
gels of a single percentage of acrylamide, depending on the application.   It has been 
reported that two dimensional gels are able to resolve 3000 proteins on a single gel 
(Wilkins et al, 1996).   Although there are several disadvantages of 2DE based 
proteomics it has remained the leading technique because of its ability to:  
a)  ‘visualise a very large number of proteins simultaneously’ (Haynes & 
Yates, 2000) and  
b)  be used in a ‘differential display format’ (Haynes & Yates, 2000).    
 
The deficiencies of two dimensional electrophoresis based Proteomics: 
It is accepted that two dimensional gels are deficient in the resolution of several 
classes of proteins including those with: 
- extreme pI (<4 and >10) (Gygi & Aebersold, 2000, Gygi, Rist & Aebersold, 
2000, Washburn, Wolters & Yates, 2000). 
- extreme molecular weight (Gygi & Aebersold, 2000, Gygi, Rist & 
Aebersold, 2000, Washburn, Wolters & Yates, 2000), for example proteins 
>100kDa are under-represented and those >150kDa are usually not separated 
in the 2nd dimension (Corthals et al, 1999), those <10kDa are unable to be 
detected (Seliger & Kellner, 2002). 
- low codon bias*/low abundance and therefore unable to be detected (Gygi & 
Aebersold, 2000, Simpson et al, 2000, Washburn, Wolters & Yates, 2000), 
- membrane associations (Gygi, Rist & Aebersold, 2000, Han et al, 2001, 
Simpson et al, 2000) 
- a high degree of hydrophobicity (Gygi, Rist & Aebersold, 2000, Han et al, 
2001, Simpson et al, 2000)  
                                                          
* Codon bias is the tendency for a given gene to preferentially use one of several potential 
codons to incorporate a specific amino acid into a protein (Liebler, 2002).   Highly expressed 
proteins have high codon bias value, conversely low abundance proteins have low codon bias 
values.   Low abundance is defined by a codon bias of <0.1. 
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Various modifications have been proposed to address the limitations of two 
dimensional gel based proteomics including:  
- pre-fractionation of sample by size, solubility or isoelectric point, 
- using a series of gels of restricted pH gradients (subproteomics), 
- improved solubilization and extraction procedures. 
 
Other approaches have sought alternatives for two dimensional electrophoretic gels in 
the separation step.   Technologies that have emerged involve the use of one or more 
of the following techniques: 
- multidimensional chromatography, or MudPit ,*
 - ion exchange chromatography, 
 - size exclusion chromatography, 
 - capillary electrophoresis,  
 - fragmentation of proteins into peptides before separation, 
 - the isotope coded affinity tag peptide labelling (ICAT) approach.   
 
Work has been completed to assess how much of a proteome is likely to be seen in 
2DE based proteomics, using yeast as a model.   Yeast is a relatively simple organism 
in terms of its genome and proteome given that it contains only 6 000 open reading 
frames and simplified post translational modifications (Liebler, 2002).   Yeast 
proteins vary over 5 orders of magnitude (Gygi et al, 2000), and an estimated 80% of 
the proteome is composed of low abundance proteins (Dr. Ben Herbert, personal 
communication).   Almost 90% of the yeast proteome can be solubilised with existing 
technology (Pedersen et al, 2003) but half of the proteins are too low in abundance to 
be detected (Griffin, Goodlet & Aebersold, 2001).   The analysis of low abundance 
yeast proteins can be improved with pre-fractionation (Gygi et al, 2000). 
                                                          
* The multidimensional protein identification technology or MudPIT approach involves the digestion of 
all of the proteins in a sample, and then separation of the resulting peptides by strong cation exchange 
chromatography and reverse phase chromatography.   The peptides are then submitted to tandem mass 
spectrometry and database searching (Link et al, 1999, Washburn, Wolters & Yates, 2001).   The 
advantage of this approach is that the peptides generated have more uniform characteristics than the 
proteins from which they were derived, in terms of size, pI and hydrophobicity (Washburn, Wolters & 
Yates, 2001). 
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When the maximum amount of whole cell lysate was run in a 2D gel the average spot 
detected represented 51 000 copies per cell (Gygi et al, 2000).   When the sample was 
pre-fractionated, proteins present at 1 000 copies per cell could be detected (Gygi et 
al, 2000).    
 
To allow the detection of low abundance proteins the relative concentrations must 
obviously be increased (Simpson et al, 2000).   Theoretically two approaches can be 
used: 
- increase the sample load (which can be impractical due to sample load 
  limitations of 2DE gels),  
- increase the concentration of the low abundance proteins (which alters the 
composition of the sample), 
- fractionate the sample and analyse each fraction separately (pre-fractionation 
or sub-proteomics). 
 
If the sample composition is altered to allow the detection of low abundance proteins 
the final sample will not  
1. reflect the proteome 
2. remain quantitative 
Sample alterations may involve: 
 - the removal of high abundance proteins such as albumin, 
 - pre fractionation.  
 
Proteomics in medicine: 
There is significant potential for proteomic research in the biomedical field.   
Proteomics can identify disease specific proteins which could then be used as 
diagnostic markers, markers for the monitoring of disease progression, therapy 
effectiveness, toxicity or drug targeting.   Proteomics has several advantages over 
genomic based research in the biomedical field.   For example: 
- examination of the genome cannot provide information on multi-gene 
processes such as aging, stress or many diseases, 
 - most drugs target proteins rather than genes, 
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- post translational modifications may be critically important in disease and 
these modifications cannot be predicted from the genetic sequence (Banks et 
al, 2000). 
 
The vast potential of proteomics in biomedical research is yet to be realised (Banks et 
al, 2000).   This is thought to be due to a lack of awareness of the advances that have 
been made in the field (Banks et al, 2000) and the concept that the technique is 
unrefined.  Proteomic investigations of pathophysiological conditions have generally 
focussed on a variety of cancers.   Cancer proteome databases have been constructed 
for a hepatocellular carcinoma cell line (Liang et al, 2002) and a colon cancer cell line 
(Simpson et al, 2000).   Human proteome maps also exist for plasma, urine, 
cerebrospinal fluid, breast tissue and heart tissue (Banks et al, 2000).   Proteomics has 
allowed the identification of: 
- several protein variants associated with the development of liver cancer 
(Zeindl-Eberhart et al, 1994), 
- proteins differentially expressed between non tumorigenic and metastatic 
prostate epithelial cells (Griffin, Goodlet & Aebersold, 2001), 
-several proteins that are differentially expressed between benign prostate 
tissue and prostate carcinoma (Alaiya et al, 2001), 
-a number of protein alterations in a neuropsychiatric disease (Merril & 
Goldman, 1982), 
- a number of novel serum markers in patients with lung cancer (Hanash, 
Brichory & Beer, 2001), 
- microheterogeneity of proteins (perhaps glycoproteins) in pancreatic juice of 
patients with pancreatic cancer and pancreatitis (Scheele, 1982), 
- a putative urinary marker of bladder squamous cell carcinoma (Celis & 
Gromov, 1999). 
 
The importance of low abundance proteins in medicine: 
A large section of the proteome is composed of low abundance proteins (Gygi et al, 
2000).   The use of proteomics to study disease raises the issue of low abundance 
proteins for a number of reasons: 
- many important classes of proteins, for example transcriptional control 
proteins are present in low abundance (Hoffman et al, 2001), 
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- many disease associated proteins are expected to be present in low copy 
number (Griffin, Goodlet & Aebersold, 2001), 
- the relative changes in the amount of a particular protein between a normal 
and disease state are expected to be quite low (Gabor Miklos & Maleszka, 
2001), 
- micro-dissection of tissue and tumours is often used to obtain pure cell 
populations, resulting in prohibitively small samples, in which low abundance 
proteins cannot be identified (Adam et al, 2001). 
 
Plasma Proteomics: 
In this review, the focus will be on the plasma proteome rather than the serum 
proteome, for simplicity and to include the largest range of proteins of the soluble 
component of blood (Anderson & Anderson, 2002).   An assessment of the 
advantages and disadvantages of investigating proteins either in serum or plasma is 
currently a priority of HUPO (the worldwide Human Proteome Organisation).   
Plasma is the primary clinical specimen because it is one of the most easily obtained 
and reflects many physiological and pathophysiological processes.   The plasma 
proteome can be regarded as the ‘largest and deepest’ version of the human proteome, 
because plasma contains not only classical plasma proteins, but leakage proteins from 
all tissues in addition to immunoglobulins (Anderson & Anderson, 2002).   Plasma is 
also one of the most difficult proteomes to work with, because of the number of 
protein present, the number of protein variants (degradation products and post 
translationally modified proteins) and the large dynamic range.   It is common for 
small number of proteins (albumin, α1-antitrypsin, α2 macroglobulin, transferrin, γ 
globulins) to represent over 80% of the total protein in plasma (Georgiou, Rice & 
Baker, 2001).   The abundance of plasma proteins varies over ten orders of magnitude 
(Anderson & Anderson, 2002).   It is difficult to analyse a large proportion of the 
plasma proteome using any single method.   For example: two dimensional gel 
electrophoresis based proteomics is likely to detect only the high abundance and/or 
long lived proteins of a sample (Haynes & Yates, 2000), at the expense of the short 
lived or low abundance proteins. 
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Detectable in 2D gels Likely to be not detectable in 2D gels 
↓C-reactive protein
↑Haptoglobin 
↑Serum 
amyloid A
↓PLA2
↑Haemoglobin
 
Figure 3.1: 
The Plasma Proteome.   Modified from Anderson N.L. & Anderson N.G.   The 
Human Plasma Proteome: History, Character and Diagnostic Prospects.   
Molecular and Cellular Proteomics 2002; 1 (11): 845-867, with permission from 
the author. 
 
Plasma proteins encompass proteins with function within the plasma (haemoglobin, 
albumin), proteins that have been released from tissues, immunoglobulins and 
cytokines.   Tissue leakage proteins are those proteins that are generally retained 
within a particular tissue but are released into plasma during tissue damage because of 
cell death or injury (Anderson & Anderson, 2002).   In this way, cellular factors 
including proteins can be used as markers of tissue damage in plasma (Noe, 2001).   
An ideal marker of tissue damage would be present only in the tissue or organ of 
interest (Noe, 2001).   A number of highly tissue specific proteins have been 
identified, such as pancreatic α amylase and cardiac muscle creatine kinase MB (Noe, 
2001).   The concentration of tissue leakage proteins in plasma varies greatly 
according to the amount present in the tissue, the distribution of the protein within the 
tissue, the mode of release into circulation and the clearance or catabolism of the 
protein from circulation.   A highly abundant protein in a particular tissue can become 
a very attractive marker, as even moderately elevated levels in plasma can reflect 
small amounts of tissue damage (Anderson & Anderson, 2002).   For example, 
cardiac myoglobin is released during myocardial infarction.   A myocardial infarction 
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affecting less than 3g of cardiac tissue (a typical moderate infarct affects 45g) would 
release cardiac myoglobin into plasma to a substantial concentration of 3µg/mL 
(Anderson & Anderson, 2002).    
 
Tissue damage proteins may be released from tissues during injury due to: 
 - leakage of cytoplasmic proteins, 
 - heat shock response, 
 - inflammatory response, 
 - signalling, 
 - protective mechanisms. 
 
Plasma proteomics offers a method of evaluating protein differences between patients 
with a disease of interest and control patients.   If a suitable tissue damage marker can 
be identified by a proteomic investigation, this becomes a significant result because 
the test sample (plasma) is the same in a clinical situation.   Obtaining plasma is a 
minimally invasive procedure and samples would be routinely taken from patients for 
a multitude of other tests, during diagnosis and treatment.    
 
Serum Amyloid A, an important and abundant disease associated protein. 
Serum amyloid A (SAA) is a protein family comprised of several isoforms, that have 
high homology (50-95%) and similar size (see Figure 3.11, for sequence alignment of 
human serum amyloid A variants).   The SAA family can be divided into two groups- 
the acute phase SAA isoforms (A-SAA) and the constituent isoforms (C-SAA).   The 
acute phase SAA are highly conserved and have been found in all vertebrates studied 
(Uhlar & Whitehead, 1999).   As the name suggests, the acute phase SAA are 
involved in the acute phase response, where the concentration in blood can increase 
up to 1000 fold (Uhlar & Whitehead, 1999).   Acute phase SAA isoforms are among 
the most responsive acute phase proteins (Ensenauer et al, 1994), with mRNA 
detectable within 2 hours of inflammation (Pruzanski et al, 1995).   Plasma levels of 
acute phase SAA can increase from baseline levels (2-5µg/mL (Malle et al, 1997)) to 
1mg/mL within 20 hours (de Beer et al, 1994).    SAA is also one of the most rapidly 
cleared acute phase proteins, with a half life of only 90 minutes under both normal 
and inflammatory states (Husby et al, 1994).   The acute phase SAA are the 
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precursors of the amyloid fibril protein A found in secondary or reactive amyloidosis 
(Husby et al, 1994).   Amyloidosis refers to a group of diseases characterised by 
deposition of amyloid in a variety of tissues and organs (Husby et al, 1994), most 
commonly the spleen, liver and kidney (Buxbaum & Tagoe, 2000).   Constitutive 
SAA (C-SAA) is maintained at a relatively constant concentration in blood at 
approximately 50µg/mL (Yamada et al, 2001).   C-SAA is only minimally inducible 
during the acute phase response, for example, during renal allograft transplantation, 
C-SAA only rises approximately 3 fold (Yamada et al, 2001).  Constitutive SAA has 
only been found in humans and mice (Uhlar & Whitehead, 1999).   The relevance of 
C-SAA is unknown (Husby et al, 1994).   Unlike the acute phase SAA, the C-SAA 
gene lacks IL-1 and IL-6 responsive elements (Watson, Coade & Woo, 1992). 
 
In humans one isoform of SAA is predominant (SAA1), and this isoform comprises 
95% of the total SAA (Malle et al, 1997).   In humans four SAA genes have been 
detected, SAA1 (five alleles), SAA2 (the acute phase isoforms, two alleles), SAA3 (a 
pseudogene) and SAA4 (the constitutive isoform, one allele).   SAA3 is a pseudogene 
due to a single base insertion which causes an early stop signal.   No mRNA or 
protein have been found for this gene (Uhlar & Whitehead, 1999).    These genes are 
all located on chromosome 11, and are thought to be the result of gene duplication and 
conversion (Buxbaum & Tagoe, 2000).   The serum amyloid A proteins are produced 
primarily in the liver, and circulate in blood complexed to lipids (Buxbaum & Tagoe, 
2000).   SAA synthesis has also been detected in epithelial and endothelial cells, 
smooth muscle, macrophages and lymphocytes (Sipe, 2000).   The precise function of 
SAA is unknown, but the massive increase of SAA during the acute phase and high 
degree of conservation across species suggests an important role in defence (Uhlar & 
Whitehead, 1999).   Possible SAA functions include lipid metabolism or transport, 
regulation of extracellular matrix degrading enzymes, inflammatory cell recruitment 
(Uhlar & Whitehead, 1999), bacteria clearance (Alsemgeest et al, 1995), tissue repair 
and cholesterol metabolism during inflammation (Ensenauer et al, 1994).  
 
There are six electrophoretic variants of human acute phase SAA which occur in three 
possible phenotypes (Betts et al, 1991).   Two of these isoforms occur in all 
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phenotypes, and in addition two or four other isotypes distinguish the phenotypes.   
The acute phase SAA isoforms are summarised in Table 3.1: 
 
 
Table 3.3.   Acute Phase Serum Amyloid A Variants. 
 
Isoelectric 
point 
N-terminal 
amino acids 
Identification Reference 
6.0 SFFSFL SAA-1α des arg Dwulet, Wallace 
& Benson, 1988. 
6.0 FFSFL SAA-1α des arg 
minor variant 
Strachan et al, 
1989. 
6.4/6.6 RSFFSFL SAA-1α Foyn Bruun et 
al, 1995, 
Strachan et al, 
1989. 
7.0 SFFSFLG SAA-2α des arg Beach et al, 
1992. 
7.0 FFSFL SAA-2α des arg 
minor variant 
Strachan et al, 
1989. 
7.4 SFFSFLG SAA-2β des arg Beach et al, 
1992. 
7.5 RSFFSFL SAA-2α Beach et al, 
1992. 
8.0 RSFFSFL SAA-2β Beach et al, 
1992. 
 
 
All humans express the pI 6.0/6.4 pair, and individuals can be divided into three 
groups based on the patterns of the additional acute phase SAA expressed: 
Phenotype 1: isotypes with pI values of 7.0, 7.4, 7.5 & 8.0, exists in 33% of 
individuals. 
Phenotype 2: isotypes with pI values 7.0 & 7.5, exists in 61% of individuals.  
Phenotype 3: isotypes with pI values 7.4 & 8.0, exists in 6% of individuals, (Strachan 
et al, 1989).  
 
Most Europeans and Americans show the SAA1 +/- N terminal arginine (pI 6) and 
SAA 2α +/- N terminal arginine (pI 7 & 7.5) while the SAA 2β pair is rare (Husby et 
al, 1994).   Constitutive serum amyloid A (SAA4) also occurs as a number of 
electrophoretic variants.   The smaller variant (14kDa) is the non-glycosylated form 
and has three alternate isoelectric points (7.3, 7.9 and 8.1) (Whitehead et al, 1992).   
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The larger variant (19kDa) is glycosylated and has two alterative isoelectric points 
(7.3 and 7.9) (Whitehead et al, 1992).   
 
Serum Amyloid A as a disease marker: 
The elevation of SAA concentration in the acute phase response is a generalised 
reaction to inflammation or infection, but several groups have sought to investigate 
SAA as a disease marker.  
 
In cattle with experimental respiratory infection SAA responded more quickly than 
other acute phase proteins (Heegard et al, 2000).   In a murine model of colitis SAA 
levels in plasma preceded inflammatory signs in intestinal tissue and levels reflected 
the severity of the disease (de Villiers et al, 2000).   In the synovium of patients 
suffering from rheumatoid arthritis, SAA appears to induce degradation of the 
extracellular matrix (Migita et al, 1998).  Patients with cerebral infarction showed 
elevated SAA levels and the levels appeared to correlate with the clinical severity 
(Ilzecka & Stelmasiak, 2000). 
 
The previous examples examined the net level of SAA in disease.   Several groups 
have investigated the SAA subtype patterns in disease.   To quote Alsemgeest and 
colleagues (1995): 
“if isoforms of SAA are differentially expressed during different disease  
processes this might be of potential value in diagnostics”. 
In a murine model different expression patterns of SAA1, SAA2 and SAA3 were 
found and tissues could be categorised into those that expressed all three isoforms, 
those expressing SAA1 and SAA2 and those with predominant SAA3 expression 
(Meek & Benditt, 1986).   In cows with a variety of diseases a heterogenous pattern of 
isoforms was reported (Alsemgeest et al, 1995).   In contrast, human patients with 
sepsis, arthritis, renal or liver allograft rejection or administration of inteferon, 
showed that SAA subtype response was similar irrespective of the ‘initiating 
stimulus’ (Maury, Enholm & Lukka, 1985). 
 
Phospholipase A2, a low abundance disease associated protein. 
Phospholipase A2 is a protein implicated in several facets of disease.   Its involvement 
in inflammatory conditions has been widely studied because of its role in the 
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generation of eicosanoids by the liberation of arachidonic acid from phospholipid 
molecules.   Hydrolysis of phospholipids by phospholipase A2 also releases 
lysophospholipid which can be metabolised to platelet activating factor, both of which 
can elicit cell responses (Bomalaski & Clarke, 1993), see Figure 4.2.   The 
inactivation of phospholipase A2 by alkylation or heat prevents the inflammatory 
response, which suggests that the inflammatory response is due to the enzyme’s 
action rather than a non specific response to an inflammatory initiator such as 
endotoxin (Bomalaski & Clarke, 1993). 
 
Phospholipase A2 in bowel injury: 
Phospholipase A2 levels have been shown to be increased in the plasma (Minami et 
al, 1992) and the intestinal tissue (Lilja et al, 1995) of patients with Crohn’s disease. 
Phospholipase A2 may be involved in the pathogenesis of bowel injury.   The isoform 
of phospholipase A2, type II is thought to be involved in the development of intestinal 
inflammation in both Crohn’s disease and ulcerative colitis (Minami & Tojo, 1997).   
Serum phospholipase A2 correlates well with the activity of ulcerative colitis and 
Crohn’s disease (Nevalainen, Gronroos & Kortesuo, 1993).   Inhibition of 
phospholipase A2 has been shown to be partially protective against intestinal mucosal 
injury in a model of shock (Xu, Lu & Deitch, 1995) and against lung injury caused by 
intestinal handling (Thomas, Karnik & Balasubramanian, 2002).    
 
Phospholipase A2 in gut ischaemia/reperfusion: 
In rat models of intestinal ischaemia/reperfusion injury, increased levels of 
phospholipase hydrolysis products have been observed in the mucosa (Otamiri et al, 
1987, Otamiri & Tagesson, 1989).   Phospholipase activity in the portal circulation of 
rats with experimental ischaemia/reperfusion was ten fold higher than in the systemic 
circulation suggesting that the enzyme was being released from the injured gut (Koike 
et al, 2000).   Inhibition of phospholipase A2 reduced mucosal injury and permeability 
in a rat model of ischaemia/reperfusion (Otamiri, Lindahl & Tagesson, 1988).   The 
involvement of phospholipase A2 in disease including bowel injury is discussed in 
greater detail in the introduction to Chapter 5. 
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Pre-fractionation to identify low abundance proteins: 
The problem of analysing low abundance proteins in complex mixtures can be 
overcome by pre-fractionation of the sample into a number of discrete sub-samples.   
The sub-samples can then be further separated using two dimensional gel 
electrophoresis based proteomics or another technique such as a series of 
chromatographic columns.   The pre-fractionation approach can be applied to a global 
analysis scheme, which allows greater resolution, particularly in regions which are 
usually distorted by high abundance proteins.   Pre-fractionation can also be applied in 
a targeted approach to purify a particular protein of interest.  A number of pre-
fractionation techniques have been designed to overcome the limitations of current 
proteomic, and include subproteomics or preparative isoelectric focussing prior to the 
global protein separation. 
 
Subproteomics: 
Subproteomics involves the use of sequential protein extraction procedures followed 
by several 2DE gels of each fraction.   By using a series of protein extraction 
solutions a biological sample can be fractionated according to relative solubility, 
which also reflects the protein’s cellular compartment (secreted, cytosolic or 
membrane).   Numerous 2DE gels (down to a single pH unit IPG strips) can then be 
run from each fraction and a composite map constructed (Cordwell et al, 2000).   By 
using this approach low abundance proteins can be identified because of increased 
sample loading and resolving power (Cordwell et al, 2000).   An additional advantage 
if that the sequential protein extraction provides some information about the cellular 
location of proteins identified (Cordwell et al, 2000). 
 
Preparative IEF techniques: 
The use of preparative iso-electric focussing as the preliminary pre-fractionation step 
is a powerful approach that is particularly suited to low abundance and/or membrane 
proteins.   Isoelectric focussing (IEF) separates proteins on the basis of their 
isoelectric point or pI, the pH at which there is no net charge on the protein.   
Isoelectric focussing can be conducted using small amounts of sample on an IEF gel, 
or an IPG strip.   Preparative IEF uses large amount of sample and can be performed 
using large gel tubes or in the liquid phase.   The multi-compartment electrolyzer, free 
flow electrophoresis and the Rotofor® apparatus are examples of preparative 
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isoelectric focussing systems.   For further discussion of the Rotofor® apparatus, see 
Chapter 4. 
 
Multi-compartment electrolyzer: 
The multi-compartment electrolyzer is a liquid based preparative IEF system 
composed of a variable number of compartments (typically six) separated by 
isoelectric membranes (Herbert & Righetti, 2000).   Each compartment is capable of 
producing a sub-sample with a discrete range of isoelectric points.   The fractions can 
then be analysed (without alteration of the chemical composition) using 2DE gels.   
Disadvantages of this approach include possible loss of protein on the membrane 
surface or precipitation of the proteins onto membranes at their pI (Herbert & 
Righetti, 2000).   This approach led to the identification of several acidic proteins 
from human plasma that were unable to be seen in un-fractionated plasma (Herbert & 
Righetti, 2000). 
 
Free flow electrophoresis: 
Free flow electrophoresis is another liquid based IEF system that can be used to 
fractionate samples prior to 2DE gels.   Sample recovery is optimal due to the absence 
of solid membrane supports and sample load is less of a concern than with other 
techniques due to continuous sample application (Hoffman et al, 2001).   Free flow 
electrophoresis has allowed the identification of a number of intact protein complexes 
and membrane associated proteins (Hoffman et al, 2001).  
 
Determining the Accuracy of Diagnostic Markers: 
The effectiveness of a new diagnostic marker can be assessed in a number of different 
ways.   The accuracy of a test is assessed by the sensitivity and specificity.   
Sensitivity is the ability of a test to correctly identify patients that have the condition 
in question.   Specificity is the ability of the test to correctly discount the patients who 
do not have the condition in question.   The positive predictive value of a test is the 
probability that a subject is positive if a positive result is obtained.   Conversely, the 
negative predictive value is the probability that a negative subject results in a negative 
result.   Positive/negative predictive values are dependent on the prevalence of the 
disease.   Diagnostic likelihood ratios are independent on the prevalence of the 
disease, and represent the odds ratio of obtaining a positive result among a negative 
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population, compared with the likelihood of obtaining a positive result among a 
positive population.   Other techniques to measure the effectiveness of a diagnostic 
marker include univariate/multivariate analysis and receiver operating characteristic 
(ROC) curves. 
 
The Receiver Operating Characteristic Plot: 
The accuracy of a particular test in the diagnosis of a particular disease is often 
evaluated using the concepts of sensitivity and specificity.   The specificity and 
sensitivity of a test depend on the decision threshold or cut-off point for the test.    
 
ROC plots were first introduced to evaluate radar in the 1950s and have since been 
employed  in radiography, experimental psychology and pathology testing fields 
(reviewed by Zweig & Campbell, 1993).   ROC plots evaluate the test’s  
‘ability to discriminate between alternating states of health over the complete  
spectrum of operating conditions’ (Zweig & Campbell, 1993).    
 
ROC graphs plot sensitivity against 1-specificity.   Each point represents the 
specificity/sensitivity pair for a particular cut-off point for a particular test.   ROC 
plots are useful in situations where    
- there is no ‘gold standard’ with which to compare a new test (Zweig & 
Campbell, 1993), 
- if the accepted test has an associated bias (Zweig & Campbell, 1993),  
- if the decision threshold has not been decided. 
ROC plots are advantageous because 
 - the entire range of threshold values is assessed, 
 - a common scale is used, unlike a frequency diagram   
 which usually has different scales (Zweig & Campbell,    
 1993). 
The ROC plot has a number of disadvantages:  
- the decision threshold is not visually obvious from the graph (Zweig & 
Campbell, 1993), 
- the number of subjects is not shown by the graph (Zweig & Campbell, 1993). 
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When a plot is created the area under the curve is a measure of the discriminatory 
power of that test.   The closer the area under the curve is to 1, the better 
discriminating power the test has.   Conversely, an area of 0.5 has no more 
discriminating ability than random chance.   
 
Plasma Variables assessed in this Study: 
APACHE II: 
The APACHE system is a scoring system that was devised by a group at Washington 
University and was first published in 1981 (Knaus et al, 1981).   APACHE II 
represented an improved version of the original APACHE system designed to predict 
patients’ outcome in ICU based on twelve physiological variables, the Glasgow Coma 
Score, chronic health status and age (Knaus et al, 1985, Siegel & Rixen, 2002).   
APACHE II has been used as an indicator of patient status and to predict mortality in 
patients with multiple trauma (Knaus et al, 1985, Rhee et al, 1990). 
 
SAA: 
SAA is one of the most reactive and most quickly cleared acute phase proteins in 
humans.   SAA can increase in concentration in the circulation from baseline levels to 
200 to 500 times that level within 20 hours (de Beer et al, 1994).   The half life of 
SAA in normal and inflammatory states is only 90 minutes (Husby et al, 1994), and 
therefore the clearance of this protein from circulation can be very rapid. 
 
CRP: 
CRP is the most widely used marker of inflammation in clinical practice at present 
(Bellamy, Lansbury & Murdoch, 2002).   CRP can reach levels of 500mg/L within 6 
hours of the induction of the acute phase response (Bellamy, Lansbury & Murdoch, 
2002).   Ongoing infection or inflammation usually results in continually elevated 
levels of CRP whereas declining levels usually indicate resolution of the condition  
(Bellamy, Lansbury & Murdoch, 2002). 
 
PLA2: 
PLA2 is a rate limiting enzyme in the generation of a variety of inflammatory 
mediators including the eicosanoids, lysophospholipid and platelet activating factor 
(Dennis, 1997).   Phospholipase A2 production and release into plasma/extracellular 
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fluid is increased during inflammation (Kallajoki & Nevalainen, 1997, Kudo et al, 
1993).   Extracellular phospholipase A2 levels can reach concentrations of up to 1000 
times baseline during inflammation (Weinrauch et al, 1998). 
 
LACTATE: 
Elevated lactate concentration has been described as  
 “the best marker of mesenteric ischaemia to date” (Lange & Jackel, 1994).    
A high lactate concentration is not a finding that is unique to mesenteric ischaemia, 
but indicates the need for immediate surgery to avert life threatening deterioration.   
Shock, diabetic ketoacidosis, convulsion and hepatic or renal failure can also lead to 
elevated lactate levels, but if these conditions can be discounted then the likelihood of 
mesenteric ischaemia increases (Lange & Jackel, 1994).                            
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Chapter 3: Proteomics and plasma investigations. 
A proteomic investigation of potential differences between the plasma proteins of 
patients with surgically confirmed bowel infarction and control patients was 
undertaken.   The control patients in this study were intensive care patients that were 
being successfully fed, and therefore had functioning bowels.   An initial investigation 
of the neutral to acidic (pI of 4 to 7) proteins was undertaken as a starting point.   The 
major protein differences were found to be variants of haptoglobin (results not 
shown).   The basic plasma proteins (pI of 7 to 10) were investigated in greater depth 
as it was thought that small basic proteins may be the first to transverse the gut barrier 
into circulation.   It is known that gut permeability increases as a result of ischaemia 
(Kong et al, 1998).   Well resolved plasma protein gels were achieved using cup 
loading rather than in-gel rehydration, and a methanol precipitation cleanup step 
(Figures 3.2 and 3.3).   A number of protein differences were evident between the 
samples from patients with bowel infarction and control patients (Figure 3.4).   
Proteins of interest were identified using MALDI-TOF mass spectrometry and 
database searching.   If MALDI-TOF did not provide an adequate database match, the 
protein was identified using Q-TOF tandem mass spectrometry and database 
searching.   The relative quantities of each of the proteins were assessed using image 
analysis software (Figure 3.5).   The presence or absence of each spot in each gel was 
also noted (Figure 3.6).   From the analysis of protein quantity, serum amyloid A 
appeared to warrant further investigation.   The mass spectrometry analysis of serum 
amyloid A gave good sequence coverage (Figure 3.7), and Q-TOF was also able to 
distinguish between SAA2 and SAA1 (Figure 3.8), two proteins that share very high 
homology (96%).   Three serum amyloid protein variants were identified in this study, 
and the relative proportions of each is shown in Figure 3.9, though there is no clear 
pattern that distinguishes the bowel infarction patients from controls.    
 
An analysis was conducted to compare the ability of the following variables in 
distinguishing patients with bowel infarction from control patients: 
- a commonly used clinical marker (C-reactive protein) 
- a commonly used clinical scoring system (APACHE II)  
- an indicator of bowel infarction (lactate) 
- a protein suspected to be released from infarcted bowel (phospholipase A2) 
- serum amyloid A 
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The analysis of serum amyloid A was conducted using an ELISA system, due to a 
superior limit of detection than image analysis of gel spots.   SAA levels were not 
significantly different between the plasma of control and bowel infarction patients 
(Figure 3.13).    
 
Previous research had shown that phospholipase A2 activity was increased in the 
intestinal mucosa in rat models of ischaemia/reperfusion injury (Koike et al, 1992, 
Koike et al, 1995, Otamiri & Tagesson, 1989).   In this investigation we wished to 
investigate the possible release of phospholipase activity into the plasma of patients 
with bowel infarction.   Phospholipase A2 activity was measured in the plasma of 
patients involved in this study (Figure 3.10).   Each variable was assessed in groups of 
patients with bowel infarction and control patients (Figure 3.11).   C-reactive protein 
showed a trend (p<0.025) toward increased levels in the patients with bowel 
infarction, but the other variables showed poor discrimination between the two groups 
of patients, as assessed by t-tests of the mean data.   Receiver operating characteristic 
curves of the five variables were constructed to allow comparison on a common scale 
(Figure 3.12).   The variable that showed the best discrimination power was 
phospholipase A2, though none of the variables assessed were ideal for use in a 
clinical setting.   The next investigations focused on the phospholipase A2 activity in 
normal and infarcted human bowel (Chapter 4) and the purification of the protein 
responsible for the increased phospholipase A2 activity (Chapter 5). 
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A B C 
D E F 
Figure 3.2: Two Dimensional gels of plasma proteins from control patients A to F.   Large 
format gels (8-18% gradient) and basic IPG strips (pH 7-10) were employed.   These gels 
were stained with the colloidal Coomassie stain.   These gels have been cropped to show 
proteins smaller than 50kDa.
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Figure 3.3: Two Dimensional gels of plasma from patients with confirmed bowel infarction, 
labelled here as patients G to L.   Large format gels (8-18% gradient) and basic region IPG strips 
(pH 7-10) were employed.   These gels were stained with the colloidal Coomassie stain.   These 
gels have been cropped to show proteins smaller than 50kDa.
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Figure 3.5: Relative quantities of spots selected for Mass Spectrometry analysis.   Analysis 
was performed using BioRad Quantity One Software, version 4.1.1.   Proteins that were 
significantly different by the student’s t-test are highlighted with asterisks (* for p<0.05,   
** for p<0.02, *** for p<0.01 levels of significance).
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Protein: Control Plasma: Bowel Infarction plasma: 
Haemoglobin α 6/6 6/6 
Haemoglobin β fragment a 6/6 6/6 
Haemoglobin β fragment b 5/6 6/6 
Q9NV34 theoretical protein 6/6 6/6 
Q9P1I9 theoretical protein 1/6 0/6 
SAA 
(insufficient peptide information to 
distinguish the specific variant) 
5/6 6/6 
SAA 2 3/6 6/6 
SAA A2 5/6 6/6 
Table 3.4: Protein spots present in 2DE gels of plasma.
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Spot Type of Mass 
Spec. 
Identity Number of peptides 
obtained 
Sequence coverage
A2 MALDI SAA, 
(unknown 
variant) 
7 58.70% 
A5 MALDI SAA 2-α 7 61.51% 
A7 MALDI - 0 - 
A7 Q-TOF SAA2 3+sequence data 25.96% by amino 
acids 
 
Figure 3.6: Serum amyloid identification by Mass Spectrometry.
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SAA1  MKLLTGLVFCSLVLGVSSRSFFSFLGEAFDGARDMWRAYSDMREANYI 
SAA2  MKLLTGLVFCSLVLGVSSRSFFSFLGEAFDGARDMWRAYSDMREANYI 
SAA3  MKLSTGIIFCSLVLGVSSQGWLTFLKAAGQGAKDMWRAYSDMKEANYK 
SAA4  MRLFTGIVFCSLVMGVTSESWRSFFKEALQGVGDMGRAYWDIMISNHQ 
 
SAA1  GSDKYFHARGNYDAAKRGPGGAWAAEVISDARENIQRFFGHGAEDSLA 
SAA2  GSDKYFHARGNYDAAKRGPGGAWAAEVISNARENIQRLTGHGAEDSLA 
SAA3  KSDKYFHARGNYDAVQRGPGGVWATEVISDARENVQRLTGDHAEDSLA 
SAA4  NSNRYLYARGNYDAAQRGPGGVWAAKLISRSRVYLQGLIDYYLFGNSS 
 
SAA1  DQAANEWGRSGKDPNHFRPAGLPEKY 
SAA2  DQAANKWGRSGRDPNHFRPAGLPEKY 
SAA3  GQATNKWGQSGKDPNHFRPAGLPEKY 
SAA4  TVLEDSKSNEKAEEWGRSGKDPDRFRPDGLPKKY 
 
PEPTIDE A  SFFSFLGEAFDGAR 
PEPTIDE B  SFLGEAFD  
PEPTIDE C  GPGGAWAAEVISNAR 
Figure 3.7: Sequence alignment of serum amyloid isoforms SAA1-4.   Q-TOF Mass 
Spectrometry allowed the spot ‘A7’ to be identified as SAA2 from peptide denoted ‘C’.   
SAA1 and SAA2 differ by only 5 from 104 amino acids, and share the same Swiss-Prot entry 
because of this homology.   The high degree of homology between the isoforms
is likely to be the reason that it was not possible to determine the specific isoform
corresponding to spot A2.
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SAA gel spots- control patients.
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Figure 3.8: Serum amyloid proteins present in plasma of control patients and 
patients with confirmed bowel infarction.   Analysis was performed using 
BioRad Quantity One software version 4.1.1.   Spot A2= SAA, spot A5= 
SAA 2α, spot A7= SAA 2.
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SAA1 MKLLTGLVFCSLVLGVSSRSFFSFLGEAFDGARDMWRAYSDMREANYI
SAA2 MKLLTGLVFCSLVLGVSSRSFFSFLGEAFDGARDMWRAYSDMREANYI
SAA3 MKLSTGIIFCSLVLGVSSQGWLTFLKAAGQGAKDMWRAYSDMKEANYK
SAA4 MRLFTGIVFCSLVMGVTSESWRSFFKEALQGVGDMGRAYWDIMISNHQ
SAA1 GSDKYFHARGNYDAAKRGPGGAWAAEVISDARENIQRFFGHGAEDSLA
SAA2 GSDKYFHARGNYDAAKRGPGGAWAAEVISNARENIQRLTGHGAEDSLA
SAA3 KSDKYFHARGNYDAVQRGPGGVWATEVISDARENVQRLTGDHAEDSLA
SAA4 NSNRYLYARGNYDAAQRGPGGVWAAKLISRSRVYLQGLIDYYLFGNSS
SAA1 DQAANEWGRSGKDPNHFRPAGLPEKY
SAA2 DQAANKWGRSGRDPNHFRPAGLPEKY
SAA3 GQATNKWGQSGKDPNHFRPAGLPEKY
SAA4 TVLEDSKSNEKAEEWGRSGKDPDRFRPDGLPKKY
Leader peptide: residues 1-18
Heparin binding sites: residues 78-104
SAA4 octapeptide extension: residues 70-77
Figure 3.9: Serum amyloid A isoform sequence alignment.   The leader peptide (18 
amino acids in length) is cleaved to form the mature protein.   
The serum amyloid 4 octapeptide extension is not present in the acute phase isoforms.   
This octapeptide is the only potential N-linked glycosylation site in the molecule.   
Studies have shown that 50% of the proteins are glycosylated giving rise to two size 
classes differing by 5kDa (Whitehead et al, 1992).
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Figure 3.10: PLA2 activity in the plasma of bowel infarction patients and 
control patients.   Results are expressed as the mean +/- standard error of 
the PLA2 activity of bowel infarction (n=10) and control plasma (n=9).  
The PLA2 activity in the plasma of bowel infarction patients and control
patients is not significantly different. 
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Figure 3.11: A visual comparison of the five variables measured in the plasma of 
control patients and patients with confirmed bowel infarction.
The differences for each of these variables was not significant except for CRP 
levels, (* p<0.025, student’s t test).   Data are represented as the mean +/- standard 
error.   Number of samples in bowel infarction group and control group 
respectively: CRP n=7 in each group, Lactate n=7 & n=10, APACHE n=10 in each 
group, PLA2 n=10 & n=9, and SAA n=10 & n=9.   The numbers of samples in each 
group varies because of differences in the availability of clinical testing.
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Figure 3.12:  The ROC plot and the area under the curve obtained for each variable 
measured in the plasma of control patients and patients with surgically confirmed 
bowel infarction.   The separator variable was the presence or absence of bowel 
infarction.   As the area under the ROC curve approaches 1, the test approaches 
perfect discrimination power.
Discussion 
Chapter 3 Discussion: 
Our proteomic investigation examined possible plasma protein differences between 
patients with surgically confirmed bowel infarction and control patients.   This 
investigation was undertaken as a starting point for this project and to assess whether 
a highly abundant marker of tissue damage or a diagnostic protein was evident in the 
plasma of bowel infarction patients but not in controls.   The control patients were 
Intensive Care patients that were being successfully fed, and thus had functioning 
bowels.   The control patients had been admitted to intensive care for a wide variety 
of conditions.   Our investigation did not recruit normal healthy volunteers as 
controls, to try to limit protein differences that were simply indicative of health status.    
 
The majority of proteomic investigations of disease associated proteins have focussed 
on a variety of cancers, often at the tissue level.   The control patients in proteomic 
investigations of plasma proteins tend to be healthy volunteers.   We chose to use 
plasma (rather than bowel tissue, for example) as our sample of choice, as a clinically 
useful diagnostic test would be minimally invasive, and be able to be used to 
continually monitor ‘at risk’ patients.   Our pilot investigation focussed on the neutral 
to acidic (pH 4-7) proteins.   The specific proteins identified from this region in 
patients with confirmed bowel infarction were variants of haptoglobin. 
 
Haptoglobin variants have been observed in two dimensional electrophoretic gels of 
human serum during and after the acute phase, and were predictably more abundant 
during the acute phase (Bini et al, 1996).   Haptoglobin is thought to aid in tissue 
repair by stimulating angiogenesis, which may compensate for the decreased oxygen 
supply during ischaemia (Cid et al, 1993).   Haptoglobin also has antioxidant 
properties and protects against damage by reactive oxygen species (Gabay & 
Kushner, 1999).   The increased levels of haptoglobin observed during infection and 
inflammation are a non-specific response triggered by cytokines (Cid et al, 1993) and 
is therefore not of specific diagnostic value for bowel infarction.   Although the role 
of haptoglobin in ischaemic injury to bowel may be an interesting area for further 
research, it was not investigated in greater detail in this project due to its non specific 
increase during the acute phase. 
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Cup loading and methanol precipitation: 
Our investigation then focused on the small basic proteins present in the plasma of 
patients with and without surgically confirmed bowel infarction.   The small, charged 
proteins were thought to be the first to be released from injured bowel (into the lumen 
and subsequently into general circulation).   Bowel permeability is known to increase 
as a result of ischaemia (Kong et al, 1998).   Basic proteins are known to be difficult 
to resolve by in gel rehydration, which is the usual method of uptake of proteins into 
IPG strips.   Cup loading is commonly recommended for uptake of proteins into 
alkaline IPG strips (Gorg et al, 1999, Gorg et al, 2000).   Our work confirmed that 
cup loading of basic proteins was more successful than in gel rehydration (results not 
shown).   It is also thought that plasma proteins in general are more successfully 
resolved with cup loading than in gel rehydration (Australian Proteome Analysis 
Facility, personal communication).   Methanol precipitation was also found to give 
superior results, in terms of superior resolution of protein spots and less streaking.   
Methanol precipitation has been reported to improve resolution by removing non-
protein contaminants such as lipids, polysaccharides, salts and nucleic acids 
(Amersham Pharmacia applications manual).   The improved resolution provided by a 
methanol precipitation step was even more evident with gels of bowel content 
samples, which are likely to contain more non-protein contaminants than plasma.   
The gels of bowel content samples are not shown in this report, as the protein patterns 
were too heterogenous to draw any conclusions or locate particular proteins for 
identification by mass spectrometry. 
 
PROTEIN DIFFERENCES FOUND BY 2D-PAGE: 
A number of protein differences were evident from a composite synthetic gel 
constructed from the gels of plasma proteins from the two groups of patients.   A 
number of haemoglobin variants were found, and, not surprisingly, the levels of these 
proteins were similar between the two groups of patients.   Two proteins that were 
identified by MALDI-TOF mass spectrometry had been entered into the protein 
databases as ‘theoretical proteins’.   These two proteins had little potential as 
diagnostic proteins as one was present in all samples at similar levels (Q9NV34), and 
the other was present in only one sample (Q9P1I9), but were interesting nevertheless.    
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Q9NV34 was present in all controls and all patients with confirmed bowel infarction.   
Q9NV34 was an excellent match for v-maf musculoaponeurotic fibrosarcoma 
oncogene family proteins (BLASTN, BLASTP).   Maf genes are highly conserved in 
vertebrates (Iwata et al, 1998) and have been implicated in a variety of physiological 
processes including the stress response (Moran, Dahl & Mulcahy, 2002).   The maf 
proteins in disease would be an interesting area for further investigation.   It is 
interesting to note that the level of Q9NV34 was similar in the plasma of each control 
patient, despite the heterogenous disease pattern of this group.   Q9P1I9 was present 
in only 1/6 control patients and no patients with bowel infarction.   The amino acid 
sequence of Q9P1I9 showed no matches to any entered sequence in either the 
nucleotide or protein databases.   Q9P1I9 showed limited similarity to a 
metalloproteinase inhibitor (Propsearch), but matched no recognised motifs (Prosite).   
Propsearch uses amino acid composition instead of sequence to find similar proteins.   
Propsearch can provide information about molecular weight, hydrophobicity, charged 
residues and distribution of residue sizes.   Motif scan (Prosite) identifies similarities 
to recognised protein motifs (Falquet et al, 2002). 
 
SERUM AMYLOID A: 
Three variants of serum amyloid A were identified in the plasma of patients with 
surgically confirmed bowel infarction by mass spectrometry in this study.    Serum 
amyloid A exists as a complex family of proteins, and includes six electrophoretic 
variants of the acute phase types (Betts et al, 1991) in addition to five electrophoretic 
variants of the constitutive type (Whitehead et al, 1992).   Serum amyloid A variants 
exist in three recognised phenotypes, with either four and six acute phase variants, in 
addition to up to five constitutive variants.   All of the constitutive variants and either 
two or four acute phase variants (depending on phenotype) will theoretically resolve 
in the pH region 7-10 of a two dimensional gel, though some are likely to be below 
the detection limit of the gel stains.   In this study, the quantity of the SAA2 and 
SAA2α variants appeared to be elevated in the plasma of patients with bowel 
infarction, compared with control patients.   This is an interesting finding as the level 
of SAA and other acute phase proteins would be expected to be similar among 
intensive care patients with similar levels of critical illness. 
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If the expression profile of the SAA variants was different in various tissues and/or 
different diseases then this protein family may be of diagnostic significance.   This 
idea has been proposed by groups studying a variety of diseases in both cattle 
(Alsemgeest et al, 1995) and humans (Maury, Enholm & Lukka, 1985).   Human 
patients with a variety of diseases showed a similar SAA subtype pattern regardless of 
the disease (Maury, Enholm & Lukka, 1985).   Serum amyloid A variants have been 
observed in two dimensional gels of human serum during the acute phase, but never 
after recovery (Bini et al, 1996).   In cattle, a heterogenous pattern of SAA isoforms 
was observed (Alsemgeest et al, 1995).   In our study the SAA variants were 
generally higher in the patients with confirmed bowel infarction than in controls, but 
no clear pattern of variants was evident between the two patient groups.    
 
The function of serum amyloid A during the acute phase is not yet known, but 
functions such as lipid metabolism, recruitment of inflammatory cells (Uhlar & 
Whitehead, 1999), cell adhesion and chemotaxis of phagocytes and lymphocytes 
(Berliner et al, 1995), tissue repair (Ensenauer et al, 1994) or bacterial clearance 
(Alsemgeest et al, 1995) have been proposed. 
 
Mass spectrometry analysis of serum amyloid A: 
One variant of SAA (SAA2) was unable to be identified by MALDI-TOF mass 
spectrometry, but was successfully identified by Q-TOF tandem mass spectrometry.   
The variant submitted to Q-TOF analysis was identified as SAA2, which was a 
fortuitous result, as SAA1 and SAA2 differ by only 4 out of 105 amino acids (Betts et 
al, 1991), and share the same entry in protein databases because of their very high 
homology.   SAA1 is thought to be the major SAA variant in humans, comprising 
over 95% of the total SAA in plasma (Malle et al, 1997), so it was interesting to 
identify variants other than SAA1 in this study.   The SAA1 variants have the 
isoelectric points 6.0, 6.4 and 6.6, and therefore would not have resolved within the 
IPG strip range employed in this study. 
 
Serum Amyloid A ELISA: 
The plasma levels of serum amyloid A in bowel infarction and control patients were 
assessed in greater depth using an ELISA.   It was expected that the levels of SAA 
would be greater in the plasma of patients with bowel infarction compared with 
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controls, from the proteomic results.   The ELISA was employed because of its 
superior limit of detection compared to the quantification of gel spots (ELISA limit of 
detection 5ng/mL, compared to a gel spot which represents 0.8-1µg/mL).   There was 
a trend toward increased serum amyloid A levels in the plasma of bowel infarction 
patients compared with controls, but the difference was not significant    The antibody 
used in the ELISA cross reacts with both SAA1 and SAA2 (TriDelta laboratories, 
personal communication).   Any subtle differences in the subtype patterns of SAA 
between the two patient groups is therefore likely to have been overlooked with this 
approach.   To our knowledge, no antibodies have been raised that can distinguish the 
SAA subtypes, therefore subtype specific ELISA are not yet possible.   As SAA1 is 
the predominant SAA isoform, this may have masked subtle differences in other SAA 
variants.    To test this hypothesis, western blotting could be undertaken using an 
acute phase SAA antibody and proteins arrayed by pH 3-10 two dimensional gels.   
Although the use of an acute phase protein as a possible diagnostic marker may seem 
inappropriate, a number of examples of this approach have been reported: 
- CRP has been recently recommended as a marker of coronary disease risk 
(Pearson et al, 2003). 
- All of the patients with bacterial infections in one study showed elevated 
SAA, while only 6/16 patients with viral infection had elevated SAA levels 
(Bini et al, 1996). 
Until subtype specific SAA antibodies can be generated and corresponding ELISAs 
developed, the increased levels of SAA and possible involvement of SAA variants in 
bowel ischaemia/infarction are difficult areas to study in greater depth. 
 
PHOSPHOLIPASE A2: 
Another protein liberated in response to tissue injury, phospholipase A2, was 
suggested in the literature to be of possible importance in bowel ischaemia and 
infarction.   For example, a rat model of ischaemia/reperfusion injury showed that 
phospholipase A2 was increased in the portal circulation to a tenfold higher level than 
in the systemic circulation, suggesting that circulating phospholipase A2 in ischaemia 
was released by the injured gut (Koike et al, 2000).   Phospholipase A2 could not be 
studied using a two dimensional proteomic approach because of its low abundance, 
and was studied using catalytic activity assay as an alternative.   The patients with 
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confirmed bowel infarction in this study showed higher plasma PLA2 activity than 
control patients, but the difference was not significant.   The phospholipase 
complement of bowel is complex, and a subtle difference between bowel infarction 
and control patients could not be examined using a catalytic activity assay.   The 
phospholipase A2 assay employed in this project, and many other publications 
quantifies the net in vitro catalytic activity and is not able to determine the presence or 
contribution of the various isoenzymes (Farrugia et al, 1993).   The aim of these 
experiments was to assay the catalytic activity of the enzyme (rather than the amount 
of protein which may not be active or bound to inhibitors).   It is possible that the 
hydrolysis products of this enzyme may be of greater importance than the protein 
isoform itself.   Protein purification was undertaken to identify the protein responsible 
for the increased phospholipase activity (Chapter 5). 
 
APPLICATION OF PROTEOMICS TO BIOMARKER DISCOVERY: 
A number of issues were presented by the proteomic investigations.   Although the 
number of patients in each group was large in terms of a proteomic investigation (10 
samples from each group), this number is small in terms of a clinical investigation.   
Biological variability results in large differences in protein expression between 
patients.   There are also significant fluctuations in protein levels within a patient.   
For example; one study investigated C-reactive protein in a group of healthy 
individuals and found that protein levels fluctuated over a six month period (Macy, 
Hayes & Tracy, 1997).   These fluctuations equated to coefficients of variation of 
42% within an individual and 93% between individuals (Macy, Hayes & Tracy, 
1997).   There are also fluctuations in disease associated proteins, such as the acute 
phase proteins (see Figure 3.14), over the time course of the development of the 
disease.   These fluctuations add even greater complexity to the development of 
reference ranges and subsequent diagnostic tests. 
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Figure 3.14   The Acute Phase proteins. 
Modified from Gitlin J.D. & Colten H.R., Molecular Biology of the acute phase 
plasma proteins. Lymphokines 1987; 14: 123-153 with permission from Elsevier.    
 
Low abundance proteins: 
Low abundance plasma proteins are more likely to be more clinically important than 
highly abundant or long lived proteins (Griffin, Goodlet & Aebersold, 2001).   
However, the majority of the proteins identified by proteomics in this study were high 
abundance and/or acute phase proteins.   There was a clear need for pre-fractionation 
of a clinical sample prior to two-dimensional gels in order to identify low abundance 
proteins, and this would become the basis for future proteomic investigations for this 
project.   Calculation based on our sample volumes and protein stain capabilities show 
that a protein would need to present in a concentration of greater than 0.8µg/mL to be 
identified in our two dimensional gel electrophoresis system, which is a relatively 
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high level.   This level of abundance is likely to represent very few tissue 
damage/leakage proteins (as shown by Figure 3.1). 
 
Multiple biomarker approach: 
The process of identifying a diagnostic test for bowel infarction may benefit from the 
simultaneous investigation of several potential markers.   A diagnostic test for bowel 
ischaemia/infarction need not be based on the detection of a single protein, but may 
involve a combination of protein(s), radiographic features and/or clinical signs.   The 
use of a panel of diagnostic markers has been proposed by a number of groups.   
Anderson and Anderson recently stated that there is a:  
“significant theoretical problem with the notion that there should be a single 
protein in plasma whose levels change in response to one specific disease”. 
Adam and colleagues (2002) state that ‘no single marker is likely to prove sufficiently 
predictive’, while Seliger and Kellner (2002) suggest that ‘preferably small clusters of 
proteins represent the ideal diagnostic markers”.   Conversely, the number of 
diagnostic variable must be kept as low as possible to keep costs to a minimum. 
 
ROC PLOTS: 
Receiver Operating Characteristic curves are very useful in assessing a number of 
diagnostic tests on a common scale.   ROC plots are also very useful when the cut-off 
point has not been decided, or even if a cut-off point is known it can be omitted from 
the analysis and thus does not bias the evaluation.   In this project, the numbers of 
patients were too low to obtain an accurate assessment of the value of the variables by 
univariate or multivariate analysis.   It has been recommended that multivariate 
analysis only be undertaken when the study involves more than thirty subjects in each 
group (Dr. M. Henry, personal communication).   If the numbers of patients recruited 
in the future were increased, then multivariate analysis is likely to be valuable in 
identifying the most useful diagnostic marker, or combination of diagnostic markers.   
Higher numbers of patients in each group (bowel infarction and control) would also 
begin to overcome problems associated with biological variation and protein 
fluctuation. 
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Chapter 4: Phospholipase A2 in Mesenteric Ischaemia and Infarction: 
 
Phospholipase A2:
 
The phospholipases are a diverse range of enzymes that have been grouped by their ability to 
hydrolyse phospholipids.   The phospholipase family is divided into the subgroups A1, A2, B, 
C and D according to the site of action within the generalised phospholipid molecule (see 
Figure 4.1).   The subgroup A2 hydrolyses phospholipids at the middle or sn-2 fatty acid to 
produce a free fatty acid and the corresponding lysophospholipid molecule.   Phospholipase 
A2 has been studied extensively because of the physiological importance of the hydrolysis 
products and the role of these products in disease (see Figure 4.2).   For example: the most 
common fatty acid occurring in the sn-2 position is arachidonic acid, the fatty acid central to 
the eicosanoid mediator pathway in inflammation.   The lysophospholipids liberated by the 
action of phospholipase A2 have also been implicated in various pathophysiological 
processes.  
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Figure 4.1: Site of action of the phospholipase enzymes on a generalised phospholipid 
molecule.   X can represent choline, ethanolamine, inositol, serine, glycerol, 
diacylglycerol etc (Mansbach, 1990). 
 
The physiological roles that phospholipase A2 plays are diverse, ranging from digestion of 
dietary phospholipids, cell membrane remodelling, host defence (Hanasaki & Arita, 1999), 
cell signalling, biosynthesis of eicosanoids (Lambeau & Lazdunski, 1999) to envenomation 
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(Gelb et al, 2000).   Phospholipase A2 exists as a family of isoforms, the recognised number 
of which has increased rapidly over the last five to ten years.   The isoforms can be grouped 
into secretory isoforms, cytosolic isoforms, calcium independent isoforms and platelet 
activating factor (PAF) acetylhydrolases (Hanasaki & Arita, 2002). 
 
Phospholipase A2 proteins utilising a catalytic Histidine: 
Typical phospholipase A2 isoforms (Group I, II, III, V, IX, X and XI) have phospholipid 
hydrolysing capability due to a catalytic histidine which is conserved along with an aspartate 
residue in the active site.   All secretory phospholipase A2 (groups I, II, II, V, X, XII) isoforms 
show a catalytic histidine and share a number of common features including: 
 - a conserved calcium binding loop, 
 - low molecular weight (13-18kDa1), 
- low milli-molar calcium dependency (Hanasaki & Arita, 2002) and  
- high sensitivity to reduction by chemicals such as DTT (Clark, Milona & Knopf, 
1990).   
 
The number of secretory phospholipase A2 isoforms recognised in mammals has increased 
from two isoforms in 1990 (IB and IIA) to ten (Hanasaki & Arita, 1999, Scott, Graham & 
Bryant, 2003).   The mammalian secretory phospholipase A2 isoforms that have identified 
(IB, IIA, IIC, IID, IIE, IIF, III, V, X and XII) all occur in humans except for IIC which 
appears to be a pseudogene.   The secretory phospholipases A2 have low homology and 
Singer et al (2002) state ‘different sPLA2 paralogs are not closely related isoforms since 
amino acid identity between any two is in the range <15% to 50%’. 
 
Phospholipase A2 proteins utilising a catalytic Serine: 
As discussed in the previous section, the catalytic activity of secretory phospholipase A2 
isoforms is dependent on a conserved histidine that occurs in a Histidine-Aspartate dyad.   
Several phospholipase A2 variants exist that do not exhibit a catalytic histidine, and the 
phospholipase A2 activity of these ‘orphans’ is dependent on a catalytic serine (Six & Dennis, 
2000).   Platelet activating factor (PAF) acetylhydrolase is one of the serine phospholipase A2 
variants.   PAF acetylhydrolase (group VIIA PLA2) shows the lipase consensus motif Gly-X-
Ser-X-Gly and the classic hydrolase triad of Ser273Asp296His351 (Six & Dennis, 2000).   Group 
                                                          
1 Human type III is an exception, the active protein forms a section of a larger protein of 55kDa (Scott, Graham 
& Bryant, 2003). 
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VIIIA and B are subunits of the PAF acetylhydrolase Ib protein and both exhibit the ‘pseudo 
lipase’ consensus motif of Gly-X-Ser-X-Val (Six & Dennis, 2000).   Group VIA 
phospholipase A2 (iPLA2) also contains the hydrolase (Gly-X-Ser-X-Gly) motif (Six & 
Dennis, 2000).   Groups IVA (cPLA2), IVB and IVC phospholipases A2 also exhibit a serine 
aspartate active site (Six & Dennis, 2000).   1-cysteine peroxiredoxin, (or bifunctional lung 
enzyme) was another unusual protein reported to exhibit phospholipase A2 activity (Chen et 
al, 2000, Kim et al, 1997).   Six and Dennis (2000) argue that this protein should not be 
classified as a phospholipase A2 because mutation of the serine (and cysteine) had no effect 
on phospholipase A2 activity (Kang, Baines & Rhee, 1998).   Six and Dennis (2000) proposed 
that the classification of a phospholipase A2 may only occur when a protein can be shown to 
catalyse the hydrolysis of the sn-2 bond of a phospholipid substrate, and when the complete 
amino acid sequence is known. 
 
The complexity of Phospholipase A2 Research: 
The enzyme characteristics and tissue distribution of phospholipase A2 isoforms show 
considerable overlap, making the study of specific isoforms at the protein level difficult.   The 
functions of many of the recently identified isoforms are yet to be elucidated and detailed 
investigations of tissue and cellular distribution and enzyme characteristics are yet to be 
performed.   The source of circulating secretory phospholipase A2 activity is unknown 
(Nevalainen, Gronroos & Kallajoki, 1995, Nevalainen, Haapamaki & Gronroos, 2000). 
 
The precise roles of phospholipase A2 has not been clearly defined in physiology, membrane 
maintenance or cellular signalling.   Even less is understood about the roles and interactions 
of the multitude of secretory PLA2 isoforms.   The complexity of the functions of the 
secretory PLA2 isoforms is likely to increase further during pathophysiological situations.   
Organs (Scott, Graham & Bryant, 2003), cells and tissues (Yang et al, 1999) are all known to 
contain multiple forms of phospholipase A2 proteins. 
 
Phospholipase A2 in disease: 
Since the physiological roles of recently described PLA2 isoforms is unclear, the role in 
disease states is essentially unknown.  
The study of phospholipase A2 in relation to disease has focussed on several key areas: 
- the role of phospholipase A2 at the site of inflammation or tissue damage, 
- the use of phospholipase A2 as a diagnostic or prognostic marker,  
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- the role of phospholipase A2 in the generation of eicosanoids,  
- the possibility of inhibition of phospholipase A2 to treat inflammatory conditions. 
 
 
Figure 4.2:   The multitude of products of phospholipase A2 Hydrolysis and their 
Cellular Response (Bomalaski & Clark, 1993). 
 
PLA2 involved in the pathogenesis of disease: 
Synovial fluid from patients with rheumatoid arthritis shows elevated levels of PLA2 (Hara et 
al, 1989, Lai & Wada, 1988).   Type II PLA2 is proposed to be involved in the pathogenesis 
of intestinal inflammation in Crohn’s disease and ulcerative colitis (Minami & Tojo, 1997).   
PLA2 levels correlate to mortality rates in patients with established MODS (Uhl et al, 1990, 
Uhl et al, 1995).   Recently it has been proposed that PLA2-II may “contribute to the 
induction of organ dysfunction but less of a role in sustaining organ system failure” (Abraham 
et al, 2003).  Elevated levels of sPLA2 have been shown to be a significant risk factor for 
presence of coronary artery disease (Kugiyama et al, 1999).   PLA2 is thought to be a 
circulating mediator of typhoid fever (Keuter et al, 1995). 
 
Elevated levels of PLA2 in serum of patients: 
Elevated levels of phospholipase A2 type II have been reported in the plasma of patients with 
septic shock (Green et al, 1991, Nevalainen et al, 1993), Crohn’s disease (Minami et al, 
1992), systemic lupus erythrematosus (Pruzanski et al, 1994) and ARDS (Arbibe, Vial & 
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Touqui, 1997, Romashin et al, 1992).   Serum concentrations of PLA2-II are considerably 
elevated in patients with surgical intensive care patients (Nyman et al, 1996). 
PLA2 as a marker: 
PLA2 is regarded as a sensitive marker for inflammatory activity in rheumatoid arthritis 
(Nevalainen & Gronroos, 1997).   Serum PLA2 correlates with the activity of Crohn’s disease 
and ulcerative colitis (Minami et al, 1992).   PLA2 type I in serum is useful in the diagnosis of 
acute pancreatitis but does not aid in predicting the severity of the condition (Nevalainen, 
Gronroos & Kortesuo, 1993).   Enhanced PLA2-IIA expression has been correlated to poor 5 
year survival in patients with prostate cancer (Graff et al, 2001, Jiang et al, 2002).  Elevated 
levels of secretory phospholipase A2 have been found to predict coronary events in patients 
with coronary artery disease, independent of other risk factors (Kugiyama et al, 1999). 
PLA2 as a eicosanoid producing enzyme: 
Synovial fluid from patients with arthritis shows elevated levels of arachidonic acid and 
downstream factors (PAF, leukotrienes and prostaglandins) derived from the hydrolysis by 
PLA2 (Bomalaski & Clark, 1993). 
PLA2 as a therapeutic target: 
The inhibition of PLA2 as a therapeutic strategy has been proposed for many years.   PLA2 
could be directly inhibited, inactivated by dephosphorylation or indirectly regulated by 
inhibiting mRNA translation of agents such as TNF or interlukins that activate PLA2 
expression (Waage & Bakke, 1988). There are many considerations for the use of 
phospholipase A2 inhibition as a  therapeutic strategy including: 
 - difficulty in targeting single isoforms, 
 - potential disruption to essential phospholipase A2 functions (membrane remodelling,
  digestion), 
 - the presence of multiple PLA2 receptors may mean that catalytically inactive 
  enzymes may still be able to act via signalling pathways (Scott, Graham & Bryant,
  2003). 
Recent results of the clinical trial of a type IIA selective inhibitor have shown no survival 
benefit but a statistically significant dose dependent improvement in patients with sepsis 
induced organ failure in the first 18 hours (Abraham et al, 2003). 
 
Assay of Phospholipase A2.  
Phospholipase A2 can be studied using biochemical enzyme activity assays based on the 
hydrolysis of phospholipids.   Biochemical assays are generally of limited value in the study 
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of phospholipase A2 isoenzymes in crude samples because of the difficulty in differentiating 
isoforms and the low abundance of PLA2 in mammalian tissue.   Conversely, biochemical 
assays for PLA2 can be very sensitive and robust.   PLA2 assays can be used for monitoring 
protein purification progress and examining enzyme characteristics.   Results obtained from 
different types of PLA2 assays (vesicle assays, mixed micelle assays, synthetic or natural 
membrane assays) can be difficult to compare on absolute terms, but one study showed that, 
in general, different assays showed similar relative results (Ghomashchi et al, 1999). 
 
Species differences: 
Although the use of an animal model would seem advantageous to study such a complex 
enzyme, there are significant limitations associated with phospholipase A2.   The species 
differences that exist encompass distinct enzyme characteristics, function and tissue 
distribution (Dr. K. Scott, personal communication).   Some examples of the species 
differences in phospholipase A2 are noted below: 
- In rats and humans the predominant secretory isoform is type IIA (Murakami et al, 
1998), whereas in mice the major secretory isoform is type V (Chen et al, 1994 (a), 
Sawada et al, 1999),  
 - In some strains of mice, type IIA is found only in the intestine (Sawada et al, 1999) 
- Humans have a soluble form of PLA2 receptor which is not found in other animals 
(Tischfield, 1997), 
- Patterns of PLA2 receptors are distinctly different in rabbits and humans (Tischfield, 
1997), 
- Expression profiles show that genes are regulated differently in humans and rodents 
(Scott, Graham & Bryant, 2003). 
 
General PLA2 Assay difficulties: 
The complexity of the kinetics of phospholipase A2 hydrolysis has ensured that this enzyme is 
a popular kinetics model.   Part of the complexity of the PLA2 kinetics arises from the ability 
of PLA2 to act at the interface of the hydrophobic membrane and the hydrophilic extracellular 
fluid.   Phospholipase A2 hydrolysis is dependent on traditional enzyme activity variables (for 
example, temperature, pH, cofactors, ionic strength, aqueous environment).   In addition PLA2 
activity is dependent on : 
 - substrate presentation (vesicles, micelles, bilayers), 
 - size of substrate aggregates (small or large vesicles), 
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 - presence of detergents or other enhancing agents, 
- whether substrate contains one or more phospholipid species. 
These variables can make interpretation of results and the comparison of results from different 
assays very difficult.   For example: 
- type V shows a preference for choline phospholipids over ethanolamine 
phospholipids when deoxycholate is present and the opposite preference when the 
detergent is omitted (Chen et al, 1994), 
- the production of lysophospholipid can inhibit the hydrolysis reaction (Lawrence & 
Moores, 1975). 
Many groups have tried to differentiate PLA2 isoforms using hydrolysis assays with different 
substrates, but it is not possible to draw conclusions from the results obtained due to 
significant overlap of results.   Studies of PLA2 inhibitors have shown that in general, PLA2 
assays show similar patterns, even though absolute results cannot be compared (Ghomaschi et 
al, 1999). 
 
Phospholipase A2 in the gastrointestinal tract: 
The study of phospholipases in the human gastrointestinal tract is complicated by difficulty 
obtaining tissue in suitably good condition (as the gut undergoes spontaneous autolysis after 
death).   In animal models it is difficult to obtain gut tissue without sacrificing the animal.   
Access to human tissue is very difficult but is essential in investigations of human gut 
pathologies due to significant species differences. 
 
Biochemical PLA2 assays; 
Early investigations found clear patterns in the distribution of phospholipases throughout the 
gastrointestinal tract, through cross sections of small intestinal mucosa and were able to 
discount a number of possible sources of the phospholipase activity.    Mansbach and 
colleagues (1982) showed that the phospholipase A2 in rat gut did not originate from 
pancreatic, salivary or gastric secretions by diverting relevant ducts away from the small 
intestine.   This group also showed that the phospholipase A2 activity was not bacterial by 
repeating their experiments in germ free rat lines.   They also found that the phospholipase A2 
activity in the small intestinal mucosa was ten fold greater in the crypts than at the villi tips.   
Secretory PLA2 was also found to increase with increasing distance from the ligament of 
Treitz to the ileo-cecal valve in rats (Sonnino & Pigatt, 1996). 
 
 89
Chapter 4 Introduction 
Type IIA Phospholipase A2 in Human Gut: 
Human Paneth cells (particularly the secretory apparatus) have been shown to have strong 
immunoreactivity to type IIA PLA2 (Kiyohara et al, 1992).   Morita and colleagues (1999) 
found that human ileal mucosa reacted with an antisynovial PLA2 antibody (and was therefore 
likely to be type IIA).   The Paneth cells were found to be the only cell type in the gut found 
to secrete type II PLA2 mRNA (Nevalainen, Gronroos & Kallajoki, 1995).  Differential 
display polymerase chain reaction (DD-PCR) was used to examine genes that were 
differentially expressed between the small and large intestine in mice (Keshav et al, 1997).   
A secretory phospholipase A2 isoform was found using this technique (Keshav et al, 1997) 
and was found to have significant homology to mouse enhancing factor and to rat and human 
secretory PLA2 type II proteins.    
 
Other phospholipase A2 isoforms in Human Gut: 
In the past five years attempts have been made to study the phospholipase A2 isoenzymes in a 
clear and systematic manner.   With the identification of each new secretory isoform came the 
probing of panels of human tissue for mRNA transcripts.   In normal human gut the 
transcripts corresponding to four of the isoforms have been detected (reviewed by Scott, 
Graham & Bryant, 2003): namely IIA (Cupillard et al, 1997), IID (Ishizaki et al, 1999), V 
(Cupillard et al, 1997) and XII-1 (Gelb et al, 2000). These results were obtained using either 
RT-PCR or Northern blotting.   The expression of type X in normal human gut has been 
shown by one group (Suzuki et al, 2000) but not by another group (Cupillard et al, 1997).  
These results are an indication of the complexity of phospholipase A2 in human gut but even 
then may be an oversimplification because: 
- northern hybridisation panels can be composed of a single sample (Scott, Graham & Bryant, 
2003) which may not be representative of the typical pattern, 
- they are an indication of the normal situation, likely to be complicated further in disease 
states, 
- as yet unidentified isoforms may exist (Scott, Graham and Bryant, 2003), 
- isoforms expressed at very low levels may not have been detected. 
 
In conclusion, Morita and colleagues (1999) state that there is a: 
“complex involvement of several phospholipases A2 in normal gastrointestinal tissues”.  
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A summary of the research conducted on the topic of phospholipase A2 involvement in gut 
pathology is presented in the following tables:
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 Table 4.1.   Phospholipase A2 in Intestinal Disease Research.
Group   Year Disease Study
group 
 Conclusions 
Otamiri et al   1987 Ischaemia/
reperfusion injury 
Rat Increased levels of lysophosphatidylcholine in 
ischaemic gut mucosa compared with non-
ischaemic control.   Increased 
lysophosphatidylcholine or PLA2 may mediate 
mucosal injury.  
Otamiri, Lindahl 
& Tagesson 
1988  Ischaemia/
reperfusion injury 
Rat Mucosal injury and increased mucosal 
permeability seen in I/R is prevented by inhibition 
of PLA2. 
Otamiri & 
Tagesson 
1989   Ischemia/
reperfusion injury 
Rat PLA2 increased in mucosa during I/R, and was 
significantly different to control mucosa. 
Koike et al   1992 Ischemia/
reperfusion injury 
 Rat Gut PLA2 was increased.   Inhibition of PLA2 
reduced distant organ injury by preventing PMN 
influx, PMN superoxide production and lung leak. 
Minami et al 1993 Crohn’s disease Human Levels of PLA2 type II (mRNA and protein) were 
higher in ileal than cecal mucosa.   Increased 
serum levels of PLA2 seen in Crohn’s patients 
may be due to leakage of protein from the gut 
mucosa. 
Minami et al   1994 Crohn’s disease
and ulcerative 
colitis 
Human Actively inflamed mucosa of Crohn’s disease 
showed higher levels of PLA2 activity and type II 
immunoreactivity.   Severely inflamed mucosa of 
ulcerative colitis patients showed higher levels of 
PLA2 and type II immunoreactivity than control 
mucosa. 
Koike et al    1995 Ischemia/
reperfusion injury 
Rat PLA2 activated by I/R.  Remote organ damage 
caused by I/R could be reduced with a PLA2 
inhibitor 
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Lilja et al 1995 Crohn’s disease Human Increased levels of PLA2 may contribute to 
inflammation in Crohn’s disease and in recurrent 
Crohn’s after resection.   Increased levels of 
mRNA of type I, II and cytosolic PLA2 observed, 
but type II was predominant. 
Lilja et al 1995 Crohn’s disease Human Increased levels of PLA2 may contribute to 
inflammation in Crohn’s disease and in recurrent 
Crohn’s after resection.   Increased levels of 
mRNA of type I, II and cytosolic PLA2 observed, 
but type II was predominant. 
Nevalainen, 
Gronroos & 
Kallajoki 
1995  Crohn’s disease
and ulcerative 
colitis 
Human Paneth cells were the only cells that showed 
mRNA for type II PLA2.   Type II 
immunoreactivity in blood vessel walls likely to 
reflect transport of the protein rather than 
synthesis. 
Qu et al   1996 LPS infusion Rat PLA2 release from Paneth cells was able to be 
triggered by LPS. 
Sonnino et al 1997 Graft preservation Rat Calcium dependent, secretory PLA2 accumulated 
rapidly during preservation.  PLA2 likely to be 
proinflammatory and a priming agent for intestinal 
tissue damage. 
Arcuni et al   1999 Graft preservation Rat PLA2 released in response to other proteins, 
perhaps cytokines, but not due to cell death.   
PLA2 inhibition improves the outcome of 
preservation. 
Haapamaki et al   1999 Crohn’s disease
  
Human Columnar epithelial cells in Crohn’s mucosa 
responsible for the synthesis of PLA2-II in colon 
and small intestine, but not in control mucosa. 
Morita et al   1999 Inflammatory
bowel disease  
Human Isoform hydrolysing PE more closely related to 
inflammation than the PC hydrolysing PLA2 
which was found irrespective of inflammation.  
Table 4.1 continued.   Phospholipase A2 in Intestinal Disease Research. 
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 Table 4.1 continued.   Phospholipase A2 in Intestinal Disease Research. 
Koike et al    2000 Ischemia/
reperfusion injury 
Rat PLA2 activity in portal circulation was  
10 fold higher than systemic circulation, 
suggesting that the serum PLA2 activity arises 
from ischaemic gut. 
Weifeng et al   2001 Ischaemia/
reperfusion injury 
Rat Inhibition of PLA2 early in the 
ischaemia/reperfusion process decreased bacterial 
translocation, endotoxin release, pro-inflammatory 
mediator and cytokine levels.   This reduced the 
injury to remote organs. 
Thomas, Karnik 
& 
Balasubramanian 
2002  Surgical
manipulation of 
intestine. 
Rat Inhibitors of PLA2 were protective against lung 
damage which may be due to reduced neutrophil 
infiltration, reduced oxidative stress or reduced 
permeability. 
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Chapter 4: Phospholipase A2 activity in ischaemic/infarcted human bowel: 
Previous research had detected phospholipase A2 in bowel and had identified the 
major isoform as type IIA (Kiyohara et al, 1992, Morita et al, 1999, Nevalainen, 
Gronroos & Kallajoki, 1995).   There is some evidence that suggests that a complex 
pattern of phospholipase proteins in the bowel (Morita et al, 1999, Scott, Graham & 
Bryant, 2003).   As a preliminary control experiment, immunodepletion was 
conducted to remove the phospholipase A2 isoform type IIA and its closely related 
isoform type V from a recombinant type IIA standard (Figure 4.3).   Immunodepletion 
of phospholipase A2 types IIA and V from human bowel showed that types IIA/V 
were present in infarcted human bowel content (Figure 4.4), but did not account for 
all of the phospholipase A2 activity (Figure 4.5). 
 
The phospholipase A2 activity was measured in several patients with matched tissue 
homogenate and bowel lumen content (Figure 4.6).   These results are expressed as 
specific activity of phospholipase A2 due to the large variation of total protein 
between these samples.   Phospholipase A2 activity was significantly increased in the 
lumen content (Fisher’s exact test, p=0.048), compared with the matched tissue 
homogenate.   On one occasion ischaemic (tissue damage rating 2-3) and infarcted 
tissue (tissue damage rating 3) were obtained from the one patient, and the infarcted 
tissue showed significantly higher phospholipase A2 activity (p<0.0005), (Figure 4.7).   
The tissue damage rating and the PLA2 activity were compared in several samples of 
bowel tissue homogenate (Figure 4.8).   The next section details the purification of the 
protein responsible for this phospholipase A2 activity (Chapter 5). 
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Figure 4.3 Immunodepletion of PLA2 from recombinant PLA2-IIA 
protein with antibodies 4A1 (type IIA specific) and 10B2 (type IIA+V 
specific).   Results are expressed as the mean +/- standard error of 
triplicate assays.   The recombinant protein was a generous gift from 
Dr. Kieran Scott.
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Figure 4.4 Silver stained gel  of the antibody-bead-PLA2 complex after 
immunodepletion from bowel samples.  SDS-PAGE gel:  4-20% Tris Glycine 
gel, Novex.
Lanes:
1- See Blue Plus2 markers.
2- immunodepletion with 4A1 antibody.
3-immunodepletion with 10B2 antibody.
4-recombinant sPLA2-IIA standard.
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Figure 4.5 Western blotting of immunodepleted bowel autolysis 
sample, and phospholipase A2 activity before and after 
immunodepletion of phospholipase A2 isoforms IIA and V.   
The arrow indicates the immunoreactive protein of interest.
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Figure 4.6 PLA2 activity in matched homogenised bowel tissue and 
lumen content.   These results are significantly different, Fisher’s 
exact test, two tailed p=0.048.   Fisher’s exact test was chosen due to 
the small number of samples.   These results are presented as the 
mean +/- standard error of triplicate assays.
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Figure 4.7 Two homogenised bowel tissue samples from same 
patient.   The results are presented here as the mean +/- standard error 
of triplicate assays.   The tissue damage rating for these tissues was 3 
for the infarcted tissue and 2-3 for the ischaemic tissue, using the 
scale published by Sun et al, 1997.
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Figure 4.8 Tissue damage rating of Sun et al, 1997 and corresponding  
PLA2 activity of various homogenised bowel tissue samples.   These 
results are presented as the mean +/- standard error of at least triplicate 
assays.
Discussion 
Chapter 4 Discussion: 
Type IIA PLA2 had been described in the bowel by many other groups, using a 
variety of techniques (immunohistochemistry, in situ hybridisation, differential 
display PCR).   Type V PLA2 is another secretory PLA2 isoform and shares very 
similar enzyme characteristics to type IIA.   Type V PLA2 has been detected at low 
levels in normal human small bowel by Northern blotting (Cupillard et al, 1997).   In 
this study, we chose to investigate phospholipase A2 at the protein level, as we wanted 
to focus on the activity of the enzyme and were concerned about mRNA degradation 
that may occur as a result of bowel injury.   Immunoprecipitation of secretory 
phospholipase A2 types IIA and V from bowel samples was conducted.   The 
immunoprecipitation experiment was verified by duplicating the same set of 
conditions using recombinant human type IIA PLA2 as the enzyme source.   The 
antibodies 4A1 (IIA specific) and 10B2 (cross reactive with types IIA and V) were 
used.   As expected, phospholipase A2 types IIA/V were found to be present in human 
bowel samples as shown by silver stained gels of the proteins attracted to the resin-
immobilised antibodies.   Also as expected, type V PLA2 is likely to be a minor PLA2 
isoform in human bowel, as the difference between the enzyme activity remaining 
after depletion with either antibody 4A1 or 10B2 was very similar.   The more 
surprising but interesting result was that removal of types IIA/V from the bowel 
samples failed to abolish all of the phospholipase enzyme activity.   An average of 
approximately one third of the phospholipase activity remained after removal of types 
IIA/V phospholipase A2.   This result was not simply due to an inadequate amount of 
antibody, as when an additional ten fold excess of immobilised antibody was used, the 
enzyme activity remained.   The immunoprecipitated samples were analysed by 
Western blotting and the remaining immunoreactive band appeared to be of low 
molecular weight.   The gels for Western blotting were run under non-reducing 
conditions, as the epitope recognised by the antibody 4A1 is reported to be lost upon 
reduction (Rice et al, 1998).   A protein purification process was then undertaken with 
the aim of identifying the protein responsible for this unexpected phospholipase 
activity (Chapter 5). 
 
We were fortunate to have access to human bowel excised during surgery to examine 
the phospholipase activity.   Access to human bowel tissue in suitably good condition 
can be difficult due to post mortem autolysis.   We had access to infarcted small 
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bowel tissue and lumen contents, and also to normal small bowel from patients 
undergoing right hemicolectomy.   The normal bowel samples were always from the 
terminal ileum.   The samples of infarcted bowel were obtained from a number of 
regions along the length of the resected small bowel.   As phospholipase activity is 
reported to increase along the length of the small intestine (a study in rats, Sonnino et 
al, 1996) we did not try to compare all of the absolute results between samples.   
Samples of tissue and lumen content were frozen as soon after surgery as practical.   
Phospholipase activity has been reported to remain constant with freezing and 
extended storage.   For example, the phospholipase A2 from peritoneal exudate was 
reported to be stable for four months at 4oC (Chang et al, 1987).   Our investigations 
also verified that the phospholipase activity was stable with storage at –80oC for 
several months and also with repeated freeze-thaw cycles (results not shown). 
 
The study of phospholipase A2 in the bowel has generally focussed on normal rodent 
bowel tissue.   Human bowel phospholipase A2 research has typically focussed on 
normal tissue, at the RNA level, due to the difficulties obtaining sufficient diseased 
tissue for protein studies (for example, biopsy samples), and the complexity of this 
protein family.   Few publications, particularly in these past decade, have been 
reported that combine: 
 - human bowel tissue 
 - phospholipase at the protein level 
 - diseased tissue 
 - bowel ischaemia/reperfusion injury. 
We have chosen to investigate phospholipase enzyme activity, at the protein level in 
normal and ischaemic/infarcted human bowel with the aim of better understanding the 
role of this disease associated protein. 
 
On a number of occasions, matched infarcted bowel tissue and lumen content were 
obtained from the same patient.   The phospholipase activity in the lumen was 
significantly higher than its corresponding tissue homogenate.   This may reflect the 
release of the enzyme into the bowel lumen from a storage site in the tissue, and may 
provide a route for entry into general circulation.   This idea is supported by evidence 
that intestinal permeability increases in response to ischaemia and infarction, and 
results in the release of gut derived factors into circulation (Kong et al, 1998).   
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Alternatively, the enzyme may be actively synthesised and released into the lumen in 
response to the ischaemic damage and may subsequently enter circulation.   The 
alternate possibility is that the presence of increased phospholipase activity in the 
lumen simply reflects cell death and therefore leakage of the protein.   A study 
investigating the release of phospholipase into bowel preservation fluid concluded 
that the release of the enzyme was not due to leakage of protein from dying cells 
(Sonnino et al, 1997).   This group provided data showing the absence of release of 
lactate dehydrogenase to support their argument (Sonnino et al, 1997).   An approach 
like this would be valuable to assess whether the increased phospholipase activity is 
due to cell death, or active release, and requires further elucidation. 
 
The increased phospholipase activity observed as a consequence of tissue injury, 
infection or inflammation may be a beneficial response to the patient in a number of 
ways.   Phospholipase A2 is known to have anti-bacterial properties (Nevalainen, 
Haapamaki & Gronroos, 2000).   Phospholipases are likely to aid in the removal or 
rebuilding of peroxidised or damaged phospholipids (Vadas et al, 1993).   
Conversely, phospholipase hydrolysis products have many tissue and cell damaging 
effects, and inflammatory properties, as discussed in the introduction to this chapter 
(Figure 4.2).   For example, lysophospholipids are cytotoxic (Schoenberg & Beger, 
1993).   The roles of phospholipase A2 and its corresponding hydrolysis products in 
inflammation, infection and tissue injury require detailed investigation.   Conceivably 
the important concept is the balance between the beneficial roles and damaging 
effects of phospholipase during disease development. 
 
On one occasion two bowel tissue samples were obtained from one patient, each 
showing a different level of ischaemic damage.   It is not unusual for the bowel to 
show areas of severe damage and areas of mild damage in close proximity because of 
the arrangement of the blood supply to the bowel.   The infarcted tissue was given a 
tissue damage rating of 3, according to the scale proposed by Sun and colleagues 
(1997).   The infarcted tissue showed significantly higher phospholipase activity than 
the adjacent ischaemic tissue (tissue damage rating of 2-3).   This is an interesting 
finding (even though this is sample size of only one) as there may be a positive 
relationship between the severity of tissue damage (from normal to severe infarction) 
and the phospholipase activity of the tissue homogenate.   Many biomarkers of bowel 
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infarction have been found to appear too late to be clinically useful, or decrease 
before the condition has been rectified.    
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Chapter 5: Protein purification. 
 
Purification of non-pancreatic Phospholipase A2 from mammalian tissue: 
The primary structure of pancreatic phospholipase A2 was reported by Puijk, Verheij 
& de Haas (1977).   Venom and pancreatic tissue contain high amounts of 
phospholipase A2 (typically 1-10% of total protein) (Verheij, Slotboom & de Haas, 
1981).  In 1982, a phospholipase A2 of similar size to the pancreatic isoform was 
isolated from the ileum of pigs, and was found to have distinctly different 
characteristics (N-terminal amino acid sequence, isoelectric point, high proportion of 
basic to acidic amino acid residues)(Verger et al, 1982).   Extracellular phospholipase 
A2 found at the sites of inflammation sparked great interest.   A soluble phospholipase 
A2 from the synovial fluid of patients with rheumatoid arthritis was purified and its 
characteristics were found to be distinct from the pancreatic isoform (Stefanski et al, 
1986).   Phospholipase A2 is thought to be central in the eicosanoid biosynthetic 
pathway due to the release of arachidonic acid.  The purification of secretory 
phospholipase A2 from rheumatoid arthritis synovial fluid (to obtain sequence data or 
amino acid composition) was achieved almost simultaneously by three groups (Hara 
et al, 1989, Kramer et al, 1989, Seilhamer et al, 1989).   The latter two groups also 
reported the identification of the N-terminal amino acid sequence: 
 
Group: Source of PLA2: Manuscript 
submitted: 
Amino acid sequence 
published: 
Kramer et al, 
1989 
Platelets and 
Rheumatoid 
arthritis synovial 
fluid 
December 20, 
1988 
NLVNFHRMIKLTTGKEAAL
Hara et al, 1989 Rheumatoid 
arthritis synovial 
fluid 
September 28, 
1988 
NO SEQUENCE DATA. 
Seilhamer et al, 
1989 
Rheumatoid 
arthritis synovial 
fluid 
December 27, 
1988. 
?LVNFHRMIKLTTGKEAAL 
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Type II phospholipase A2 has been purified to homogeneity and at least partial amino 
acid sequence determined from: 
 
Normal animal tissues/fluids: 
Porcine ileum (Verger et al, 1982). 
Stimulated rat platelets (Hayakawa et al, 1987). 
Rat liver (Aarsman et al, 1989). 
Rat spleen (Ono et al, 1988). 
Normal human tissues/fluids: 
Platelet concentrate (Kramer et al, 1989). 
Spleen (Kanda et al, 1989). 
Ileal mucosa (Minami et al, 1993). 
Diseased animal tissue/fluids: 
In models of peritonitis:  
-rabbit ascitic fluid treated with glycogen IP (Forst et al, 1986). 
-rat peritoneal fluid treated with casein IP (Chang et al, 1986, Chang et al, 
1987). 
Diseased human tissue/fluids: 
Synovial fluid from rheumatoid arthritis patients (Lai & Wada, 1988). 
Synovial fluid from arthritis patients (Kramer et al, 1989). 
 
The purification schemes used in the research cited above generally involved the use 
of a series of different chromatography columns (ion exchange, hydrophobic 
interaction, gel filtration, affinity, RP-HPLC).   The purification processes have 
monitored phospholipase A2 using activity assays of column fractions at all stages of 
the purifications.   These purification schemes are laborious, time consuming and 
expensive. 
 
The purification of phospholipase A2 from animal tissues or fluids can be difficult due 
to the low abundance of the protein in samples and unusual characteristics such as 
tendency to adhere to glass and some column packings.   The number of isoforms, 
difficulty in differentiating isoforms and lack of many antibodies further compound 
these problems.   Phospholipase A2 enzymes have some characteristics that are 
advantageous during purification, such as heat and acid stability.   Phospholipase A2 
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enzymes often have characteristics that are quite different to the majority of proteins 
in a sample, such as isoelectric point.   The majority of proteins have acidic to neutral 
isoelectric points (pI 4-7) whereas many phospholipase A2 isoforms tend to have basic 
isoelectric points.          
 
Heparin Sepharose affinity chromatography: 
Heparin sepharose chromatography can be used to purify several proteins types based 
on affinity binding and ion exchange interactions.   Heparin affinity is exhibited by 
many coagulation factors, enzymes, growth factors and receptor proteins (reviewed by 
Farooqui, Yang & Horrocks, 1994).  Affinity chromatography is advantageous due to 
its ability to quickly bind proteins of interest and elute the majority of contaminating 
proteins.   The specifically bound proteins can be washed extensively and eluted in 
suitable buffers.  The affinity of a protein to a ligand such as heparin can be quite 
specific and slight changes in the elution conditions can allow very narrow sample 
fractions, and therefore high purity fractions.  
 
Heparin is a group of naturally occurring glycosaminoglycans.   The heparin members 
vary greatly in size (5 to 40 kDa) but share characteristics such as being highly 
charged, highly sulphated, and composed of disaccharide repeating units of 
glucuronic acid and D-glucosamine (Dua & Cho, 1994).   In vivo, heparin occurs only 
in mast cells (Farooqui, Yang & Horrocks, 1994). 
 
The attraction of proteins to immobilised heparin in a chromatography situation is 
based on either specific interactions or electrostatic interactions (Farooqui, Yang & 
Horrocks, 1994).  It has been proposed that the specific binding of a protein to heparin 
is due to a cluster of cationic residues on the outer surface of an amphiphilic α helix 
(Dua & Cho, 1994).   Heparin can be immobilised on resin such as sepharose or 
agarose, and packed in columns for affinity purification of proteins.   The proteins 
with an affinity for the heparin are retained on the column and the rest of the material 
is washed through.   The proteins with heparin affinity can then be eluted with an 
excess of heparin or changing the elution buffer composition with salts or denaturants 
(Farooqui, Yang & Horrocks, 1994). There are some considerations for the use of 
heparin in protein purification, firstly the affinity of a particular protein to the heparin 
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may be too high, meaning that protein is lost with each chromatographic run.   
Secondly, heparin is known to inhibit some classes of protein, though this is generally 
reversible.   Heparin (at levels used for anticoagulation) reversibly inhibits 
phospholipase A2 activity.   For this reason, serum is preferable in assays when 
undiluted samples are used (such as antibacterial plate assays).   In highly sensitive 
assays where diluted samples are used, both plasma and serum are suitable 
(Weinrauch et al, 1998).   Affinity columns such as heparin columns can become 
fouled with protein build-up, but columns can be cleaned with a variety of agents to 
prevent this.   Eluted fractions can contain high concentrations of salts and may 
require dialysis before further purification steps. 
 
Heparin sepharose has been used in the purification of a variety of lipases, kinases 
and phospholipases (reviewed by Farooqui, Yang & Horrocks, 1994).      In the case 
of phospholipase A2, the enzyme can be eluted from the column with increasing 
concentrations of salts (KCl, NaCl) and thus retain native confirmation and enzyme 
activity.   Several of the secretory isoforms of phospholipase A2 have high affinity for 
heparin (IIA, IID, IIE), while others have less affinity (IB, IIF, V), (see Table 5.2). 
 
The strength of the affinity of phospholipase A2 isoforms generally follows the degree 
of basicity, therefore in general isoforms with high pI values have higher heparin 
affinity (Murakami et al, 2001), see Figure 5.7.   Heparin binding of phospholipase A2 
is due to a cluster of 5 to 7 C-terminal amino acid residues (Arni & Ward, 1996, 
Murakami, Nakatani & Kudo, 1996), see Figure 5.8.   The cluster of amino acids 
responsible for heparin binding may only be evident on examination of the three 
dimensional structure (Koduri et al, 1998).   The heparin binding site is also a 
substrate binding region, but is independent of active site residues (Dua & Cho, 
1994). 
 
Purification schemes  
Several phospholipase A2 purification schemes have employed a heparin sepharose 
column, usually preceeded by a crude sample clean-up step and followed by one or 
more RP-HPLC columns.  
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Table 5.1 Purification of PLA2 by Heparin Affinity Chromatography: 
 
Author(s) Year Source of PLA2 Purification scheme 
Hara et al 1989 Human rheumatoid 
arthritis synovial fluid 
Heparin sepharose. 
Hydrophobic interaction. 
RP-HPLC. 
Diccianni et al 1991 Porcine pancreatic PLA2 
(Sigma) 
Heparin Affigel. 
Kim, Kudo & 
Inoue 
1991 Rabbit platelet enriched 
plasma, cytosolic PLA2
Heparin sepharose. 
Ion exchange. 
Hydrophobic interaction. 
Ion exchange. 
Gel filtration. 
Murakami et al 1998 Culture supernatent 
CHO/HEK stable 
transfectants. 
Heparin sepharose. 
Shimbara et al 1999 Baculovirus derived 
recombinant rat and 
mouse PLA2. 
Heparin Sepharose. 
Anti-sPLA2-IIA 
immunoaffinity column. 
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Table 5.2.   Heparin affinity of Phospholipase A2 Isoforms: 
 
Phospholipase A2 isoform Heparin affinity 
(Concentration of NaCl 
required for elution) 
Isolectric point (Human 
isoform), calculated from 
the Swiss Prot database) 
IB No binding 7.95 
IIA 0.8M 9.38 
IID 40% recovery at 1M  8.75 
IIE 1M 8.53 
IIF No binding 4.51 
III* Unknown 9.1 
V 0.4M 8.72 
X No binding 5.1 
XII Unknown 6.3 
 
The Rotofor ® preparative isoelectric focussing system:   
The BioRad Rotofor® cell is a liquid phase preparative isoelectric focussing 
apparatus characterised by the short length of time required for separation 
(approximately 4 hours for an average analysis).   The Rotofor® cell has been 
successfully used in the study of proteome of cerebrospinal fluid, specific enzymes in 
whole plasma, purification of haemoglobin variants A, C and F, and separation of 
peanut lectin isoenzymes. 
 
Liquid based isoelectric focussing such as the Rotofor® cell establish a pH gradient 
with carrier ampholytes in a liquid medium containing a low concentration of 
detergent.   Urea and denaturants such as DTE can be added as required.   Urea can be 
added to aid in the prevention of precipitation.   Glycerol can be added to maintain 
solubility and stability of proteins.   A constant current is then applied which causes 
proteins and ampholytes to migrate toward the anode or cathode according to their net 
charge until they reach their pI.   The liquid fractions are collected simultaneously and 
quickly to avoid loss to the pH gradient using vacuum.   The fractions can then be 
                                                          
*Mammalian sPLA2 type III occurs as a central PLA2 like domain flanked by two protein domains of 
unknown function.   The central sPLA2 like domain has no heparan sulphate proteoglycan binding 
(Scott, Graham & Bryant, 2003). 
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analysed for pH, total protein, a specific target protein or run on one or two 
dimensional gels.   The use of a liquid phase for the protein separation is 
advantageous as there is no need for elution from a solid medium.   Another 
advantage of liquid based IEF is that toxic polymerisation agents are avoided and 
ampholyes could be omitted in favour of creating the pH gradient by ‘seeding’ the 
IEF fluid with a pure protein of interest.   This may have potential in the 
pharmaceutical industry for production of purified proteins (Righetti, Wenisch & 
Faupel, 1989).  
 
Advantages of Preparative IEF: 
The advantages of preparative isoelectric focussing include the retention of biological 
activity, a high degrees of purification in a single step and flexibility in terms of 
sample type and size.   Isoelectric focussing is capable of high resolution separations, 
is able to concentrate the protein of interest and defines a physical parameter of the 
protein.   The use of the Rotofor ® as a prefractionation step before 2DE has been 
reported to improve the mass spectrometry sequence coverage in comparison to 2DE 
alone and aids in the identification of low abundance and post translationally modified 
proteins (Westman-Brinkmalm & Davidsson, 2002). 
 
Disadvantages of Preparative IEF: 
The introduction of ampholytes can be disadvantageous.   Ampholytes can be difficult 
to remove (Bloomster & Watson, 1983) and can interfere with post separation 
analysis.   Ampholytes can be removed with dialysis, gel filtration, ultrafiltration, ion 
exchange chromatography or protein precipitation, though removal may be 
incomplete.   It has been suggested that ampholytes may bind irreversibly with 
proteins, but Baumann and Chrambach (1975) found that this was not the case. 
 
Considerations for the use of Preparative IEF: 
The pH gradient in a liquid phase isoelectric focussing apparatus is achieved with a 
mixture of carrier ampholytes.   Ampholytes are small, amphoteric molecules that 
have a high buffering capacity centered at their pI.   Because ampholytes behave in a 
similar fashion to proteins or peptides, care must be taken to avoid interference in 
protein analysis.   For example, carrier ampholytes will interfere with total protein 
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assays and give inflated estimates of protein concentrations (Bloomster & Watson, 
1983).   Ampholytes are incompatible with the commonly used total protein assays 
bicinchoninic acid (BCA) (Brown, Jarvis & Hyland, 1989), Bradford and Lowry 
assays (Guttenberger, Neuhoff & Hampp, 1991).   The precipitation of the protein or 
immobilisation of the protein on a membrane can overcome the interference by 
ampholytes.  
 
Detergent is added to the isoelectric focussing buffer to solubilise the proteins and to 
prevent aggregation.   The detergent used must carry no net charge (non-ionic or 
zwitterionic) to enable the detergent to remain in the system under high currents.   
Detergents may interfere with some biological assays, for example total protein assays 
or those based on lipid or membrane substrates.   The interference of detergent in total 
protein assays can be overcome by precipitating or immobilising the protein and 
thoroughly washing the sample.   The interference in other assays can be more 
difficult to overcome. 
 
Some proteins are inherently unstable and may not tolerate complicated, multiple step 
purification procedures.   The isoelectric focussing procedure can lead to protein loss 
for the following reasons: 
-proteins may be unstable at their pI and may precipitate 
-proteins may not tolerate very dilute solutions 
-the detergent, reductants etc may alter the biological activity or structure of the 
protein 
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Chapter 5: Protein purification: 
The protein of interest was purified from bowel tissue rather than from blood because 
the tissue showed higher specific activity for phospholipase A2, was available in 
larger quantities and was more likely to express a tissue specific protein.   The 
separation techniques were chosen because they retained the native enzyme activity, 
exploited an unusual protein characteristic and removed large amounts of 
contaminating protein at each step.   The purification progress was monitored by 
analysis of all fractions for PLA2 activity with a 14carbon labelled phospholipid mixed 
micelle assay. 
 
Unfortunately, a number of preliminary purification processes, each with different 
separation steps, resulted in the identification of haemoglobin as the protein of 
interest.   These purification schemes are summarised in Figures 5.1 to 5.3.   To verify 
that haemoglobin was not responsible for the phospholipase A2 activity, a variety of 
concentrations were assayed for activity (Figure 5.4), and, as expected, none showed 
PLA2 activity.   The absence of PLA2 activity in haemoglobin was verified by 
comparison to ultrapure water, the diluting buffer used (acetate) and an equivalent 
concentration of albumin (Figure 5.5).   To show that haemoglobin did not 
synergistically enhance phospholipase A2 activity, various amounts of haemoglobin 
were incubated with pancreatic phospholipase A2 and then assayed for enzyme 
activity (Figure 5.6). 
 
Heparin sepharose affinity chromatography was performed using a step gradient of 
sodium chloride to elute bound proteins.   The major peak of total protein was eluted 
from the chromatography column with 0.05M sodium chloride (Figure 5.9 and 5.10).   
The majority of phospholipase A2 enzyme activity required 0.5M sodium chloride for 
elution (Figure 5.10).   The fractions with the highest phospholipase A2 activity were 
then pooled for the next purification step.   A step gradient of the elution buffers was 
used, and 20 column volumes were routinely employed due to the low contaminating 
protein levels that resulted (Figure 5.11).   Due to the high salt concentration of the 
heparin sepharose column fractions, the pooled fractions were dialysed against 
phosphate buffer to reduce the molarity to 10mM.   The dialysis step did not reduce 
the enzyme activity of the samples (Figure 5.12). 
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Preparative isoelectric focussing was performed using the Rotofor® system.   A 
preliminary experiment was conducted to confirm that the isoelectric focussing buffer 
(detergent, ampholytes, glycerol) did not interfere with the phospholipase A2 activity 
assay (Figure 5.13).   The Rotofor® experiments were run until the power output had 
stabilised for an hour (Figure 5.14).   The fractions obtained from Rotofor® 
experiments were analysed for pH, phospholipase A2 activity (Figure 5.15) and were 
run on reducing SDS-PAGE (Figure 5.16).   Five consecutive Rotofor® experiments 
were conducted to investigate the reproducibility of the system, which was found to 
be very good (Figure 5.17).   Gels of typical fractions show that the majority of the 
contaminating protein focussed in the neutral to acidic range of isoelectric points 
(Figure 5.18), while the phospholipase A2 activity focussed in the basic region (Figure 
5.15).   The active fractions from a representative Rotofor® experiment were pooled 
and re-fractionated (Figure 5.18), which allowed a better estimation of the isoelectric 
point of the protein of interest (~9.7).   The re-fractionation experiment extended the 
number of fractions with a pH of between 7.5 and 10 (Figure 5.19).   The basic 
fractions of the re-fractionation experiment were run on SDS-PAGE, but no protein 
band was evident of the expected size (Figure 5.18), and for this reason, a scaled up 
purification was undertaken to obtain enough protein for identification . 
 
Active fractions from a Rotofor® run were pooled and run under non-reducing 
conditions, to retain phospholipase A2 activity.   Proteins were electro-eluted from the 
gel and analysed for phospholipase A2 activity.   Pre-stained protein molecular weight 
markers were run at the same time and their mobilities were used to construct a 
standard curve (Figure 5.20).   Enzyme activity was present in fractions 8&9, 
corresponding to a protein of between 16 and 20 kilodaltons.   The pH of optimal 
enzyme activity was 9 (Figure 5.21).   An overview of the purification scheme is 
presented in Figure 5.22, and this represents an approximately 9700 fold purification. 
 
The scaled up purification system resulted in highly purified material for protein 
identification.   A typical silver stained gel of active Rotofor® fractions is shown in 
Figure 5.23, and this indicates that the protein was >95% pure.   The fractions 
exhibiting phospholipase A2 activity matched well with the fractions exhibiting a 
protein band at approximately 21 kDa.   The active fractions were pooled and 
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concentrated by Vivaspin centrifugal cartridges.   These cartridges appeared to 
concentrate the protein of interest more effectively than ethanol precipitation, 
although the latter was superior for removing ampholytes (Figure 5.24).   The active 
fractions concentrated using the Vivaspin cartridges were run on two different gel 
systems, (BisTris, Invitrogen and TrisGly, Gradipore), digested with trypsin and 
analysed by mass spectrometry.   Positive (various protein markers) and negative (gel 
pieces from no-protein lanes) controls were also digested and analysed in the same 
manner.   The unknown protein from the BisTris system was identified as peptidyl 
prolyl isomerase/cyclophilin B (Figure 5.26).   The positive control from the BisTris 
system was correctly identified as lysozyme (Figure 5.26).   The unknown protein 
from the TrisGly system was also identified as peptidyl prolyl isomerase/cyclophilin 
B (Figure 5.27).   The positive control from the BisTris system was correctly 
identified as restriction endonuclease (Figure 5.27).   The presence of cyclophilin B in 
a variety of human samples was then investigated (Chapter 6). 
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Bowel content samples
Ammonium sulphate precipitation
Alkaline urea gel
Gel slices assayed for 
PLA2 activity.
Electrotransfer of proteins 
to PVDF membrane.
Region corresponding to 
PLA2 activity submitted to 
N-terminal sequencing.
Results: proteins identified 
as Haemoglobin α and β.
Figure 5.1
Purification scheme 1.
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Bowel content samples
Heparin sepharose chromatography
Fractions with 
highest PLA2
activity retained.
Alkaline urea gel to 
verify mobility of 
PLA2 activity.
Concentrated ten fold 
(SpeedVac).
SDS-PAGE and 
electrotransfer of proteins 
to PVDF membrane.
N-terminal sequencing
Results: proteins identified 
as Haemoglobin α and β.Figure 5.2
Purification scheme 2.
120
Bowel content samples
Heparin sepharose chromatography
Fractions with highest PLA2
activity retained.
Preparative isoelectric 
focussing (Rotofor®).
Fractions with highest 
PLA2 activity retained.
Concentrated up to three 
fold (SpeedVac).
SDS-PAGE, silver stained, trypsin 
digest of protein bands.
Nano ES/MS/MS
Figure 5.3
Purification scheme  3.
Results: proteins identified 
as Haemoglobin β.
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Figure 5.4: The lack of phospholipase A2 activity of 
haemoglobin.   Haemoglobin (human, Sigma) was 
diluted in acetate buffer (pH 5.5).   These results are 
presented as the mean +/- standard error of 
triplicate assays.
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Figure 5.5: The lack of phospholipase A2 activity in 
haemoglobin (25µM), bovine serum albumin (25µM), ultrapure
water and acetate buffer (pH 5.5).
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Figure 5.6: Pancreatic phospholipase A2 (0.1µg/mL 
containing 1mg/mL BSA, 10mM Tris) activity with 
various amounts of added haemoglobin.
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Figure 5.7:   Heparin binding of PLA2 isoforms.   
The sodium chloride concentration required to elute the PLA2 isoform from 
heparin sepharose shows high correlation to the isoelectric point (pI) of 
the isoform (Murakami et al, 2001, graph a) and to the pI (graph b) and 
number of basic residues in the C-terminal portion of 25 amino acid 
residues (graph c).   Characteristics of the isoforms IIA, IID, IIE, IIF, V & 
X were used to construct these graphs.
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Figure 5.8: Sequence Alignment of Secretory Phospholipase A2 isoenzymes & 
Heparin binding regions.   The C-terminal 25 amino acids shown in red.   The 
basic residues in the C-terminal amino acids are underlined.   Additional 
amino acids that are likely to be involved in heparin binding are shown in blue 
(Koduri et al, 1998). 
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Figure 5.9: Typical elution of the total protein a homogenised 
infarcted bowel sample from a heparin sepharose column.  The 
majority of the total protein eluted with 0.05M NaCl.
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Figure 5.10: The elution of total protein and PLA2 activity 
from a typical heparin sepharose chromatography column.   
There was no detectable total protein or phospholipase A2
activity with either 2 or 5M NaCl elution.
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Figure 5.11: Effect on total protein content of elution from heparin 
sepharose chromatography  column using either 15 or  20 column 
volumes per elution buffer.   The use of twenty column volumes 
decreased the amount of contaminating total protein while retaining the 
majority of the enzyme activity.
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Figure 5.12: PLA2 activity before and after dialysis against 
phosphate buffer (10mM).  Dialysis of the active heparin 
column fractions was required before application to the 
Rotofor IEF system.
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Figure 5.13: Confirmation that the Rotofor® buffer did not 
interfere with assay of PLA2 activity.   Three sources of PLA2
(bee venom sPLA2, bowel homogenate and purified type IIA 
PLA2) and a negative control (water) were diluted in either 
water or Rotofor® buffer. 
Results are expressed as the mean +/- standard error of 
triplicate assays.
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Figure 5.14: The power, current & voltage changes over 
the duration of a typical  Rotofor® run.   The system was 
run until the plateau phase had been reached and 
maintained for an hour.   A typical run took 3.5 hours.
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Figure 5.15: The pH and PLA2 activity of the fractions of a 
typical Rotofor® experiment.
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Figure 5.16: Typical Rotofor® fractions from pooled active 
heparin fractions of infarcted bowel content  eluted by 0.5M NaCl 
and dialysed against 10mM phosphate.   Rotofor fractions 15-18 
exhibited PLA2 activity.
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Figure 5.17: The reproducibility of Rotofor® system.   The 
pH of each of the 20 fractions of five consecutive 
Rotofor® experiments is shown in this graph.
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Figure 5.18: Refractionation of a typical Rotofor® experiment.   No 
extra ampholytes were added, and the active fractions were 10-17.
The maximum phospholipase A2 activity was observed in fraction  17 
which corresponded to a pH of 9.7.   The arrow points to the region of 
gel where phospholipase A2 was predicted to run to, as determined by 
electroelution.   The red line shows the phospholipase activity in each 
Rotofor fraction, while the blue line shows the phospholipase activity 
in each re-fractionated Rotofor fraction.
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Figure 5.19: The pH profile of Rotofor®  fractions before 
and after re-fractionation.
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Figure 5.20: A standard curve representing the electroelution of 
PLA2 from active Rotofor®  fractions.   The sample was run on a 
non-reducing gel.   PLA2 activity was focussed in fractions 8 & 9, 
corresponding to a protein of 16-20kDa in size.
139
0
1
2
3
4
5
6.5 7 7.5 8 8.5 9 9.5
pH
PL
A 2
 a
ct
iv
it
y 
(%
 h
yd
ro
ly
si
s )
Figure 5.21: The pH of maximum activity of the semi purified bowel 
phospholipase.   Results are expressed as the mean +/- standard 
error of triplicate assays.
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Figure 5.22:  Purification summary of a typical experiment.   
This purification experiment is equivalent to an average 9700 
fold purification from the crude sample.
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Figure 5.23: A typical result from a Rotofor® run during the 
scaled up purification, as shown by a silver stained gel of 
active Rotofor® fractions.   The arrow indicates a protein of 
approximately 21kDa which was present in the fractions with 
phospholipase activity.
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Figure 5.24: Gel showing the effect of concentrating 
protein and removing ampholytes using either 
VivaSpin centrifuge filters or ethanol precipitation.
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Sample Top 1-2 
identifications
Number of 
peptides
Mowse
score
Unknown 
protein 
~20kDa.
Peptidylprolyl
isomerase.*
Keratin.
15
8
465
414
Positive 
control, 
lysozyme.
Lysozyme (chicken). 5 204
Negative 
control.
Keratin. 15 588
*Proteins matching the same set of peptides:
•Cyclophilin B (ICYNA)
•Cyclophilin B (Q9BVK5)
•Human cyclophilin
Figure 5.25: Mass spectrometry of the unknown protein from trypsin 
digests of gel pieces (BisTris gel, Invitrogen).
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Sample Top 1-2 
identifications.
Number of 
peptides.
Mowse score.
Unknown protein 
~20kDa-A.
Peptidylprolyl
isomerase.*
Keratin.
13
5
427
272
Unknown protein 
~20kDa-B.
Keratin.
Peptidylprolyl
isomerase.*
8
10
435
386
Unknown protein 
~20kDa-C.
Peptidylprolyl
isomerase.*
Bovine cyclophilin B.
10
16
426
331
Postive control, 
Restriction 
endonuclease 
E.Coli.
Restriction 
endonuclease Bacillus 
sp.
48 723
Negative control Keratin. 6 333
*Proteins matching the same set of peptides:
•Cyclophilin B (ICYNA)
•Cyclophilin B (Q9BVK5)
•Human cyclophilin
Figure 5.26: Mass spectrometry of the unknown protein from trypsin 
digests of gel pieces (TrisGly gel, Gradipore).
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Figure 5.27:  Final purification scheme.   This protein purification scheme 
resulted in sufficient purified protein for identification of the protein of interest 
by mass spectrometry. 
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Discussion 
Chapter 5 Discussion: 
The aim of the protein purification experiments was to identify the protein responsible 
for the phospholipase activity that remained when phospholipase A2 isoforms IIA and 
V were removed from human bowel.   The protein of interest was purified from 
infarcted gut tissue homogenate rather than blood for a number of reasons: 
- a larger amount of tissue was available, 
- the tissue showed higher specific activity, 
- a bowel tissue specific protein was more likely to be found.    
The separation techniques were chosen because they retained the native enzyme 
activity of proteins and they removed large quantities of contaminating protein at each 
step.   The separation techniques also exploited unusual characteristics of the protein 
of interest (namely heparin affinity and very alkaline isoelectric point).   The progress 
of the purification was monitored by analysing all fractions obtained for phospholipid 
hydrolysing activity.   The assay used for monitoring phospholipase activity (the 
mixed micelle assay) has been well described and is very sensitive (Farrugia et al, 
1993, Green et al, 1991).   This assay was chosen for its sensitivity, ability to be used 
with crude and purified samples and ability to detect net phospholipase activity.   A 
series of PLA2 isoenzyme specific assays have been published (Yang et al, 1999), but 
this was not suitable as we required an assay to monitor net phospholipase activity for 
the widest range of phospholipase proteins.    
 
Because of the low abundance of non-pancreatic phospholipase A2 in biological 
samples, proteins need to be purified several thousand fold (Stefanski et al, 1986).   In 
the past, purification of phospholipase A2 from animal tissues has involved the use of 
several sequential chromatographic columns, often in conjunction with phospholipase 
assays of the fractions obtained where compatible.   A typical phospholipase A2 
purification process may involve one or more anion or cation exchange columns, a 
hydrophobic interaction column, one or more gel filtration columns, and a final 
reversed phase high performance liquid chromatography (RP-HPLC) column.   For 
example, Minami and colleagues used a cation exchange column (run and then 
repeated) followed by a gel filtration column (also run twice), another cation 
exchange column and a final RP-HPLC column to purify phospholipase A2 type II 
from human ileal mucosa (Minami et al, 1993).   For tissues such as spleen, multiple 
ion exchange columns (cation and anion), a hydrophobic interaction column and RP-
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HPLC column have been used (Kanda et al, 1989, Ono et al, 1988).   For biological 
fluids such as synovial fluid, generally fewer columns are required, for example an 
ion exchange and a gel filtration column followed by RP-HPLC and PAGE (Kramer 
et al, 1989) or hydrophobic interaction, HPLC and PAGE (Seilhamer et al, 1989).    
 
The use of multiple chromatography columns is associated with the risk that 
phospholipase activity may be lost because of the buffers or solvents used or the 
numerous manipulations, and therefore the activity of the protein of interest may be 
reduced or lost during purification.   For this project we chose to employ a small 
number of purification techniques to exploit the unusual characteristic of 
phospholipase A2 instead of a large number of chromatography columns.    
 
Heparin sepharose chromatography was used for a number of reasons: 
- it removed a large amount of contaminating protein in one experiment, and 
retained enzyme activity, 
- discrete fractions could be achieved with high specific activity by using a 
step gradient of salt concentrations, 
- the high salt concentrations required to elute the tightly bound protein could 
be reduced by dialysis without altering the enzyme activity, 
 - the system could be scaled up or down relatively easily. 
Groups that have used heparin affinity chromatography in protein purification have 
generally employed a linear gradient of salt rather than a step gradient, but we found a 
step gradient useful in terms of reproducibility and obtaining highly purified fractions. 
 
Preparative isoelectric focussing was conducted using the BioRad Rotofor® 
apparatus.   The buffer used in the Rotofor® system did not appear to interfere with 
the PLA2 assay, which was an advantage because the fractions could be analysed 
without any modification, such as dialysis.   The Rotofor® system was useful for a 
number of reasons: 
 - the system was highly reproducible, 
- the fractions obtained could be analysed in a number of different ways (pH, 
enzyme activity, total protein, SDS-PAGE, electroelution), 
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- the interference of the ampholytes in total protein assays and in protein 
staining in  SDS-PAGE could be overcome via a number of different strategies 
(Coomassie G-250 stains with or without copper and protein precipitation 
prior to total protein analysis).  
 
The majority of the publications involving the Rotofor® system have investigated the 
proteins of the cerebrospinal fluid which may reflect the development of Alzheimer’s 
disease (Davidsson, BioRad technote 2859).   Westman-Brinkmalm and Davidsson 
(2002) found that the Rotofor® apparatus could be used as a pre-fractionation step for 
cerebrospinal fluid proteins, and this pre-fractionation resulted in increased sequence 
coverage and greater identification of low abundance proteins.   The Rotofor® 
apparatus is an excellent tool in protein purification and is particularly suited to 
enzymes with compatible assays.   At present, such a valuable tool in protein 
purification and proteomics appears to be under-utilised.  
 
The initial purification system of heparin sepharose chromatography, Rotofor® 
fractionation and Rotofor® refractionation did not provide sufficient protein for 
identification so the system was scaled up approximately twenty fold.   The scaled up 
purification resulted in a protein that was >95% pure on a silver stained gel, and 
represented a 9700 fold purification.   Throughout the purification system, a number 
of protein characteristics were recognized: 
 - the protein size appeared to be between 16 and 20kDa, 
- the phospholipase activity of the protein appeared to be sensitive to reduction 
by DTT, 
 - the phospholipase activity of the protein appeared to be calcium dependent, 
 - the pH of optimal phospholipase activity appeared to be approximately 9, 
 - the isoelectric point of the protein appeared to be between 8.6 and 9.8, 
- the protein appeared to have heparin affinity up to conditions of 
approximately 0.5M sodium chloride. 
 
Many of these features were suggestive of a secretory phospholipase isoform, but no 
clear match was evident.   Therefore a conclusive identification was required, 
preferably by mass spectrometry. 
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Identification of the protein of interest: 
Haemoglobin was identified on a number of occasions (by Edman degradation and 
mass spectrometry), due to haemoglobin either: 
-co-purifying with the protein of interest, 
- contaminating the samples simply because it was present in high 
concentration or because of its ‘sticky’ nature (Associate Professor Mark 
Kirkland, personal communication). 
The problems with proteins co-purifying with phospholipase A2 has been encountered 
previously, for example, histone proteins co-purified with phospholipase A2-IIA from 
synovial fluid (Dr. Kieran Scott, personal communication).   The possibility that 
haemoglobin may have intrinsic phospholipase A2 activity was dismissed by assaying 
a range of haemoglobin concentrations for phospholipase activity.   None of the 
haemoglobin concentrations showed phospholipase activity above background levels 
(similar to the background seen in ultrapure water, buffers or albumin solution).   In 
addition, haemoglobin did not appear to enhance phospholipase activity.   
Haemoglobin was not irreversibly bound to the protein of interest, as the size of the 
protein as determined by electroelution under non reducing conditions was too small 
to be complexed to haemoglobin (molecular weight of ~16kDa).   When a solution of 
standard haemoglobin and phospholipase A2 from either pancreas or bee venom was 
run on a gradient SDS-PAGE, distinct bands for each protein were visible, suggesting 
that: 
- if the haemoglobin binds to phospholipase A2 proteins, the association is 
disrupted by SDS, 
- a gradient SDS-PAGE gel was required as the final purification step to limit 
the possibility of identifying haemoglobin in subsequent experiments. 
 
The final purification system was comprised of heparin sepharose affinity 
chromatography (with twenty column volume elution), preparative IEF (Rotofor® 
apparatus) and a gradient SDS gel.   The final identification of the protein of interest 
was made using nano-LC MS/MS.   The final identification was made from two 
highly purified fractions, each run in a different gel system with separate positive 
controls.   The two different gel systems were used to add strength to the 
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identification, and to overcome the possibility that one type of gel may be 
incompatible with the mass spectrometry system.   The protein of interest was an 
excellent match for cyclophilin B, a protein that is also referred to as peptidylprolyl 
isomerase.   Cyclophilin B is an inflammatory protein (Allain et al, 2002, Carpentier 
et al, 1999) that had been previously identified in rodent intestine at the mRNA level 
(Hasel et al, 1991, Kainer & Doris, 2000).    
 
Cyclophilin B is known to have heparin sulphate binding ability (De Ceuninck et al, 
2003).   Heparin affinity chromatography has been used to semi-purify cyclophilin 
proteins previously (Carpentier et al, 1999, De Ceuninck et al, 2003, Sherry et al, 
1992).   Cyclophilin A (64% homology to cyclophilin B) cannot interact with 
glycosaminoglycans such as heparin because it lacks the required N-terminal binding 
residues, likely to involve a triplet lysine (Allain et al, 2002, Bukrinsky, 2002).   The 
binding of cyclophilin B with glycosaminoglycans is thought to contribute to 
cyclophilin involvement in inflammation (Allain et al, 2002).   The affinity of 
cyclophilin B to heparin is quite strong, and this protein is not eluted from a heparin 
column until sodium chloride concentration exceeds 0.6M sodium chloride 
(Carpentier et al, 1999). 
 
The size (20.289kDa, Carpentier et al, 1999), isoelectric point (9.25) and heparin 
affinity (0.6M NaCl, Carpentier et al, 1999) of cyclophilin B were consistent with the 
characteristics that had been determined throughout the protein purification 
experiments.   The next chapter details our investigations into cyclophilin B in human 
bowel. 
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Chapter 6: Cyclophilin B. 
 
Immunophilins: 
The immunophilins are a family of heterogenous proteins grouped by their ability to 
bind the immunosuppressive agents cyclosporin A (the cyclophilin proteins), FK506 
(FK506 binding proteins) or rapamycin (target of rapamycin or Tor proteins, (Ivery, 
2000)).   The FK506 binding proteins have no sequence homology to the cyclophilins 
(Snyder & Sabatini, 1995).   Immunophilins have peptidyl prolyl isomerase activity, 
which catalyses folding of proline containing proteins in vivo and in vitro.   This 
isomerase activity is inhibited on binding to the relevant immunosuppressive drug 
(Bochelen, Rudin & Sauter, 1999).   Immunophilins have the ability to interact with 
many signal transduction molecules, in particular those involving calcium or 
phosphorylation (Snyder & Sabatini, 1995).    
 
Cyclophilins: 
Cyclophilin was first purified from bovine thymus and human spleen (Harding, 
Handschumacher & Speicher, 1986).   To date, more than forty gene encoded 
cyclophilins have been recognised (Fanghanel & Fischer, 2003).   The major human 
isoforms are described in Table 6.1.   Cyclophilins have been found in all cell types 
investigated (Price et al, 1991) and are highly conserved (Allain et al, 1995).   The 
widespread distribution and significant levels of expression suggest an important 
biological role (Ivery, 2000), but the relevance of their biological activity is unknown 
(Denys et al, 1998).   Cyclophilins may function as catalysts of protein folding (Kay, 
1996), or protein stabilisation (Galat & Metcalfe, 1995), as molecular chaperones 
(Yoo et al, 1997) or cytokines (Tegeder et al, 1997).    
 
The two major isoforms of cyclophilin, cyclophilins A and B, are only 64% 
homologous (Price et al, 1991), and the major difference between the two is the signal 
sequence in cyclophilin B directing it into a secretory pathway (Price et al, 1991, 
Price et al, 1994).   Cyclophilin A is a cytosolic protein (Price et al, 1994), and can 
comprise up to 0.1-0.4% of the soluble protein in the cytoplasm (Harding, 
Handschumacher & Speicher, 1986).   Cyclophilin A is the most abundant cyclophilin 
in human cells (Fanghanel & Fischer, 2003).   It is assumed that cyclophilin A is non-
secretory, although this protein has been detected in the synovial fluid from patients 
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with rheumatoid arthritis (Billich et al, 1997).   Cyclophilin A is present in leukocytes 
at around 10 fold higher levels than cyclophilin B, but is not released into the plasma 
(Allain et al, 1995).   Cyclophilin B is a secreted protein which has been detected in 
human blood (Allain et al, 1995) and breast milk (Spik et al, 1991).    
 
Cyclophilin C (23kDa) localises to the endoplasmic reticulum (Snyder & Sabatini, 
1995) and has been shown to be a secretory protein (Price et al, 1994).   Cyclophilin 
40 is a component of the inactive form of the glucocorticoid receptor (Synder & 
Sabatini, 1995).   Cyclophilin NK plays an important role in natural killer cell 
cytotoxicity (Anderson et al, 1993). 
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Table 6.1.   The Major Human Cyclophilins: 
Protein Alternate names Molecular 
weight, kDa 
Isoelectric 
point 
Signal 
peptide 
Abundant 
sources 
Cyclophilin A Cyclophilin 1 
Cyclophilin 18 
18 7.8  None. Cytosolic, 
ubiquitous 
(Hasel et al, 
1991). 
Cyclophilin B S-cyclophilin 
SCYLP 
Cyclophilin 2 
Cyclophilin 20 
22.74, 
unprocessed 
20.29 
(mature) 
9.25 (mature) 1-25 signal 
26-208 mature 
protein 
Liver, 
intestine and 
placenta 
(Hasel et al, 
1991). 
Cyclophilin C Not applicable. 23 8.48 None. Liver, lung, 
heart, 
pancreas, 
skeletal 
muscle 
(Schneider et 
al, 1994). 
Cyclophilin D Cyclophilin 3 
Cyclophilin M 
Mitochondrial 
cyclophilin. 
18 8.97 1-29 potential 
signal, 30-207 
chain. 
Muscle, heart, 
liver, kidney, 
brain 
(ExPASY 
database). 
Cyclophilin 
40 
Not applicable. 40 6.77 None Heart, brain, 
placenta, 
skeletal 
muscle, 
pancreas, liver 
(Kieffer et al, 
1993). 
Cyclophilin 
NK 
Not applicable. 150 (mature 
protein), 
19.5 
(cyclophilin 
like domain). 
10.01 None. Membrane 
anchored on 
natural killer 
cells.  Spleen, 
lung, liver 
(Anderson et 
al, 1993). 
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Cyclophilin B in human disease: 
The levels of cyclophilin B have been investigated in relation to sepsis, HIV and 
organ transplant in clinical settings.   A 1997 study investigated the levels of 
cyclophilins A and B in the plasma of patients with severe sepsis, other diagnoses and 
healthy controls using western blotting and a peptidyl prolyl isomerase activity assay 
(Tegeder et al, 1997).   The healthy control plasma showed a weak but distinct 
cyclophilin B signal, but no cyclophilin A signal.   Patients with severe sepsis showed 
high levels of cyclophilin B and some (6/22) patients also showed a cyclophilin A 
signal.   Patients with diagnoses other than sepsis showed variable levels of 
cyclophilin B, but no cyclophilin A (Tegeder et al, 1997). 
 
Organ transplant patients showed significantly elevated levels of cyclophilin B in 
plasma compared with health controls (Denys et al, 1998).   It was postulated that 
cyclophilin B levels may effect a patient’s sensitivity to the immunosuppressive drug 
cyclosporin A (Denys et al, 1998).   Levels of cyclophilins A and B were found to be 
increased in the serum of patients with HIV infection (Endrich & Gehring, 1998). 
 
The cyclophilin B-Cyclosporin A complex: 
The pharmacological ligand of cyclophilins, cyclosporin A is known for its 
immunosuppressive effects.   The binding of cyclosporin A to a cyclophilin is 
required for the immunosuppressive effect associated with this drug (Gonzalez-
Cuadrado et al, 1996).   The cyclophilin-cyclosporin A complex then interacts with 
protein targets such as calcinuerin (Ivery, 2000), to exert the immunosuppressive 
effect.   All of the therapeutic and toxic effects of cyclosporin A (and FK506) have 
been found to be due to the inhibition of calcinuerin (Ho et al, 1996).   The 
cyclophilin B-cyclosporin A complex shows the most potent binding to calcineurin of 
all cyclophilins (Kay, 1996).    
 
Cyclosporin A and cyclophilin B appear to exert effects on each other.   Cyclosporin 
A has been shown to increase levels of cyclophilin B mRNA in a dose dependent 
manner (Galat & Metcalfe, 1995, Gonzalez-Cuadrado et al, 1996, Price et al, 1994).   
Cyclosporin A has been shown to significantly increase levels of cyclophilin B 
protein in plasma compared with healthy donors (Denys et al, 1998).   Cyclosporin A 
has been shown to increase the secretion of cyclophilin B in cultured chondrocytes 
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(De Ceuninck et al, 2003).   Cyclophilin B modifies the distribution of cyclosporin A 
in blood, channelling the drug into peripheral blood mononuclear cells (PBMC) or 
retaining the drug-protein complex extracellularly (Denys et al, 1998).   Cyclosporin 
A redirects cyclophilin B from the endoplasmic reticulum into a secretory pathway 
(Price et al, 1994).   The CyPB-CsA complex inhibits T cell proliferation more 
effectively than cyclosporin A alone (Denys et al, 1998).    
 
Use of cyclophilin B antibodies: 
Due to the high homology of cyclophilins, antibodies generated to intact cyclophilin 
proteins tend to cross react with multiple cyclophilin forms.   For example antibodies 
raised to recombinant cyclophilin B crossreact with cyclophilin A (Allain et al, 1995).   
Useful antibodies to cyclophilin B have been generated by using a 14 residue peptide 
from the C-terminal, variable region, coupled to keyhole limpet hemocyanin (KLH) to 
improve the immunogenicity of the peptide (Vaitukaitis et al, 1971). 
 
Western blotting for cyclophilin B: 
One study employed an antibody raised in the mode discussed above to investigate 
cyclophilin B in Jurkat cells (Bergsma et al, 1991).   Jurkat cells showed four 
immunoreactive bands in Western blots, but only one band could be removed by 
incubating the extract with an excess of the peptide used to generate the antibody 
(Bergsma et al, 1991). 
 
ELISA studies of cyclophilin B: 
Another study employing a peptide derived cyclophilin B antibody devised an ELISA 
to assay blood cells and serum from blood transfusion samples (Allain et al, 1995).   
A modified version of this ELISA was used to investigate cyclophilin B in organ 
transplant patients (Denys et al, 1998). 
 
Cyclophilin B in gut: 
Studies in rats have shown evidence of cyclophilin B mRNA transcripts in the 
intestine using competitive RT-PCR (Kainer & Doris, 2000) and Northern blotting 
(Hasel et al, 1991).   Competitive RT-PCR of rat tissues showed that the highest 
expression of cyclophilin B occurred in the kidney, followed by the ventricle, liver 
and small intestine (Kainer & Doris, 2000).   Northern blotting of rat tissues showed 
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that the highest expression was in the placenta and liver, followed by the intestine and 
uterus (Hasel et al, 1991). 
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Chapter 6: Cyclophilin B in human bowel: 
Previous research had identified cyclophilin B in Jurkat cells, (a T-cell lymphoma cell 
line) therefore whole cell lysate was used as a positive control in these investigations.   
Jurkat cell lysate and cell culture medium were run on SDS-PAGE to estimate protein 
loading (Figure 6.1).   Bowel tissue from patients with surgically confirmed bowel 
infarction and control patients with normal bowel all showed cyclophilin B protein by 
Western blotting (Figures 6.2, 6.3 & 6.4).   Plasma from patients with confirmed 
bowel infarction showed variable levels of cyclophilin B, but control patients showed 
no cyclophilin B (Figure 6.7).   Some lumen content from infarcted bowel showed 
cyclophilin B protein, though at much lower levels than tissue homogenates (Figure 
6.5).   Immunoprecipitation of cyclophilin B from highly purified fractions removed 
all of the phospholipase activity from these samples (Figure 6.6).   The phospholipase 
activity was not altered by the addition of cyclosporin A (Figure 6.10).   
Immunohistochemistry was performed using an immunoperoxidase method and the 
commercially available polyclonal antibody raised to a cyclophilin B peptide.   After 
the antibody dilution had been optimised, the ubiquitous expression of cyclophilin B 
was confirmed (Figure 6.9).    
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Figure 6.1: Colloidal Coomassie stained gel of Jurkat cell lysate and cell culture 
medium. 
Lanes 1-3  Jurkat cell lysate, increasing amounts of sample loaded
Lane  4   No protein loaded
Lanes 5-8   Jurkat cell culture medium, increasing amounts of sample loaded
Lane  9 Protein Markers
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Figure 6.2: Western blotting of cyclophilin B in infarcted human bowel samples, 
30µg total protein per lane.
1   Markers
2   Jurkat cell lysate
3   Jurkat cell culture medium
4   no protein loaded
5   Bowel tissue A
6   Bowel mucosa A
7   Bowel tissue B
8   Bowel mucosa B
9   Bowel tissue C
10 Bowel mucosa C
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Figure 6.3: Western blotting of cyclophilin B in infarcted human 
bowel samples, 30µg total protein per lane.
1   Markers
2   Jurkat cell lysate
3   Jurkat cell culture medium
4   no protein loaded
5   Bowel tissue D
6   Bowel tissue E
7   Bowel tissue F
8   Bowel tissue G
9   Bowel tissue (infarcted)
10 Bowel tissue (ischaemic)
162
2        3      4       5     6      7      8     9     10
26kDa
0
20000
40000
60000
80000
100000
2 3 4 5 6 7 8 9 10
N
et
 in
te
ns
ity
 o
f s
ig
na
l
Figure 6.4: Western blotting of cyclophilin B in control (normal) 
human bowel samples, 30µg total protein per lane.
2   Jurkat cell lysate
3   Jurkat cell culture medium
4   no protein loaded
5   Control bowel tissue A
6   Control bowel tissue B
7   Control bowel tissue C
8   Control bowel tissue D
9   Control bowel tissue E
10 Control bowel content
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Figure 6.5: Western blotting of cyclophilin B in bowel 
content samples, 40µg total protein loaded per lane.
2    Jurkat cell culture medium
3    Infarcted bowel content A
4   Infarcted bowel content B
5   Infarcted bowel content C
6   Infarcted bowel content D
7   Infarcted bowel content E
8   Infarcted bowel content F
9   Infarcted bowel content G
10 Infarcted bowel content H
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Figure 6.6: Phospholipase activity before and after immunoprecipitation  
(IP) of cyclophilin B from Rotofor®  fractions.   Results are expressed as 
the mean +/- standard error of duplicate assays.
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Figure 6.7: Western blotting of cyclophilin B in plasma, 30µg total protein per lane.   
Patients 1-10 had surgically confirmed bowel infarction while patients 11-20 were 
control ICU patients.   The positive control used in these blots was Jurkat cell culture 
medium.
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Figure 6.9: Immunohistochemistry of cyclophilin B in normal and infarcted 
human intestine.   Picture a) shows the normal bowel test slide (cyclophilin B 
immunohistochemistry (brown staining), counterstained with haemotoxylin
(blue staining)) .   Picture b) shows the infarcted bowel test slide.   Picture c) 
shows the negative control slide (haematoxylin stained).   These
photomicrographs were taken at a 200X magnification.   The scale bars 
represent 100µm.
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Figure 6.10: Cyclosporin A (1µg/mL, Sigma)  does not affect 
phospholipase activity of cyclophilin B containing samples.   Results 
are expressed as the mean +/- standard error of triplicate assays.
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Chapter 6 Discussion: 
The unknown protein purified in this project was identified as cyclophilin B by nano-
LC tandem mass spectrometry.   The accuracy of the mass spectrometry was verified 
by the addition of positive controls (lysozyme and restriction endonuclease), all of 
which gave very good matches upon database searching.   The identification was 
repeated from two different highly purified fractions, in two different gel systems.   
Each of the samples from the two gel systems showed that the best match was 
cyclophilin B, also referred to as peptidyl prolyl isomerase.   This was an unexpected 
finding because the progress of the protein purification had been monitored at each 
stage by phospholipase hydrolysis assays, and cyclophilin B has not been reported to 
have phospholipid hydrolysing activity.   To investigate the possibility that 
cyclophilin B had the ability to hydrolyse phospholipids, the cyclophilin B was 
removed from highly purified fractions via immunoprecipitation with a commercially 
available polyclonal antibody raised to a cyclophilin B peptide.   The peptide used to 
raise the antibody (194GKIEVEKPFAIAKE208) was one of the peptides identified by 
the tandem mass spectrometry, which added clarity to the experiment.   The presence 
of cyclophilin B in the highly purified samples was verified by Western blotting of the 
protein attracted to the resin immobilised antibody.   This result also suggested that 
the conditions for immunoprecipitation (for example: ionic strength of the buffer, 
incubation times) were adequate for the removal of cyclophilin B from solution.   The 
samples devoid of cyclophilin B were then analysed for phospholipid hydrolysing 
activity, and found to have no remaining activity.   This result suggests that 
cyclophilin B is able to hydrolyse phospholipid substrates.   The converse experiment 
(examining the possible phospholipid hydrolysing activity of a recombinant source of 
cyclophilin B) would be a valuable exercise, but an application to the only known 
pharmaceutical supplier of this protein was unsuccessful.   To our knowledge there is 
no commercial source of the recombinant protein.    
 
A similar experiment employing the commercially available cyclophilin A protein 
was not performed, as cyclophilins A and B have only moderate homology (64%) and 
quite distinct roles in inflammation.   The addition of cyclosporin A did not appear to 
affect the phospholipase activity of the highly purified cyclophilin samples.   This 
suggests that amino acids involved in the proposed phospholipid hydrolysis are likely 
to be separate from residues involved in cyclosporin binding. 
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Western blotting was undertaken to assess the presence of cyclophilin B in a variety 
of bowel samples.   For these experiments, Jurkat cell lysate and the culture medium 
form Jurkat cell culture were used as positive controls.   Jurkat cells (a T-cell 
lymphoma cell line) have been shown to express significant quantities of cyclophilin 
B (Bergsma et al, 1991).   An appropriate negative control tissue could not be found, 
as the expression of cyclophilin is reported to be ubiquitous (Allain et al, 1995, 
Tegeder et al, 1997).   Jurkat cell extracts were also used as an internal control in the 
Western blots, to control for signal intensity in the semi-quantitative ECL Western 
system employed in this project.   The Jurkat cell lysate and cell culture fluid were 
used as the controls in blots of samples with high (eg tissue) and low (eg plasma) 
levels of cyclophilin B respectively. 
 
Western blots of cyclophilin B protein exhibited a number of non-specific bands of 
different sizes than expected for cyclophilin B protein.   The non specific bands could 
be removed by more stringent washing procedures or stripping the membranes and re-
probing.   The non-specific bands seen with this polyclonal cyclophilin B antibody 
have also been shown by Bergsma and colleagues (1991).   This group showed that 
only one band was due to cyclophilin B by incubating the samples with an excess of 
the peptide used to generated the antibody, which cleared the cyclophilin B band from 
the blot (Bergsma et al, 1991).   This approach would be a valuable control 
experiment in future blotting experiments. 
 
Bowel tissue homogenates from both normal bowel and infarcted bowel all showed 
very strong signal for cyclophilin B of the expected size.   This is not a surprising 
result given the reported ubiquitous expression of cyclophilin B, and the reported high 
mRNA expression in rodent gut (Hasel et al, 1991, Kainer & Doris, 2000).   However, 
it is supporting evidence of similar expression patterns in human tissue, at the protein 
level.   The infarcted bowel lumen content samples contained variable signal intensity 
of cyclophilin B, but were generally lower than the signal intensity of tissue 
homogenates.   Although only one sample of lumen content from normal human 
bowel could be obtained, this sample contained no signal for cyclophilin B.   This is 
an interesting finding as it supports the concept that cyclophilin B is present in large 
amount in bowel tissue and may be released in response to the ischaemic conditions.   
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In the two tissue samples obtained from one patient, the infarcted tissue showed a 
higher cyclophilin B signal than the ischaemic tissue.   None of the control patients’ 
plasma displayed cyclophilin B, while several samples of plasma from bowel 
infarction patients exhibited this protein.   The possible role of cyclophilin B as a 
mediator, or marker of ischaemic damage to the human bowel is an interesting 
concept that requires further investigation.   Interestingly, this observation is in 
accordance with previous reports in other human diseases. 
 
THE ROLE OF CYCLOPHILIN B IN INFLAMMATION: 
Increased levels of cyclophilin B protein have been observed in the plasma of patients 
with sepsis (Tegeder et al, 1997), HIV infection (Endrich & Gehring, 1998) and organ 
transplant (Denys et al, 1998).   As such, it has been postulated that cyclophilin B has 
an important role in inflammation (Allain et al, 2002), and this role is due in part to 
the induction of chemotaxis and proliferation of T lymphocytes (Denys et al, 1997).    
 
Chemotaxis: 
Cyclophilins induce chemotactic activity with neutrophils (Billich et al, 1997), T 
lymphocytes (Allain et al, 2002), polymorphonuclear leukocytes (Sherry et al, 1992) 
and monocytes (Xu et al, 1992).   Cyclophilin B, in particular, induces the migration 
of neutrophils and T lymphocytes (De Ceuninck et al, 2003), which induces the 
inflammatory cascade (Denys et al, 1997).   Chemotactic inducing activity of 
cyclophilins B is thought to be due to the same binding site as cyclosporin A, as the 
addition of cyclosporin A abolishes chemotactic ability (Allain et al, 2002).    
 
Cyclophilin binding sites: 
Cyclophilin B shows pro-inflammatory effects and enhances integrin mediated 
adhesion of CD4+ T-lymphocytes to the extracellular matrix, through interaction with 
glycosaminoglycans via the type II binding site (Allain et al, 2002).   The binding 
sites for glycosaminoglycans and cyclosporin A are independent and located on 
opposite sides of the cyclophilin B molecule (De Ceuninck et al, 2003, Mikol, Kallen 
& Walkinshaw, 1994).   The cyclosporin A binding site, or type I binding site is due 
to a cluster of residues in the central core of the cyclophilin B molecule (De Ceuninck 
et al, 2003, Denys et al, 1998).   The type II binding site is responsible for the binding 
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of glycosaminoglycans, and is due to a cluster of N terminal cationic residues (De 
Ceuninck et al, 2003, Denys et al, 1998).     
 
The possible involvement of cyclophilin B in oxidative stress: 
Cyclophilin B has been implicated in the development of oxidative stress.   Oxidative 
stress in vascular smooth muscle cells increases cyclophilin B secretion (Liao et al, 
2000).   More extensive research has focussed on the role of other cyclophilins (A and 
D) during oxidative stress.   Cyclophilin D appears to have an important role in 
mitochondrial membrane pore opening and the consequential necrosis or apoptosis 
(Halestrap, McStay & Clarke, 2002).   Mitochondria are known to have a critical role 
in apoptosis, which is a favourable alternative to the inflammatory necrotic process.   
Under normal conditions membrane pores are non permeable.   Under conditions of 
moderate stress membrane pores remain closed and cells are channelled into the 
favourable apoptotic pathway.   Under conditions of high calcium (mM 
concentrations), pores become non-specifically permeable, cells swell and necrosis 
ensues.   Under conditions of moderated calcium (µM concentrations), in the presence 
of cyclophilin D the permeable, non-specific pore opening also occurs and cells are 
channelled into the necrotic pathway (see Figure 6.11).   This process is greatly 
enhanced by oxidative stress, such as reperfusion after ischaemic episodes.   The pore 
opening can be inhibited by cyclosporin A and its analogues, at similar affinities to 
peptidyl prolyl isomerase activity inhibition (Halestrap, McStay & Clarke, 2002).   It 
is unknown whether this phenomenon is specific to cyclophilin D, or a general 
cyclophilin process. 
 
When antisense technology was used to knockout cyclophilin A, cardiac myocytes 
were more sensitive to oxidative stress, but the protective action of cyclosporin A was 
more pronounced (Doyle, Virji & Crompton, 1999).   This study concluded that two 
cyclophilin isoforms were involved in the oxidative stress response.   Cyclophilin A 
had a protective role, and a second, unknown cyclophilin isoform had a detrimental 
effect on cells (Doyle, Virji & Crompton, 1999).   The protective role of cyclophilin A 
was also observed in a model of oxidative stress in vascular smooth muscle cells 
where this protein prevented apoptosis (Jin et al, 2000). 
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It is unclear whether the effects shown by cyclophilins A and D are specific 
responses, or general cyclophilin responses to oxidative stress.   It would be valuable 
to investigate the role of each of the major cyclophilin isoforms in oxidative stress and 
ischaemic episodes, and the possible protective role of cyclophilin inhibitors. 
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Figure 6.11.   Cyclophilins and Pathological Pore opening.   Modified from 
Halestrap A. The Mitochondrial Permeability Transition- A Pore Way for the 
Heart to Die.   J. Clin. Basic Cardiol. 2002; 5:29-41, with permission from the 
author. 
 
Cyclophilin B inhibition. 
There are several examples of the inhibition of cyclophilins by cyclosporin A having 
a protective or anti-inflammatory role, for example: 
 - inhibition of cyclophilin B reduced T-cell proliferation (Denys et al, 1998), 
-inhibition of cyclophilin D avoided pore formation, preventing cellular 
necrosis (Halestrap, 2002), 
-inhibition of murine macrophage cyclophilin inhibited chemotactic induction 
in monocytes (Sherry et al, 1992), 
 175
Discussion 
- disruption of the binding of cyclophilin to a HIV capsid protein which 
resulted in non infectious virions (Francke, Yuan & Luban, 1994, Thali et al, 
1994), 
- inhibition of chemotactic enhancing effect on eosinophils and neutrophils 
(Xu et al, 1992). 
 
Cyclosporin A can have unwanted effects such as inducing increased secretion of 
cyclophilin B and has uncontrolled cellular distribution.   Analogues of cyclosporin A 
that specifically target one cyclophilin isoform (such as cyclophilin B) would be 
advantageous, and may help to: 
- prevent the drug compartmentalisation/distribution changes in presence of 
cyclophilin B, 
- retain the drug extracellularly (Endrich & Gehring, 1998), 
- prevent the increased secretion of cyclophilin B seen when cyclosporin A is 
administered (De Ceuninck et al, 2003), 
- prevent the inhibition of possibly protective cyclophilin isoforms, such as 
cyclophilin A (Halestrap, McStay & Clarke, 2002, Jin et al, 2000). 
A synthetic analogue of cyclosporin A (SDZ-NIM811) was devised to have no 
immunosuppressive effects.   SDZ-NIM811 has been shown to disrupt the binding of 
cyclophilin A to a critical protein domain in the HIV virion, and as a result the virion 
was less infectious (Yoo et al, 1997). 
 
The source of circulating cyclophilin B is unknown (Endrich & Gehring, 1998), and 
this would be an area of importance in understanding role in inflammation.   The 
patterns of secretion also need to be better understood.   The possible protective 
features of cyclophilin B inhibitors in inflammation and infection require further 
investigation. 
 176
Chapter 7 Introduction 
Chapter 7: Alkaline Urea gels: 
Traditional protein electrophoresis (SDS-PAGE) involves the separation of proteins in their 
denatured (via SDS interactions) and reduced (via DTT or β-mercaptoethanol) state.   The 
separation of proteins in SDS-PAGE is dependent exclusively on the molecular weight of the 
protein.   Protein bands in SDS gels are sharply focussed, because the proteins exist as 
monomers, are unfolded and interactions between proteins are not possible. 
 
An alternate protein electrophoresis approach retains the native state of the protein (by the 
omission of reducing agents), and any denaturation of proteins is either mild, and/or 
reversible.   Native gels are useful for investigations of protein subunit formation, protein 
degradation and binding events (Alliance protein lab).   Native gels are also useful when the 
protein of interest has enzymic activity that can be detected post electrophoresis.   Native gels 
have a number of associated problems including: 
- the mobility of proteins is not simply due to molecular weight*, [so protein band patterns 
can be difficult to interpret (Chettibi & Lawrence, 1989)], 
- bands can be indistinct, broadened or blurred due to protein-protein interactions, 
polymers or multiple forms of proteins resulting from disulfide bonding. 
 
The high concentrations of urea that are often used in native gels help to achieve high 
resolution of proteins by eliminating protein-protein interactions and ensuring that proteins 
exist in their unfolded state (Whittaker & Simpson, 1983).   The denaturation of proteins by 
urea is a reversible process, which allows for analysis of the native protein after renaturation.   
High concentrations of urea can result in the formation of cyanate ions which can cause 
artifactual spots or bands in gels via carbamylation of proteins (Gorg et al, 1997, Harris & 
Angal, 1989) and N-terminal blocking (Harwig et al, 1993).   Chemical modification as a 
result of urea is a particular concern at high temperature and at alkaline pH. 
 
Ahmad and colleagues (1994) employed a urea gel system of alkaline pH and high acrylamide 
to resolve alkaline snake venom proteins, in particular venom phospholipase A2 isoforms.   
Some 150 phospholipase A2 isoforms have been characterised in venoms (Valentin & 
Lambeau, 2000).   A single species of snake can express up to 15 distinct phospholipase A2 
isoforms (Valentin & Lambeau, 2000).   Phospholipase A2 is one of the most active venom 
                                                          
* Mobility in native gels is due to a combination of a protein’s size, shape and number of charged residues. 
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components and can exhibit a number of toxic effects including myonecrotic effects, 
cardiotoxicity, anticoagulent effects, and hemorrhagic effects (Fortes-Dias et al, 1994).   
Phospholipase A2 isoforms of high pI are of particular interest as it is thought that the most 
potent venom toxins are either basic phospholipase A2 proteins or complexes involving 
phospholipase A2 subunits (Karlsson, 1979).  Ahmad and colleagues (1994) used these gels to 
identify several PLA2 isoforms that had been unable to be resolved by IEF or ion exchange 
chromatography.   The high acrylamide content of these gels favoured the resolution of small 
proteins and large peptides.   These gels were particularly suited to the investigation of 
phospholipase A2 because:   
- they allow post separation analysis of enzyme activity,  
- phospholipase A2 enzymes from snake venom are not denatured by high  
  concentrations of urea, 
- PLA2 enzymes are stable at extreme pH, particularly high pH,    
- PLA2 can be extracted at high yield (>60%) from the gels (Ahmad & Lawrence, 
 1993),    
but most importantly: 
- PLA2 isoforms show variable numbers of charged residues, particularly numbers of 
acidic residues (Ahmad & Lawrence, 1993), which result in different mobilities in 
these gels. 
 
The relative mobility of phospholipase A2 isoforms in these gels is given by: 
Number of Aspartic acid residues + number of Glutamic acid residues + number of 
Tyrosine residues – number of Arginine residues + 1 (Ahmad, Lawrence & Moores, 
1994).    
These gels were also advantageous because they are rapid, inexpensive, use small amounts of 
sample and allowed post electrophoretic enzyme activity analysis.   These gels are also more 
suited to comparative studies than IEF. 
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Chapter 7: Alkaline urea gels: 
The two part alkaline urea gels devised by Ahmad, Lawrence and Moores (1993), for 
the analysis of venom phospholipase A2 was investigated for use in the analysis of 
mammalian phospholipase A2.   A number of extensions were possible and may 
broaden the applications available for these gels.   Transfer of proteins from alkaline 
urea gels to membranes would allow identification of proteins of interest by N-
terminal amino acid sequencing.   Proteins could be transferred to PVDF membranes 
from alkaline urea gels with no apparent loss of protein through the membrane 
(Figure 7.1).   No protein was evident in the gel after transfer (Figure 7.2).   The 
protein bands transferred to the membrane were sharp and very similar to the same 
sample run on a gel without transfer (Figure 7.2).   The transfer of small basic proteins 
from alkaline urea gels to PVDF membrane was more efficient using the CAPS 
transfer buffer than the Towbin transfer buffer (Figure 7.3).   Proteins transferred 
from alkaline urea gels to PVDF could be successfully sequenced (Figure 7.4), which 
suggests that the process did not N-terminally block the proteins.   Operating the gel 
system in an ice bath and chilling the buffer aided in lowering the temperature of the 
system (Figure 7.5), which may help to prevent protein modification.   The length of 
the gel could be more efficiently used by decreasing the acrylamide concentration and 
decreasing the pH of the stacking gel (Figure 7.6).   The protein bands in an alkaline 
urea gel could be removed and run in an SDS-PAGE system to estimate the protein 
size (Figure 7.7).   This approach appeared to give a reasonable estimation of protein 
size, and accuracy did not appear to be improved by reducing the proteins before 
electrophoresis (Figure 7.8), thought this process may lead to loss of proteins.    
 
These gels could be used to examine carbamylated and non-carbamylated protein 
(Figure 7.9).   These gels could also be used to examine forms of haemoglobin 
(Figure 7.10).   The extraction efficiency could be improved by lowering the pH of 
the extraction buffer (Figure 7.11).   Phospholipase A2 could be extracted from crude 
tiger snake venom and analysed for enzyme activity (Figure 7.12).   These gels could 
also be used to examine the mobility of a variety of available of phospholipase A2 
isoforms, which are very similar in size and difficult to resolve using SDS-PAGE 
(Figure 7.13).   These gels were able to separate the proteins with phospholipase A2 
activity from normal and infarcted gut samples (Figure 7.14).   The protein from 
infarcted gut appeared to have higher mobility than that from normal gut.   When the 
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bowel protein of interest was partially purified by heparin sepharose chromatography 
it retained high mobility in these gels (Figure 7.15).   The phospholipase A2 activity 
from synovial fluid and normal human gut appear to run to a similar position in these 
gels (Figure 7.16).    The different mobilities of proteins in these gels did not appear 
to be due to different salt concentrations/ionic strength of samples (Figure 7.18). 
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Figure 7.1: A typical PVDF membrane after blotting.   The membrane surface in 
contact with the gel is shown in the upper picture.   The opposite side of the 
membrane is shown in the lower picture.   The sample shown in these pictures is 
a bowel content sample, precipitated with ammonium sulphate (60% 
saturation).
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Figure 7.2: Appearance of gel (upper picture) after blotting and an equivalent gel 
without blotting (lower picture).    The sample shown in these pictures is a bowel 
content sample, precipitated with ammonium sulphate (60% saturation).
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Figure 7.3: Transfer of crude snake venom proteins and small basic proteins from alkaline urea 
PAGE to PVDF.   Transfer efficiency of CAPS buffer (upper membrane) and Towbin (lower 
membrane) are compared. 
Lanes 1&2 Crotalus scutulatus (Mojave rattlesnake) venom, 20µg protein.
Lanes 3&4 cytochrome c- (bovine heart) 4 µg protein.  (Cytochome C- Mr= 12.33kDa, pI=10.6).
Lanes 5&6 sPLA2-III (Apis mellifera) 4 µg protein  (sPLA2-III Mr=15.25kDa, pI=8.07).
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Figure 7.4: N-terminal amino acid sequencing of proteins transferred from alkaline urea 
gels.   
Lanes 1&2 Crotalus scutulatus (Mojave rattlesnake), crude venom, 20µg per lane.
Lanes 3&4 Cytochrome c, 4µg per lane.
Lanes 5&6 Bee venom sPLA2,  4µg per lane.
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Figure 7.5:  Running temperature of alkaline urea gels according to 
the original method or the modified method.   The running buffer was 
replaced with fresh buffer after two hours.
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Figure 7.6: Urea gels of crude snake venoms, run according to the original method or 
the modified method.
Lanes 1&2:  Agkistrodon rhodostoma (Malayan pit viper), 20µg protein per lane.
Lanes 3&4:  Crotulus scutulatus (Mojave rattlesnake), 20µg protein per lane.
Lanes 5&6:  Echis carinatus (Saw scaled viper), 20µg protein per lane.
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Figure 7.7: Extraction of protein bands from alkaline urea gels for SDS 
PAGE size estimation.   Sample used was crude venom of Crotalus
Scutulatus (Mojave rattlesnake).   SDS-PAGE: 4-20% iGEL, TrisGlycine
gel (Gradipore).   Protein bands could also be extracted for Tricine gel for 
the estimation of size of very small proteins (results not shown).
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Figure 7.8: An assessment of the accuracy of protein size determination after 
alkaline urea PAGE.   The gel shown is an SDS-PAGE gel, 8-16% iGEL, 
Gradipore.
Lanes:
1 Protein markers
2&3 Gel pieces from urea gel, reduced with method A
4&5 Gel pieces from urea gel, non reduced
6&7 Gel pieces from urea gel, reduced with method B (Davie, 1982)
8 No prior urea gel, reduced 
9 No prior urea gel, non reduced
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Figure 7.9: Carbamylation of bee venom sPLA2.   The upper gel is an alkaline 
urea gel.  The lower gel is an SDS-PAGE gel of gel pieces from the alkaline 
urea gel.
Lanes 1&2 carbamylated PLA2.
Lanes 3&4 non-carbamylated PLA2.
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Figure 7.10: Haemoglobin in alkaline urea gels.   The upper gel strip is from 
an alkaline urea gel.   The lower gel is an SDS-PAGE gel (4-20% iGEL, 
Gradipore).
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Figure 7.11: Extraction of phospholipase A2 enzyme activity from alkaline 
urea gels.   Results are expressed as the mean +/- std error as a percentage of 
the control (no prior gel separation).   The extraction buffers were 
10mM ethanolamine, Milli-Q water, or 10mM Tris pH 6.8.  The enzyme 
sample employed was  bee venom sPLA2.
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Figure 7.12: Tiger snake, crude venom, run in alkaline urea gel. Gel was sliced 
into 1mm sections and protein was eluted into solution.   Each section assayed for 
PLA2 activity.   The upper picture shows the gel stained for protein and the graph 
below shows the PLA2 activity in each 1mm slice.
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Figure 7.13: Native urea gel of available PLA2 isoenzymes and bowel PLA2.   
Type IB: purified porcine pancreatic phospholipase A2 (Sigma).   
Type IIA: recombinant human phospholipase A2, (a kind donation from Dr. 
Kieran Scott)                                
Type III: purified bee venom phospholipase A2 (Sapphire Biosciences).
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Figure 7.14: The mobility of phospholipase A2 proteins from infarcted and 
normal bowel in alkaline urea gels.   Infarcted bowel content (precipitated 
with ammonium sulphate at 60% saturation) vs normal bowel extract.
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Figure 7.15:  A heparin column of crude bowel content eluted with increasing 
NaCl.   The fraction that exhibited the highest phospholipase A2 activity was 
retained and run on an alkaline urea gel.
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Figure 7.16: PLA2 activity extracted from alkaline urea gels of 
synovial fluid and  supernatent from normal bowel.
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Figure 7.17: Mobility of bee venom sPLA2 (10µg per lane) with increasing 
concentrations of NaCl.  Data represented as mean +/- standard deviation (error 
bars <1%) of duplicate values.  Mobility is represented as the distance that the 
protein band ran from origin divided by the distance of bromophenol blue marker 
dye from origin.
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Chapter 7 Discussion: 
Alkaline urea gels were used in this project to investigate whether the protein 
responsible for the increased phospholipase activity in infarcted human bowel had 
different characteristics from normal human bowel, and other well described sources 
of phospholipase A2.   These gels were more useful than SDS-PAGE gels in this type 
of comparative analysis because the native activity of the protein was retained.   The 
process of extracting the enzyme and assaying it for phospholipase activity was far 
more sensitive that protein gel staining, and therefore able to specifically localise the 
protein of interest within the gel.   These gels were devised by Ahmad and colleagues 
(1994) for the analysis of isoforms of phospolipase A2 from snake venoms.   The 
connection between snake venom and intestinal proteins may appear questionable, but 
others have noted the: 
‘suprising similarities between the intestinal phospholipase A2 and some basic 
venom proteins’ (Verheij et al, 1981). 
These gels would be of use in many applications where the native activity of an 
enzyme could be detected after electrophoresis.   The mobility of proteins in these 
gels is a function of size, shape and number of charged residues.   This type of native 
gel is also more useful than SDS-PAGE in the study of isoforms of similar sizes.   For 
example, a similar native gel (contained 8M urea and no SDS) was able to resolve 
variants of lysyl oxidase from bovine aorta that were unable to be resolved by SDS-
PAGE (Williams & Kagan, 1985). 
 
Alkaline urea gels have been criticised for a number of reasons including; 
- the inability to assess protein size from these gels (Chettibi & Lawrence, 
1989), 
- the potential risk of carbamylation which may cause N-terminal blocking, 
and therefore inability to N-terminally sequence proteins of interest, 
 - the potential risk of artifactual protein bands.  
We considered that a number of extensions may be possible to address these issues 
and increase the number of applications available for these gels. 
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 Discussion 
Transfer of proteins to membranes: 
If proteins could be immobilised on a membrane, then they may be able to be N-
terminally sequenced by Edman chemistry or proteins of interest may be detected 
with Western blotting.   For this to be possible two issues had be addressed: 
a) The transfer of small basic proteins (which are typical of phospholipase A2 
isoforms and venom proteins) can be problematic 
b) It was unknown whether proteins could be electro-transferred from urea gels. 
The traditional transfer solution for proteins, the Tris Glycine buffer, (or Towbin 
buffer, pH 8.3) was devised for the transfer of proteins up to a pI of approximately 7 
(Towbin, Staehlin & Gordon, 1970).   The efficiency of transfer of proteins varies 
greatly, and it thought that the transfer buffer pH should be 1 to 2 pH units above the 
isoelectric point of the protein of interest.   The CAPS transfer buffer (pH 11) had 
been devised for the transfer of basic proteins from SDS-PAGE gels to nitrocellulose 
(Szewczyk & Kozloff, 1985).    
 
The CAPS transfer buffer was found to transfer small basic proteins and crude venom 
proteins from alkaline urea gels to PVDF more effectively than the Towbin buffer, 
probably because of the high pH of the CAPS buffer.   The proteins transferred to the 
membrane could be successfully sequenced by N-terminal amino acid determination 
by Edman chemistry (Edman & Begg, 1967).   This is a positive finding because it not 
only extends the applications available for these gels but suggests that N-terminal 
blocking of proteins by carbamylation is minimal.   The use of the membranes in 
Western blotting would be an interesting extension for these gels, but was not within 
the scope of this project.    
 
Carbamylation: 
The risk of carbamylation increases with increasing temperature, time and urea 
breakdown, therefore efforts were taken to reduce each of these factors.   Firstly, as 
recommended by Ahmed & Lawrence (1994), high quality urea was used and gels 
were run for two hours before the addition of the protein samples.   These steps were 
likely to reduce the risk of urea breakdown and to remove any breakdown products if 
they were present.   Secondly we chose to run the gels in an ice bath to reduce the 
buffer temperature.   Additionally, buffers could be pre-chilled.   The acrylamide 
concentration and pH of the stacking gel could both be reduced which appeared to 
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increase the mobility of the proteins in the gel.   These modifications had two results: 
firstly the increased protein mobility reduced the running time and secondly the length 
of the gel was used more efficiently.   Bee venom phospholipase A2 contains 28 
potential carbamylation sites.   Bee venom PLA2 was carbamylated for 48 hours at 
37oC, and was then run on an alkaline urea gel and SDS-PAGE.   Carbamylation adds 
only 43 atomic mass units, and this small difference could not be detected in an SDS 
gel, as expected.   Carbamylation results in the loss of positive charges from a protein, 
and therefore mobility in alkaline urea gels should theoretically be increased.   A 
slight increase in mobility was suggested in the alkaline urea gels. 
 
Native gels are excellent tools for detecting protein aggregates, unfolded 
conformations and binding events (Alliance Protein Laboratories, 2003).   A number 
of haemoglobin forms were evident in the alkaline urea gels, and the nature of each 
could be estimated by determining the size of the aggregate by SDS-PAGE.    
 
The size of the proteins of interest could be estimated by excising protein bands from 
the alkaline urea gel and re-running in an SDS-PAGE gel.   The protein bands were 
excised easily and cleanly from alkaline urea gels stained with either Coomassie R-
250 or Coomassie G-250 based stains.   The gel pieces could be stored in the freezer, 
and freezing aided in the manipulation into SDS-PAGE gels.   The proteins could be 
reduced with either a β-mercaptoethanol/equilibration technique (Davie, 1982) or a 
DTT-boiling technique (that we developed to avoid the more toxic and odorous β 
mercatoethanol).   The reduction step did not appear to improve the accuracy of the 
size determination, but may have resulted in protein losses.   The transfer of protein 
from alkaline urea gels to SDS gels was advantageous in two ways, firstly the size of 
proteins of interest could be estimated and the process added an extra dimension of 
resolution. 
 
The extraction efficiency of proteins from these gels was reported to be approximately 
60% (Ahmad & Lawrence, 1993).   We found that the extraction efficiency was 
improved by lowering the pH of the extraction buffer.   Active PLA2 could be 
extracted from crude tiger snake venom.   These gels were used to examine a number 
of different purified isoforms of PLA2 that were available to our group.   The proteins 
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with phospholipase activity from normal and infarcted human bowel were compared, 
and the mobility of each of these proteins was quite distinct.   Not surprisingly, the 
phospholipase from normal bowel appeared to have similar mobility to the 
phospholipase in synovial fluid from patient with rheumatoid arthritis.   Normal gut 
(Cupillard et al, 1997, Nevalainen, Gronroos & Kallajoki, 1995) and rheumatoid 
arthritis (Seilhamer et al, 1989) are both known to be rich sources of type IIA 
phospholipase A2.   The infarcted gut protein with phospholipase activity had high 
mobility in alkaline urea gels, and partially purified protein showed similar mobility.   
This confirmed that the unusual protein was being followed successfully by the 
protein purification process.   The isoelectric point of a protein is dependent on the 
environment (pH, ionic strength etc), so it was possible that different mobility in 
alkaline urea gels was not due to protein differences but the ionic strength or pH of 
the protein solution.   To discount this possibility a series of protein solutions were 
prepared containing 0 to 1M sodium chloride.   Even under conditions of 1M NaCl, 
the protein maintained the same mobility.   This was a reassuring finding because 
different protein mobility strongly suggests different protein composition.   The ions 
present in protein samples are likely to have high mobility under the running 
conditions and are likely to be lost quickly. 
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 Conclusions and Future Directions. 
Chapter 3, Plasma Proteomics: 
 
 
 
The proteomic investigation undertaken as part of this project identified a number of 
proteins that appeared to be increased in the plasma of patients with confirmed bowel 
infarction compared with control patients.   The aim of the investigation was to assess 
whether a tissue damage marker specific to bowel was present in high abundance in 
plasma.   The proteins that appeared to be the most differentially expressed were 
variants of haptoglobin (in the region of pH 4-7) and serum amyloid A (in the region 
pH 7-10).   These two proteins are well recognised as being disease associated 
proteins and have been shown to be present in high concentrations in inflammatory 
diseases, infection and trauma.   The elevated levels of these two proteins in disease 
suggest that they may have a role in host defence, tissue repair and inflammation. 
 
The existence of several highly homologous variants of serum amyloid A and lack of 
variant specific assays makes the study of this protein difficult.   The commercially 
available serum amyloid A ELISA (TriDelta) detects the total acute phase serum 
amyloid A (SAA 1 & 2 subtypes), with a good limit of detection and reproducibility.    
However, if subtle patterns of SAA subtype levels exist that are indicative of a 
particular disease, an ELISA such as this would not detect these patterns.   At present 
there are no serum amyloid A subtype specific antibodies available.   It may be 
interesting to probe two dimensional gel electrophoresis membranes (pH 3-10) for 
SAA variants using Western blotting to assess protein changes due to disease states. 
 
At present, the assay of haptoglobin and serum amyloid A for diagnostic purposes is 
not a clinically attractive prospect because of their likely non-specific expression in 
response to inflammation, injury or infection.   There may be haptoglobin or SAA 
subtype specific increases that are indicative of bowel infarction, but these cannot be 
studied without subtype specific techniques such as subtype specific ELISA.    
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 A proteomic approach for diagnostic marker identification is useful, but a number of 
modifications to the techniques such as those used in this project are required to 
improve the chance of finding a useful diagnostic protein.   These modifications 
include pre-fractionation of samples prior to two dimensional electrophoresis, or an 
alternate technique such as the isotope coded affinity tag (ICAT) system. 
 
Firstly, pre-fractionation of plasma (for example, by preparative isoelectric focussing 
or sub-proteomics) would allow the generation of a set of sub samples.   The sub 
samples could each be run in a two dimensional electrophoresis gel system.   Pre-
fractionation is likely to allow the identification of lower abundance proteins, which 
are more likely to be disease associated proteins or markers of specific tissue damage. 
 
Secondly, an approach such as the ICAT (isotope coded affinity tag) system may 
provide very interesting insights into protein differences between plasma from bowel 
infarction and control patients.   The ICAT technique was developed to achieve 
quantitative protein profiling to examine differences between the proteins from a 
matched pair of samples.   Briefly, this technique involves the labelling of the cysteine 
residues in sample ‘A’ with a ‘light’ (hydrogen, d0) biotin linked reagent and those in 
sample ‘B’ with a ‘heavy’ (deuterium, d8) biotin linked reagent.   Samples A and B 
are then mixed, trypsin digested and the ICAT peptides isolated by avidin affinity 
chromatography (Gygi & Aebersold, 2000).   The peptides are then identified by LC-
MS/MS and quantified by the ratio of the ICAT labelled peptide pairs.   The 
preliminary ICAT experiments focussed on the protein differences between yeast 
grown with a variety of carbon sources (Gygi et al, 1999).   Recent ICAT publications 
have reflected the diversity of potential applications (cortical neurons, wheat and 
membrane proteins). 
 
The advantages of the ICAT technique include the highly specific and robust labelling 
process and the ability to use a wide variety of protein sources and quantities.   Other 
separation techniques could be added to the ICAT procedure to identify lower 
abundance proteins (Gygi, Rist & Aebersold, 2000).   The disadvantages of the ICAT 
technique include some difficulty in database searching because of the modification 
of peptides by the tag, and some peptides are missed because they contain no cysteine 
residues (~8% of proteins in yeast contain no cysteine residues, (Gygi, Rist & 
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 Aebersold, 2000)).   In this type of project, the ICAT approach would be 
advantageous because large amounts of protein could be analysed which would 
increase the likelihood of identifying a low abundance, disease associated protein.   
The ICAT technique also allows the identification of minor protein differences 
between two states, in this case bowel ischaemia/infarction and control plasma. 
 
In a different issue, proteomics may be a valuable tool to identify protein changes 
associated with the development of remote organ injury that may be seen as a 
consequence of bowel injury, either in blood or in mesenteric lymph.   It would be of 
great interest to study protein factors in mesenteric lymph that may be: 
 - mediators of remote organ injury 
 - potential therapeutic targets for remote organ injury 
- expressed at different time points during the development of remote organ 
injury  
-involved in the induction of related processes such as increased gut 
permeability, neutrophil priming and intestinal mucosal damage. 
The study of lymph would be potentially less difficult than plasma, as lymph has only 
half the total protein of plasma (Anderson & Anderson, 2002).   Previous research 
into the potential mediators of tissue/cellular damage carried in the mesenteric lymph 
has generally been conducted in rodent models of hemorrhagic shock.   Bacteria and 
endotoxin are unlikely to be important factors, as these could not be detected in the 
post shock lymph (Deitch et al, 2001, Magnotti et al, 1998).   The potential 
importance of a neutral lipid (rather than protein or carbohydrate) factor was 
highlighted by another study (Gonzalez et al, 2001).   It would be of great interest to 
identify the nature and source of this lipid factor, and the enzyme(s) responsible for its 
production. 
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 Conclusions and Future Directions. 
Chapter 4, Phospholipase Activity in Mesenteric 
Ischaemia/Infarction: 
 
 
 
Increased mucosal phospholipase A2 activity associated with gut ischaemia 
reperfusion injury had been previously reported in rat models (Koike et al, 1992, 
Koike et al, 1995, Otamiri et al, 1987, Otamiri, & Tagesson, 1989).   The involvement 
of phospholipase A2 in the pathogenesis of ischaemia/reperfusion injury had also been 
proposed by several groups, based on the protective qualities of phospholipase 
inhibitors (Koike et al, 1992, Koike et al, 1995, Otamiri et al, 1987, Otamiri, Lindahl 
& Tagesson, 1988).   Many groups had identified the presence of the isoform of 
phospholipase A2 type II, in normal gut tissue using a variety of techniques 
(immunohistochemistry, in situ hybridisation, PCR), but few studies have investigated 
PLA2 isoforms in diseased tissue.   We were in the unusual but fortunate position to 
have access to human bowel tissue from both bowel infarction and control patients.    
 
In this project, early experiments suggested that while type IIA phospholipase A2 was 
present in injured human bowel, this isoform was not responsible for all of the 
phospholipase activity in these samples.   Phospholipase activity was significantly 
higher in the lumen of infarcted human bowel than in the corresponding bowel tissue.   
This finding suggests a possible route for the protein to enter general circulation.   It 
would be a valuable future direction to examine the synthesis and/or release of this 
protein in response to the development of the ischaemic injury.   The possibility that 
the protein is simply being leaked from dying cells needs to be eliminated.   This 
could be achieved by measuring the rate/percentage of cell lysis by assaying 
cytoplasmic proteins or cell membrane integrity.   An in depth investigation of the 
hydrolysis products of phospholipase activity and their effects during 
ischaemia/reperfusion injury and remote organ injury would also be valuable. 
 
It would also be interesting to examine the phospholipase enzyme activity in matched 
human portal and systemic circulation, ischaemic and infarcted tissue, to examine the 
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 relative enzyme activity at each stage of the possible release into circulation.   It may 
also be a valuable exercise to use a labelled protein to assess intestinal permeability 
changes in response to ischaemic injury, perhaps at the same time as the examination 
of phospholipase activity.   In a rat model of ischaemia/reperfusion, phospholipase 
activity was ten fold higher in portal than systemic circulation, and this suggested that 
the circulating phospholipase activity arose from the injured gut (Koike et al, 2000).    
 
Our results showed that phospholipase activity was significantly higher in infarcted 
than matched ischaemic tissue.   Although this was only a sample size of one, this 
result may be of significance if a spectrum of phospholipase activity reflects a 
spectrum of tissue damage.   In turn this may be of relevance in the development of a 
diagnostic test, as the level of the protein in circulation may reflect the severity of the 
condition.   In future investigations, many more matched tissue samples would assist 
in answering these questions.   Many potential diagnostic markers of bowel infarction 
have not found clinical utility because they either: 
- decrease before the condition has been rectified (Bounous et al, 1984, 
Jamieson et al, 1982). 
- continue to increase even after the condition is rectified or 
- cannot distinguish between ischaemia and infarction (Gearhart et al, 2003). 
A suitable animal model could assist in examining the correlation between the degree 
of tissue damage and protein response.   However, there are significant species 
differences in the distribution of phospholipase A2 isoforms making an animal model 
unreliable, however this may not be an issue with other potential markers of bowel 
injury.   A time course study of protein changes at the various stages of the disease 
development would also be a valuable future direction, and an animal model would be 
essential for this investigation. 
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 Conclusions and Future Directions. 
Chapter 5, Protein Purification: 
 
 
 
The protein purification experiments in this project were undertaken to identify the 
protein with phospholipase activity that was increased as a result of infarction.   
Immunodepletion results suggested that the well described phospholipase A2 isoforms 
of type IIA and V did not account for all of the phospholipase activity in infarcted 
human bowel.   The protein purification techniques used in this project were chosen 
because of their ability to exploit an unusual characteristic of the protein of interest, 
and in doing so, remove large amounts of contaminating protein at each step.   In 
addition, each purification technique used in this project retained the native enzyme 
activity of the protein of interest, and therefore the protein could be tracked at each 
stage.   A number of preliminary purification attempts identified the purified protein 
as haemoglobin.   It was quickly confirmed that haemoglobin does not possess 
phospholipase activity, nor does it enhance the activity of low levels of 
phospholipase.   It was concluded that haemoglobin was likely to have been co-
purifying with the protein of interest.   To overcome this problem, a greater number of 
column volumes were employed with the heparin affinity chromatography column.   
The purification system was also scaled up approximately twenty fold, and this is 
likely to have assisted in targeting the protein of interest for identification.   The 
scaled up purification with more stringent washing steps allowed the isolation of 
several highly purified fractions, each with sufficient protein content for identification 
by mass spectrometry.    
 
The protein purification techniques used in this project (heparin affinity 
chromatography, preparative isoelectric focussing with the Rotofor® apparatus) were 
very useful for this application.   Heparin affinity chromatography can be used to 
easily semi purify a protein with heparin binding ability, whilst generally retaining the 
native activity of the protein.   It would be of interest to automate this system, which 
may result in higher reproducibility  and larger quantity purifications while decreasing 
the currently highly labour intensive nature of this technique.   It would be of interest 
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 to optimise the protein desalting and concentration steps that are required at the 
interface of the heparin column and the next technique (in this case, preparative 
isoelectric focussing).   The optimal desalting/concentration step would remove all of 
the interfering salts or other contaminants and the majority of the water without any 
protein alteration or loss.   The dialysis step used in this project was time consuming 
and did not concentrate the protein which resulted in the need for several Rotofor® 
runs of dilute solutions, instead of one run of a pooled and concentrated sample.  
 
The final identification of the protein of interest as cyclophilin B was made by nano 
LC-MS/MS.   An unusual aspect of the identification of cyclophilin B was that the 
purification progress had been monitored at every stage by phospholipid hydrolysis 
assays, but cyclophilin B was not known to possess phospholipase activity.   A set of 
experiments were undertaken to assess the possibility that cyclophilin B possessed 
phospholipid hydrolysing ability.   Immunodepletion of cyclophilin B from the highly 
purified final fractions removed all of the phospholipase activity.   This indirect 
evidence was interesting and supported the idea that cyclophilin B had phospholipase 
activity, but the direct investigation would have been preferable.   However, an 
application to the only known supplier of human cyclophilin B protein was 
unsuccessful.   In the future it would be of interest to produce recombinant human 
cyclophilin B to examine the enzyme characteristics in detail, and to investigate its 
pro-inflammatory properties.   Recombinant human cyclophilin B has been produced 
previously (Bergsma et al, 1991, Price et al, 1991, Spik et al, 1991) and these 
methods would form the basis of this future direction. 
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 Conclusions and Future Directions. 
Chapter 6, Cyclophilin B: 
 
 
 
Cyclophilin B had been reported to be a ubiquitously expressed protein as detected by 
northern blotting of mouse tissue panels (Hasel et al, 1991).   Cyclophilin B had been 
observed previously in rodent intestinal tissue at the mRNA level (Hasel et al, 1991, 
Kainer & Doris, 2000).   Very little research has focussed on cyclophilin B at the 
protein level in tissues, but some work has detected cyclophilin B protein in cell 
culture (Bergsma et al, 1991).    
 
In this project, western blotting of cyclophilin B was performed using a commercially 
available polyclonal antibody.   Immunoreactive cyclophilin B protein was detected in 
all bowel tissues investigated, from both control and bowel infarction patients.   
Immunohistochemistry results supported the western blotting results, and showed 
widespread distribution of cyclophilin B in many cell types in both normal and 
infarcted tissue sections.   Future directions in this area include the investigation of 
cyclophilin B protein in a variety of normal and diseased human tissues via 
immunohistochemistry, and the corresponding plasma by ELISA.    
 
Another future direction for this project may include the use of recombinant human 
cyclophilin B in the development of a sensitive and specific ELISA that is suitable for 
clinical samples.   To our knowledge, two cyclophilin B ELISAs have been 
developed.   These two ELISA protocols used the same cyclophilin B peptide 
generated polyclonal antibody and constructed a standard curve using recombinant 
cyclophilin B protein. 
 
Allain et al, 1995, published a cyclophilin B ELISA with the following format: 
-anti-cyclophilin B coated plates 
-anti-cyclophilin B peroxidase conjugate 
-O-phenylenediamine substrate 
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 The limit of detection of this ELISA was reported to be 10ng/mL and the average 
normal plasma level of cyclophilin B was found to be approximately 150ng/mL. 
 
Denys et al, 1998, published a modification of the above technique with the following 
format: 
-anti-cyclophilin B coated plates 
-anti-cyclophilin B biotin conjugate 
-avidin-peroxidase conjugate 
-O-phenylenediamine substrate  
This ELISA was reported to have better sensitivity than the above method, because of 
the likely biotin signal amplification effect.   This system would be a valuable starting 
point for the development of an ELISA in this project.   Average normal plasma levels 
were reported to be approximately 87ng/mL. 
 
A sensitive and specific ELISA for cyclophilin B would allow the large scale 
screening of patients samples and this may lead to a better understanding of the 
correlation between increased cyclophilin B levels and disease states.   In this project, 
plasma cyclophilin B was not detected in any control patients, but several samples of 
plasma from patients with confirmed bowel infarction contained cyclophilin B (via 
Western blotting).   An ELISA with a very low level of detection may be able to 
establish typical ranges for plasma levels of cyclophilin B in bowel infarction, healthy 
volunteers and control ICU patients.   At present, this is not an option because 
recombinant protein could not be obtained, and therefore a standard curve could not 
be constructed. 
 
Another future direction would be the development of novel cyclophilin B inhibitors 
that blocked the inflammatory activity of this protein without altering the distribution 
of cyclosporin A in blood or extracellular fluid or initiating the expression of more 
cyclophilin B.   It would also be of great interest to examine the potential role of 
cyclophilin B as a mediator of inflammation or tissue injury, perhaps with an 
emphasis on bowel ischaemia or infarction.   Furthermore, an investigation into the 
protective roles of cyclophilin B inhibitors in inflammatory conditions, oxidative 
stress and ischemia/reperfusion injury could be extended to include bowel conditions 
such as bowel ischaemia/infarction. 
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Conclusions and Future Directions. 
Chapter 7, Alkaline Urea PAGE: 
 
 
 
The alkaline urea gel system of Ahmed, Lawrence & Moores (1994) was found to be 
useful in this project, to examine differences in protein characteristics between a 
control and disease state.   This application was more suited to an alkaline urea gel 
system than SDS PAGE because: 
-the protein of interest was present in very low abundance and could not be 
detected by protein staining, but could be detected by extracting enzyme 
activity. 
-the proteins from normal and healthy tissue were of similar size, and 
therefore unable to be resolved by SDS PAGE, but as mobility in alkaline urea 
gels is due to a number of variables, this technique could resolve these 
proteins. 
 
These gels were modified to allow greater mobility of proteins, and therefore greater 
use of the entire length of the gel.   The modified alkaline urea gel showed that the 
proteins with phospholipase activity from normal human bowel and rheumatoid 
arthritis synovial fluid (both well described and abundant sources of type II PLA2) 
were similar and focussed in a region close to the site of application.   In contrast, the 
protein with phospholipase activity from infarcted human bowel lumen content had 
distinctly different, and higher mobility.   It would be of interest to use these gels to 
examine mammalian phospholipase from normal and disease state samples. 
 
A number of limitations were associated with these gels and attempts were made to 
overcome these problems in order to extend the applications available.   We have 
proposed a method to estimate protein size of the proteins of interest from alkaline 
urea gels.   This technique resulted in a reasonable estimation of protein size which 
may give information about a protein of interest and may allow a suitable purification 
process to be planned (for example the use of gel filtration chromatography or 
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 preparative PAGE).   An additional, but unexpected, advantage of this technique was 
the extra dimension of resolution provided by this step.   For example, one protein 
band observed in an alkaline urea gel of a crude snake venom resolved into two 
protein spots when run in an SDS PAGE gel.   This may be advantageous in very 
complex protein samples, in a similar fashion to two dimensional gel electrophoresis.    
 
Future directions for this area include an investigation of the suitability of western 
blotting as an extension for these gels.   Proteins separated by alkaline urea gels can 
be successfully transferred to PVDF membrane, and it may be possible to probe these 
membranes for immunoreactive proteins including venom toxins.   This approach may 
be useful for the identification of isoforms of proteins of interest that may share 
similar size and therefore may be unable to be separated by SDS PAGE based western 
blotting.       
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